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CHAPTER I 
 
INTRODUCTION 
 
Statement of the Problem  
Pressure ulcers and the risk factors associated with their development have been 
studied for almost 50 years yet the temporal, qualitative, and quantitative relationship 
between pressure ulcer risk factors and pressure ulcer incidence is still poorly understood.  
The literature suggests that specific risk factors for pressure ulcer incidence are 
associated with specific patient populations (de Laat, Schoonhoven, Pickkers, Verbeek, & 
van Achterberg, 2006); however, methodological strategies to explain associations 
between risk factors and pressure ulcer incidence generally do not reflect a specific 
patient population orientation.  The literature identifies over 200 risk factors that may 
contribute to pressure ulcer development (Anthony, Parboteeah, Saleh, & Papanikolaou, 
2008), but methodological and definitional inconsistencies complicate and slow the 
process of translating research into clinical practice (Keller, Wille, van Ramshorst, & van 
der Werken, 2002).  Consequently, clinicians lack a specific set of risk factors on which 
to focus their prevention efforts, resulting in the diffuse application of preventive 
measures with limited effectiveness.  Hospital acquired pressure ulcer (HAPU) rates 
increased by 63% between 1993 and 2006 (Russo & Elixhauser, 2006).  These statistics 
have not been risk-adjusted for severity of illness; however, hospital admission rates 
increased only 11% during the same period, and hospital stays for patients over 65 years 
old increased by 14%, suggesting that the observed increase in HAPU rates are not 
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entirely a function of the patient demographic.  This  increase in HAPUs contributes to 
higher health care costs, increased morbidity and mortality rates (Russo & Elixhauser, 
2006), and raises concerns about the quality of care delivered in US nursing homes and 
hospitals (Needleman, Kurtzman, & Kizer, 2007).  
 Of the populations studied, patients who are critically ill (i.e., receiving care in an 
intensive care unit [ICU]) are the most prone to the development of pressure ulcers 
(Bours, de Laat, Halfens, & Lubbers, 2001; de Laat, et al., 2006),  yet few investigators 
have systematically evaluated the predictive relationships between risk factor presence 
and pressure ulcer development in this population.  The most recent International 
Pressure Ulcer Prevalence Survey (IPUPS; VanGilder, Amlung, Harrison, & Meyer, 
n.d.), conducted in 2008 through 2009, substantiates the disproportionate prevalence of 
pressure ulcers in ICUs.  Pressure ulcers acquired in the ICU had a prevalence rate of 
8.8% to 12.1% in 2008 and 2009, respectively representing approximately 8,000 to 
11,000 patients annually who developed a pressure ulcer while in the ICU in the US.  In 
2009, 3.3% of US ICU patients developed a severe facility-acquired pressure ulcer 
defined as Stage III, Stage IV, unstageable, or deep tissue injury (VanGilder et al., n.d.).  
These findings suggest that clinicians working in ICUs need prevention strategies 
focused on risk factors specific to their patient population.  
 
Purpose of the Study 
 
Pressure ulcer prevention interventions are predicated on identifying salient risk 
factors for pressure ulcer development in specific patient populations (de Laat, et al., 
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2006).  The descriptive research identifies multiple patient specific risk factors that 
contribute to pressure ulcer incidence in a variety of patient populations; however, with 
the exception of increased age, no single or combination of risk factors predicts pressure 
ulcer incidence equally well among various patient populations.  Braden and Bergstrom’s 
(1987) and Defloor’s (1999) conceptual models identify pressure ulcer risk factors, but 
have not been extensively studied in various patient populations, specifically the ICU 
population.  Critically ill patients, the most prone to pressure ulcer development, are the 
least studied patient population reported in the literature.  A search of the PubMed 
database conducted using the search terms ‘risk factors’ and ‘pressure ulcers,’ with the 
limits of all adult, humans, core clinical and nursing journals, and English with no date 
constraints yielded 574 articles published between 1975 and 2011.  To refine the search 
to risk factors for pressure ulcer development in critically ill patients, the search term 
‘intensive care’ was added using the same limits.  The search returned 57 articles 
published from 1975 to 2011.  Of those, eleven were prospective studies designed to 
identify causality between pressure ulcer risk factors and pressure ulcer incidence.  
Further studies to evaluate causal relationships between risk factors in critically ill 
patients and pressure ulcer development are needed to further understand, prevent, and 
mitigate the effects of pressure ulcers in this vulnerable population.  The purpose of this 
study was to identify risk factors that contributed to pressure ulcer development in 
critically ill patients.  
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Significance 
 
The significance of pressure ulcers is viewed within the broader contexts of their 
significance to society, healthcare, and specifically to the nursing profession. 
Significance to Society 
Prevalence and incidence of pressure ulcers in the US.  National estimates of 
pressure ulcer prevalence rates vary widely in the literature.  In a summary of findings by 
the 2004 National Nursing Home Survey, Park-Lee and Caffrey (2009) reported that 
about 159,000 (11%) of nursing home residents had a pressure ulcer.  This statistic is 
somewhat higher than those released by the Agency for Healthcare Research and Quality 
(AHRQ) in 2004.  According to AHRQ, pressure ulcer rates in nursing homes ranged 
from 8.5% to 8.7% (Agency for Healthcare Research and Quality [AHRQ], n.d.).  
National pressure ulcer prevalence rates in acute care facilities are less precise than those 
reported in nursing homes, possibly because of the dynamic nature and increased acuity 
of the acute care patient populations.  Using data from secondary sources, the Institute for 
Healthcare Improvement (IHI) estimated pressure ulcer prevalence rates in acute care 
facilities ranged from 0.4% to 38% (Lyder, 2003).  The National Pressure Ulcer Advisory 
Panel (NPUAP) estimates pressure ulcer prevalence rates in acute care facilities at 15% 
and incidence rates in acute care facilities at 7% (Cuddington, Ayello & Sussman, 2001). 
National statistics on pressure ulcer prevalence and incidence in critically ill 
patients in the US are difficult to locate.  Estimates of pressure ulcer prevalence and 
incidence rates in the ICU patient population are higher than those of the general acute 
care facility population because of their increased association with risk factors that are 
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generally thought to contribute to pressure ulcer development (Carlson, Kemp, & Shott, 
1999).  In a national benchmarking study conducted in US acute care facilities in 1999, 
Amlung, Miller, and Bosley (2001) found pressure ulcer incidence rates among critically 
ill patients to be 13%.  This statistic falls within the 7% to 15% identified by Cuddington, 
et al. (2001), although some estimates of pressure ulcer incidence rates in ICUs approach 
50% in US ICUs (Cuddington et al., 2001; Fife et al., 2001; Jiricka, Pyan, Carvalho, & 
Bukvich, 1995). 
Healthcare costs of pressure ulcers in the US.  In 2006, the national estimates 
on the costs of treating pressure ulcers in the US ranged between $1.3 and $3.5 billion per 
year (Courtney, Ruppman, & Cooper, 2006).  These costs are similar to earlier estimates 
by Whittington and Briones  (2004) of between $2.2 and $3.6 billion per year for the 
treatment of pressure ulcers.  By 2008, the Institute for Healthcare Improvement (IHI) 
estimated a total national cost of $11 billion per year to treat pressure ulcers (Institute for 
Health Care Improvement [IHI], 2008).  The IHI also estimated that the cost of treating a 
single full-thickness pressure ulcer to be as high as $70,000 per ulcer (IHI, 2008).  
Although there is no specific rationale that explains the 214% to 746% increase in 
estimated pressure ulcer treatment costs between 2006 and 2008, Leape and Berwick 
(2005) suggested that the increasing complexity of both healthcare systems and patients 
contribute to the rising costs demonstrated by these cost statistics.  
Morbidity and mortality associated with pressure ulcers.  In addition to the 
high cost of treatment, pressure ulcer presence is a poor prognostic factor (Reddy, Gill, & 
Rochon, 2006).  Prior to 2005, pressure ulcer associated morbidity and mortality in the 
US was significantly underestimated.  In a cross-sectional descriptive study of mortality 
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causes, Redelings, Lee, and Sorvillo (2005) reviewed death records of the 27,572,153 
persons who had died in the US between 1990 and 2001.  The study found that 114,380 
(0.41%) death records listed pressure ulcers as a contributing cause of death.  Of those, 
80% of pressure ulcer associated deaths occurred in persons 75 years of age or older.  In a 
prospective cohort study designed to compare hospital length of stays and complications 
in pressure ulcer positive patients compared with pressure ulcer negative patients, 
Allman, Goode, Burst, Bartolucci, and Thomas (1999) found that patients who developed 
pressure ulcers were more likely to develop nosocomial infections (45.9% vs. 20.1%, p = 
0.001).  Severity of illness adjusted costs of hospital stays were also statistically 
significantly higher in those patients who developed pressure ulcers ($14,260 vs. 
$12,382, p = 0.03) (Allman et al., 1999). 
Significance to Healthcare 
Pressure ulcers are among the serious events listed by the National Quality Forum 
(NQF) in their 2006 update (National Quality Forum [NQF], 2006).  Specifically, the 
NQF states that pressure ulcers are a product of lapses of care management, and that 
nosocomially acquired stage III or IV pressure ulcers are a serious event.  The NQF 
acknowledges that pressure ulcers may not be preventable in all cases, but suggests that 
their incidence in healthcare settings warrants scrutiny of the systems and processes 
designed to prevent and treat pressure ulcers (NQF, 2006). 
The National Quality Measures Clearinghouse (NQMC) provides 18 metrics for 
pressure ulcers that are included in either the outcome or the process domains (National 
Quality Measures Clearinghouse [NQMC], n.d.).  While most of the measures focus on 
aspects of appropriate treatment and prevalence rates of pressure ulcers within acute or 
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long-term care facilities, five evaluate the identification of pressure ulcer risk and 
presence or absence of preventive measures.  The measures do not identify a preferred 
risk-stratification tool, nor do they speak to the quality of the preventive interventions.  
The lack of specificity regarding pressure ulcer risk stratification and prevention 
measures suggests a lack of consensus on stratification of pressure ulcer risk and best 
pressure ulcer prevention practices.  Adequate risk stratification is essential for accurate 
comparisons of adverse event rates across hospitals (Needleman, et al., 2007).  The lack 
of empirical data supporting the putative link between nursing processes and pressure 
ulcer incidence (Needleman et al., 2007) suggests a need for a more rigorous risk 
adjustment method to control for the multiplicity of pressure ulcer risk factors that may 
be functioning as confounding variables in pressure ulcer research. 
Significance to Nursing   
According to the American Nurses Association (ANA), pressure ulcer prevention 
is primarily a nursing responsibility.  In 1995, the ANA introduced 10 quality measures 
described as most sensitive to nursing care (Montalvo, 2007) and integrated those 
measures into the NQF’s voluntary consensus standards for evaluating nurse sensitive 
care (Kurtzman & Corrigan, 2007).  Nosocomially acquired pressure ulcers are among 
the nurse sensitive outcomes adopted by the NQF and considered to be within the domain 
of patient-centered outcomes (Kurtzman & Corrigan, 2007).  To date, the nurse-specific 
quality metrics suggested by the ANA and the NQF are associated with patient outcomes, 
but do not imply causality.  The empirical evidence to support a causal link between 
nursing quality of care and pressure ulcer development is lacking. 
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Research Aims 
 
Further study is needed to understand the relationship between pressure ulcer risk 
factors and pressure ulcer development in critically ill patients.  The resulting knowledge 
can help more accurately stratify pressure ulcer risk in this vulnerable population and 
help nurses target prevention measures to decrease the incidence of pressure ulcer 
development in the critically ill patient population.  The aims for the proposed study 
were: 
1. To compare the frequency and magnitude of pressure ulcer risk factors 
between critically ill patients that do and do not develop a pressure ulcer 
during their ICU stay and evaluate their influence on the associations between 
the Braden subscales and pressure ulcer outcome; and 
2. To compare the frequency and magnitude of pressure ulcer risk factors 
between critically ill patients that have progression of their Stage I  pressure 
ulcer during the ICU stay to those who do not have a progression of their 
Stage I pressure ulcer during the ICU stay. 
The study was accomplished using a prospective matched case-control study 
design using convenience sampling in five ICUs at Vanderbilt University Hospital 
(VUH).  Risk factors were identified using a previously published conceptual model 
(Benoit & Mion, 2012).  Datasets were constructed that described the study sample and to 
conduct analyses that addressed the study aims.  
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Summary 
 
Nursing care processes correlate with various quality outcomes, including 
pressure ulcer development.  Despite the abundance of pressure ulcer risk factors 
identified in the literature, the HAPU incidence rate continues to rise, suggesting that 
current prevention interventions are inadequate, possibly because they lack specificity to 
various patient populations.  Critically ill patients are the most vulnerable to pressure 
ulcer formation, but commonly used risk assessment tools lack the specificity needed to 
guide focused prevention efforts in the ICU patient population.  By identifying risk 
factors that disproportionately contribute to pressure ulcer formation in the ICU patient 
population, nursing can improve patient outcomes by refining and selectively targeting 
pressure ulcer prevention efforts. 
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CHAPTER II 
 
LITERATURE REVIEW AND THEORETICAL FRAMEWORK 
 
The historical perspective of pressure ulcers indicates they have been a concern to 
the sick and injured for nearly 4000 years, but their relative importance to healthcare 
providers has fluctuated as the prevailing science and theoretical approaches to human 
disease have evolved (Parish, Witkowski, & Crissey, 1997; van Rijswijk, 2001).  Prior to 
World War I (1914-1918), the medical community largely viewed pressure ulcers as an 
unavoidable consequence of illness, and prevention efforts were virtually nonexistent 
(Parish et al., 1997).  As the prevailing view of pressure ulcers shifted toward a more 
preventive stance, the medical community began to identify risk factors for pressure ulcer 
development. The growing body of medical evidence on pressure ulcer risk factors 
indicates that some risk factors, such as advanced age and poor nutritional status, are 
common among various patient groups, while other risk factors may be unique or exhibit 
disproportionate importance within specific patient groups, such as the critically ill (de 
Laat, et al., 2006).  The purpose of this chapter is to: 
1. Identify and describe constructs related to pressure ulcer development; 
2. Discuss the relationships among those constructs as described in two 
previously published conceptual frameworks;  
3. Present a critical analysis of the extant literature on pressure ulcer risk 
factors;  
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4. Describe the validity, reliability, specificity and sensitivity of the  most 
commonly used pressure ulcer risk assessment scale in the US and discuss 
its predictive ability in critically ill patient populations;  
5. Present the conceptual framework used in this study that incorporates 
those risk factors identified in the literature review.  
 
Theoretical Framework 
 
Pressure Ulcer Constructs 
 
Factors contributing to pressure ulcer development comprise three separate but 
interrelated constructs.  External factors include compression, friction, and shearing 
forces on the skin and underlying connective tissue.  Patient-specific factors include the 
characteristics of the skin and underlying connective tissue that affect their ability to 
withstand the external forces without consequent damage (Defloor, 1999; Thompson, 
2005).  Environmental factors refer to the characteristics of the environment in which 
medical and nursing care is received that may contribute to pressure ulcer development.   
External Factors 
 Pressure ulcers develop as compressive, friction and shearing forces overwhelm 
the tissues’ ability to withstand those forces.  The resulting pressure damage can range 
from superficial disruption of the epidermis to deep ulceration involving muscle and 
associated connective tissues.  The relative importance of the type and magnitude of the 
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destructive forces and the characteristics affecting the tissues’ tolerance for those forces 
are not well understood (Thompson, 2005). 
Pressure as a construct.  Early conceptual models for pressure ulcer formation 
focused on describing the compressive force, or pressure, necessary to occlude capillary 
blood flow, creating ischemia to the involved tissues.  In 1930, Landis (cited in Defloor, 
1999) first described capillary closing pressures of 12 and 32 mm Hg at the venous and 
arterial end of a human finger capillary, respectively.  Defloor (1999) suggested that the 
commonly accepted arterial capillary closing pressure of 32 mmHg be re-evaluated with 
regard to its clinical appropriateness because Landis’ study was conducted on healthy 
persons.  Defloor reasoned that persons who were ill enough to develop pressure ulcers 
would have pathophysiologic processes that influence capillary closing pressures.  Early 
animal experiments conducted by Kosiack in 1959 (cited in Nixon, 2001) and a later 
study outlining tissue tolerance for pressure over time by Reswick and Rogers (1976) 
support an inverse parabolic relationship between the pressure intensity and time.  These 
findings suggest that minimal amounts of compressive force over long periods had the 
same effect on blood flow as did high amounts of compressive force over shorter periods.  
The findings by Reswick and Rogers (1976) and Kosiack (cited in Nixon, 2001), obviate 
the utility of capillary closing pressures in describing the pathogenesis of pressure ulcers 
in favor of multifactorial explanations.   
Compressive forces, which are those forces applied perpendicularly to the skin, 
seem to have the least destructive effects, especially when applied for short periods at a 
low magnitude (Nixon, 2001).  Uniformly distributed compressive forces briefly applied 
to the body’s surface do not have any long-term effects on the tissues.  For example, a 
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scuba diver in 33 feet of water experiences an external compressive force of about 760 
mm Hg (Springle, 2000) but does not develop pressure ulcers because the external force 
is uniformly applied and of short duration.  This observation of uniform pressure 
distribution suggests that other forces, combined with pressure, may be more destructive 
than pressure alone.  
Friction and shear as constructs.  In 1958, the concept of shearing forces was 
added to compressive forces as a second causal factor in the development of pressure 
ulcers (Defloor, 1999).  Shearing forces are those forces applied along a plane parallel to 
the skin and supporting structures.  The effects of shear and friction in combination with 
compressive forces more completely explain the synergistic effects that these forces have 
on pressure ulcer development.  Shearing forces, in combination with compressive forces, 
contribute to deformation of the deep tissues, thereby occluding blood flow and causing 
ischemic damage (Nixon, 2001).  Friction contributes to pressure ulcer development by 
mechanical debridement of the epidermal and dermis layers rather than through ischemic 
mechanisms.  Nixon (2001) described research done by Dinsdale in 1973, when he 
reported that friction initially removed the stratum corneum and separated the epidermis 
from the dermis.  It was established that friction forces alone did not result in ischemia, 
but rather produced its effects through mechanical disruption of the epidermis.  When 
combined with compressive forces, shearing and friction decrease the pressure required 
to occlude blood flow by approximately one half (Springle, 2000).  The additive effects 
of pressure, friction, and shear can overcome the skin and connective tissues’ tolerance 
for these forces, producing a disruption in the skin’s integrity.  The intensity and duration 
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of the external forces necessary to cause tissue damage is determined by the tissues’ 
ability to tolerate them.  
External factors are categorized according to their mechanism of action on the 
skin and underlying connective tissue and are composed of compressive, friction, and 
shearing forces.  These external forces, however, are not enough to produce pressure 
ulcers by themselves (Defloor, 1999).  Pressure ulcer development also depends on the 
general health of the individual, skin, and associated tissues.  These patient-specific 
characteristics determine the duration and magnitude of external forces necessary to 
produce pressure ulcers.  
Patient-Specific Factors   
Patient-specific risk factors constitute the individual’s overall tolerance of the 
tissue to withstand external forces without damage (Braden & Bergstrom, 1987).  The 
interplay between the external forces of compression, friction, and shearing forces with 
aspects of tissue tolerance are dynamic and multifactorial (Nixon, 2001), explaining 
pressure ulcer incident differences among individuals with varying exposure to external 
forces.  The concept of tissue tolerance includes factors that are known to influence the 
risk of pressure ulcer development, but do not directly affect the pressure, shear, and 
friction forces.  Risk factors are, however, just as important in the etiology of pressure 
ulcer development as the accompanying pressure, shearing, and friction forces (Meijer, 
Germs, Schneider, & Ribbe, 1994). 
Tissue tolerance as a construct.  Tissue’s tolerance for pressure, friction, and 
shear is a function of the homeostatic factors that maintain skin structure, blood and 
lymph flow to the skin and supporting structures.  The dermal layer of the skin is a 
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critical determinate in its ability to tolerate pressure, friction and shearing forces.  The 
dermis is composed of the papillary layer and the reticular layer and is responsible for 
most of the structural strength of the skin (Seeley, Stephens, & Tate, 2006).  The 
papillary layer is composed of papillae that extend upwards into the epidermis.  The 
dermal papillae contain an arteriolar and venous capillary necessary for nutrient and 
waste exchange with cells in the epidermis.  The reticular layer is composed of a mat of 
collagen, elastin, and reticular fibers that contribute to the tensile strength of the skin 
(Seeley et al., 2006).  The subcutaneous layer, or hypodermis, has an abundance of fat.  
In addition to its insulating and energy storage capabilities, fat is critical in dispersing the 
effects of extraneous pressure (Nixon, 2001).   
Cutaneous blood flow is proportional to the metabolic needs of the tissues.  Local 
blood flow is controlled by a combination of nervous and local factors associated with 
cell metabolism, such as the accumulation of metabolic byproducts.  Cutaneous blood 
flow is also affected by the nervous system, which responds to various intravascular 
systemic conditions, such as blood pressure fluctuation and fluid and electrolyte balance.  
Vasoconstrictive nerve fibers from the sympathetic nervous system extend to most parts 
of the circulatory system and are prominent in the skin. 
In addition to the extensive blood supply, human skin is permeated with a mesh of 
lymphatic vessels.  Because lymph vessels have minimal or no musculature in their walls, 
the circulation of lymph is sluggish and largely controlled by forces such as pressure, 
skeletal muscle action, massaging, and heat.  Any external pressure exerted, such as from 
a fixed dressing, interferes with its flow.  Since skin plays a major role in immunologic 
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responses of the body, its lymphatic drainage is as significant as its blood vascular system 
(Skin Anatomy, n.d.). 
In addition to the structural components of the skin, numerous types of sensory 
nerve fibers transmit signals to the brain, relaying a vast amount of information about the 
skin’s immediate environment.  Of primary importance to the concept of pressure ulcers 
are the mechanoreceptors and pain receptors located throughout the epidermis, dermis, 
and subcutaneous layers.  The ability to respond to these sensory stimuli requires an 
intact central nervous system and functional effector organs, such as muscle, to alter a 
noxious stimulus.  Alterations in any component of the central nervous system or the 
effector organs will affect the skin and supportive structure’s tolerance for pressure.  
Lymphocytes, macrophages, and mast cells are intimately associated with the skin 
and surrounding structures.  When there is damage to the skin, these cells release 
inflammatory cytokines and chemical mediators.  These chemical mediators increase 
vascular blood flow and vascular permeability at the injury site.  Increased vascular 
permeability alters the capillary exchange mechanism on both the arterial and venous 
ends, resulting in an increase in net hydrostatic pressure combined with a decrease in net 
osmotic pressure.  The result is interstitial edema because of the increase in net filtration 
pressure.  As edema increases, the metabolic demands of the tissue increase and local 
factors favor vasodilation.  Vasodilation increases edema and the cycle worsens.  
Eventually, increased edema overcomes the pressures in the capillaries and they close, 
creating an ischemic environment that leads to cell death. 
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Environmental Factors   
Additionally, environmental elements may contribute to pressure ulcer 
development.  For institutionalized (i.e. hospitalized and long-term care) patients, 
environmental variables that influence the delivery of care are important because they 
constitute elements of the clinical setting that affect patient outcomes (Kane, 2006).  
Kane described outcomes as a function of the patient’s baseline clinical, psychosocial, 
and demographic characteristics influenced by the treatments received and the setting in 
which those treatments occur.  When written as a formula, the relation between outcomes 
and contributing factors becomes “Outcomes = ƒ (baseline, patient clinical 
characteristics, patient demographic/psychosocial characteristics, treatment, setting)” 
(Kane, 2006, p. 9). 
Kane classified outcome measures as generic or condition-specific and suggested 
that outcomes under investigation should be selected based on a clear idea of what needs 
to be measured and why.  Pressure ulcers qualify as a generic outcome because their 
occurrence relates to numerous intrinsic and extrinsic factors (Nixon, 2001) and is 
associated with multiple health conditions.  Treatment and setting influences on patient 
outcomes can be categorized as nurse characteristics, such as educational level, attitude, 
and age (Aiken, Clarke, Cheung, Sloane, & Silber, 2003), and administratively mediated 
variables, such as nurse staffing levels, nurse skill mix, hospital structural characteristics, 
patient care environments, and equipment (Aiken, Clarke, Sloane, Lake, & Cheney, 
2008).   
Although environmental variables are increasingly recognized as important 
contributors to patient outcomes such as pressure ulcer development (Horn, Buerhaus, 
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Bergstrom & Smout, 2005; Seago, Williamson, & Atwood, 2006), this research focused 
on the effects of the external forces of compression, friction, and shear and those patient-
specific risk factors that comprise the tissue’s tolerance to the external forces.   
Theoretical constructs contributing to pressure ulcer development are compressive 
forces, shearing, and friction forces, and the tissues’ tolerance for those forces 
(Bergstrom, Braden, Laquzza, & Holman, 1987; Thompson, 2005).  For purposes of this 
research, pressure ulcer risk factors were categorized as either external (pressure, friction 
and shear) or patient-specific risk factors that affect the tissues’ ability to withstand the 
external forces. 
In summary, pressure ulcers are a localized area of damage to the skin and 
underlying structures caused by compressive forces, shearing and friction, or a 
combination thereof.  The skin and underlying tissues’ ability to tolerate varying degrees 
of these forces is a function of the structural integrity of the skin, the blood and lymph 
flow to the cutaneous tissues, and an intact central nervous system required to reduce the 
destructive effects of those forces.  Damage to the skin or underlying tissues results in an 
inflammatory immune response that ultimately contributes to localized ischemia and cell 
death, if the damaging element such as prolonged pressure, persists. 
Conceptual Models for Pressure Ulcer Development  
Prior to 2012, there were two conceptual models demonstrating the relationships 
between patient specific risk factors and the development of pressure ulcers.  They are 
the Braden and Bergstrom conceptual model (Figure 2.1), and the Defloor conceptual 
model (Figure 2.2).     
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Braden and Bergstrom conceptual model.  Braden and Bergstrom (1987) 
published the first conceptual model to explain the patient specific etiology of pressure 
ulcers (Figure 2.1).  Their model was the first to identify components that contributed to 
the tissues’ tolerance for pressure. 
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Figure 2. 1. Braden and Bergstrom’s Conceptual Schema Depicting Factors in the 
Etiology of Pressure Sores. 
 
(Braden and Bergstrom, 1987) 
 
 
Figure 2.1.  Braden and Bergstrom’s  Conceptual Schema Depicting Factors in the 
Etiology of Pressure Sores.  From “A Conceptual Schema for the Study of the Etiology of 
Pressure Sores” by B.J. Braden and N. Bergstrom, 1987, Journal of Rehabilitation 
Nursing, 12, p. 9. Reprinted with permission. 
 
 
The conceptual model proposed by Braden and Bergstrom (1987) identifies two 
critical determinants in the development of pressure ulcers: (1) intensity and duration of 
pressure, and (2) the tissues’ ability to tolerate pressure.  In the model, Braden and 
Bergstrom identified decreased activity, mobility, and sensory perception as those 
characteristics that influence the intensity and duration of compressive forces.  
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To explain the variability in the tissues’ tolerance for any given intensity and 
duration of compressive forces, Braden and Bergstrom (1987) drew heavily from the 
literature published on pressure ulcer incidence in patients with spinal cord injuries.  
Cross sectional, descriptive studies published in journals such as Archives of Physical 
Medicine and Rehabilitation and the Journal of Plastic and Reconstructive Surgery 
provided Braden and Bergstrom with the empirical evidence to include general and 
patient specific factors in their model.  Using the descriptive evidence in the literature, 
Braden and Bergstrom identified intrinsic and extrinsic factors known to affect skin 
integrity and included them in their construct for tissue tolerance.  Among them are 
friction and shearing forces, moisture, age, arteriolar pressure, and nutritional status.  
This model, now commonly known as the Braden model, served as the basis for the 
Braden Scale for Predicting Pressure Sore Risk© (Copyright by Barbara Braden & Nancy 
Bergstrom, 1988; Bergstrom, Braden, Laquzza, & Holman, 1987) discussed later in this 
chapter.  
Defloor Conceptual Model.  Defloor (1999) modified Braden and Bergstrom’s 
conceptual framework to include two specific components that affect tissue tolerance 
(Figure 2.2).  Rather than the intrinsic and extrinsic components of tissue tolerance 
identified by Braden and Bergstrom (1987), Defloor suggested that the overall concept of 
tissue tolerance is composed of unique factors that influence the tissue’s tolerance for 
pressure and its tolerance for alterations in oxygen supply and demand.  According to 
Defloor, the tissue’s tolerance for pressure is dependent on factors that help to distribute 
pressure.  Defloor defined pressure as the amount of force distributed over a surface area 
and reasoned that factors that increase surface area will decrease the force on any given 
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plane of the skin/pressure interface.  Tissue mass and factors that affect the skin’s ability 
to distribute pressure, such as amount and quality of collagen, are examples of factors 
that Defloor suggested influence the tissue’s tolerance for pressure and are conceptually 
similar to those identified by Braden and Bergstrom.  Defloor further modified Braden 
and Bergstrom’s conceptual model by adding the construct of tissue oxygenation as a 
determinate of tissue tolerance.  Tissue oxygenation status is a function of the supply and 
demand of the oxygen traveling to the skin and supporting connective tissues.  Defloor 
theorizes that mean arterial pressure, medications, and characteristics of the circulating 
hemoglobin will affect oxygen supply and waste removal of the involved tissues, thereby 
influencing the tissue’s tolerance for pressure.  
Braden, Bergstrom, and Defloor Conceptual Model Comparison 
Despite the multiple similarities in intrinsic, extrinsic, and determinants of 
intensity and duration of pressure, Defloor enriched Braden’s concept of tissue tolerance 
by describing factors that may contribute to either the structural or the physiologic 
components of tissue that affect its tolerance for pressure.  Although not mutually 
exclusive, the elements in Defloor’s tissue tolerance concept elaborate on characteristics 
commonly encountered in the clinical setting that are not explained in Braden’s 
conceptual model. 
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Figure 2. 2. Defloor’s Conceptual Scheme Depicting Risk Factors in the Etiology of 
Pressure Sores. 
 
(Defloor, 1999) 
 
 
Figure 2.2. Defloor’s  Conceptual Scheme. From “The Risk of Pressure Sores: A 
Conceptual Schema” by T. Defloor, 1999, Journal of Clinical Nursing, 8, p. 208.  
Reprinted with permission. 
 
 
For example, body build and tissue mass are characteristics that influence the 
development of pressure ulcers.  Several research studies support an inverse relationship 
between body mass index (BMI) and a patient’s tendency to develop a pressure ulcer.  
Fife et al. (2001), Kernozek, Wilder, Amundson, and Hummer (2002), Stinson, Porter-
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Armstrong, and Eakin, (2003), and Lindgren, Unosson, Krantz, and Ek (2005) all 
documented that patients with lower than normal body weights tend to develop pressure 
ulcers more frequently than those of normal weight or obese patients.  By including 
characteristics such as body weight, medications, and diseases known to affect oxygen 
demand and delivery, Defloor provided a more comprehensive approach to the study of 
the etiology of pressure ulcer development.  Table 2.1 compares the concepts in the 
Braden Bergstrom conceptual model with the Defloor conceptual model.  
 
Table 2. 1. Comparison of the Braden and Bergstrom and Defloor Conceptual Models 
a Adapted from “A conceptual schema for the study of the etiology of pressure sores,” by B. Braden and N. Bergstrom, 
1987, Rehabilitation Nursing, 12(1), 8-12, 16.   
b Adapted from “ The risk of pressure sores: A conceptual scheme,” by T. Defloor, 1999. 
Journal of Clinical Nursing, 8(2), 206-216. 
 
  
Conceptual 
Component 
Bradena Defloorb 
Mobility Affects intensity and duration 
of pressure 
 
Affects intensity and duration of pressure 
and shear  
Activity Affects intensity and duration 
of pressure 
 
Affects intensity and duration of pressure 
and shear 
Sensory 
Perception 
Affects intensity and duration 
of pressure 
 
Affects intensity and duration of pressure 
and shear 
Extrinsic 
Factors 
Affects tissue tolerance for 
pressure   
Includes moisture, friction and 
shear   
Affects tissue tolerance for pressure 
Includes moisture (maceration) and friction 
Adds support surface, medical/nursing 
interventions.  
 
Intrinsic 
Factors 
Affects tissue tolerance for 
pressure  
Includes nutrition, age, 
arteriolar pressure, and 
hypothetical factors (i.e., 
edema, stress, smoking and skin 
temperature)  
Affects tissue tolerance for pressure and 
oxygen   
Includes specific components of nutrition 
(tissue mass, protein, and vitamin C), stress, 
smoking, temperature, hydration status 
Adds medications that affect tissue integrity 
(i.e. corticosteroids) or blood pressure 
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Critical Analysis of the Relevant Literature 
   
State of Pressure Ulcer Risk Factor Science    
Knowledge progression and associated research questions described by Wood and 
Ross-Kerr (2006) suggests that subject knowledge progresses from descriptive, 
observational studies aimed at identifying important components of a phenomenon to 
understanding the relationships between those variables.  Once the relationships are well 
understood, the knowledge progresses to explaining cause and effect relationships 
between the variables, requiring an experimental research design (Wood & Ross-Kerr, 
2006).  The current literature about pressure ulcer risk factors suggests that the constructs 
of pressure and friction/shear are commonly accepted risk factors for pressure ulcer 
development.  A search of the PubMed database using the search terms “pressure ulcers” 
and “risk factors”, with the limits of all adult, humans, and English, but with no date 
restraints yielded 1054 articles published between 1975 and August 2012.  Of those, 206 
were cross sectional or cohort studies that described pressure ulcer risk factors in 585,729 
subjects in various settings.  Sixty-two were experimental treatment studies evaluating 
the efficacy of pressure reduction and redistribution devices in 10,168 subjects in various 
settings.  None of the experimental studies evaluated treatments aimed at improving 
tissue tolerance for pressure.  This finding suggests that the relationship between the 
magnitude and duration of pressure and pressure ulcers is understood well enough to 
warrant experimental research; however, the knowledge surrounding components of 
tissue tolerance is not advanced enough to warrant experimental intervention.  de Laat et 
al. (2006) assert that interventions for pressure ulcer preventions are predicated on 
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identifying salient risk factors for pressure ulcer development in specific patient 
populations.  As medical science evolves and patients with multiple comorbidities 
survive longer, the search for pressure ulcer risk factors segregates among various target 
populations, requiring additional study to identify salient pressure ulcer risk factors.  The 
literature is replete with studies designed to identify unique pressure ulcer risk factors in 
various patient populations.  The same literature search identified 39 studies evaluating 
pressure ulcer risk in spinal cord injury patients, 14 evaluating risk factors in patients 
with hip fractures, 13 for patients in the operating room, and 21 for critically ill patients. 
Despite the abundance of findings reported in the literature for specific patient 
populations, there is a demonstrated lack of any theoretical framework guiding the 
research efforts (de Laat et al., 2006).  Indeed, the only studies citing a theoretical 
framework were those evaluating the predictive ability of various risk assessment scales.  
The resulting findings describe a wide range of risk factors derived from author-
hypothesized risk factors and others identified by researchers through literature searches.  
According to Anthony et al. (2008), over 200 risk factors for pressure ulcer development 
are identified in the literature.  However, the ability to generalize these findings becomes 
increasingly limited as various target populations assume unique characteristics (Hulley, 
Newman, & Cummings, 2007).  Additionally there are measurement and definitional 
differences among the study variables reported in the literature (de Laat et al., 2006), 
contributing to the lack of generalizability of the risk factors identified.  Use of an 
accepted conceptual framework to guide risk factor study in the critically ill patient 
population will standardize the identification and measurement of variables, thereby 
26 
 
 
 
enhancing the generalizability of the findings to guide nursing interventions aimed at 
pressure ulcer prevention.               
Theoretical frameworks to guide risk factor study.  To evaluate the conceptual 
frameworks used to identify pressure ulcer risk factors for study, the search term 
“prospective” was added to the search limits described earlier.  “Prospective” was chosen 
because of the temporal association between prospective study designs and risk factor 
identification supporting causality.  That search returned 252 articles published between 
1982 and June 2012.  Of those, 175 were excluded because they were not relevant to 
pressure ulcer risk factors, were literature summaries, or evaluated pressure ulcer 
prevention or treatment interventions.  Of the 77 remaining, 32 evaluated risk factors that 
the authors identified from literature reviews or were included via expert opinion.  None 
of those 32 articles cited a theoretical framework guiding the research.  Fifteen of the 
articles evaluated the predictability of various pressure ulcer risk assessment scales by 
examining specificity and sensitivity results in prospective incident studies.  Braden and 
Bergstrom’s (1987) conceptual model provided the theoretical framework guiding risk 
factor identification in 30 of the studies.   
Study populations.  Study populations in the 77 articles evaluating pressure ulcer 
risk were widely distributed.  Table 2.2 provides a summary of the study populations 
evaluated relative to pressure ulcer risk factors. 
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Table 2. 2. Study Populations Included in Risk Factor Studies N = 77 
 
Study Population Number of Studies (%) 
Acute care setting 20 (26) 
 
Intensive care setting 17 (22) 
 
Hospitalized elderly or 
geriatric not confined to long 
term care 
 
15 (19) 
Spinal cord injury/neurologic 
impairment 
8 (10) 
 
Long term care 
 
7 (9) 
 
Operating rooms 
 
7 (9) 
 
Traumatized patients 
 
3 (4) 
 
 
Braden Risk Assessment Scale 
The predictive ability of the Braden Scale has been evaluated extensively in the 
literature (Pancorbo-Hidalgo, Garcia-Fernandez, Lopez-Medina, & Alvarez-Nieto, 2006), 
however its predictive ability in critically ill patient populations has not been widely 
evaluated.  The Braden Scale is derived from Braden and Bergstrom’s (1987) conceptual 
model.     
Validity of the Braden risk assessment scale.  Content and construct validity are 
important components that potentially affect the Braden risk assessment scale (RAS’) 
accuracy in predicting pressure ulcer development.  Content validity of an instrument 
depends on the extent to which a measurement tool adequately captures all aspects of a 
phenomenon that are relevant to the content under study (Mishel, 1989; Hulley, Martin, 
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& Cummings, 2007).  Construct validity refers to how well the tool in question adheres to 
a set of theoretical constructs believed to influence the outcome (Hulley, Martin, & 
Cummings, 2007).  Although there is expert consensus on the validity of the Braden RAS 
(Braden & Frantz, 2004), its predictive ability when used in various patient populations 
varies because the theoretical constructs of the tool are based on patients in long-term 
care facilities (Kottner, Dassen, & Tannen, 2009).  Because the etiology of pressure ulcer 
development is multifactorial (Nixon, 2001) and pressure ulcer etiology varies among 
different patient populations (DeLaat et al., 2006), the content validity of the Braden 
Scale may affect the accuracy of the tool in predicting pressure ulcer incidence in 
disparate populations. 
Reliability of the Braden risk assessment scale.  The reliability of an instrument 
refers to its consistency in assessing a phenomenon over time and is primarily dependent 
on the degree of random error that is experienced during measurement (Mishel, 1989).  
Reliability of a measure is a prerequisite for validity (Kottner & Dassen, 2010).  To 
determine the amount of reliability testing on the Braden RAS, a literature search was 
conducted in PubMed using the search terms Braden scale/score and reliability with the 
limits of humans, English, core clinical journals, nursing journals, and all adult.  The 
search returned 21 results.  An additional search using identical limits and the search 
terms pressure ulcer risk scales and reliability returned 19 results, 11 of which were 
duplicates.  Of the remaining 29, one was an incidence study, three were unrelated 
articles, and six evaluated the interrater reliability of a modified version of the Braden 
Scale.  Three were designed as pre-test post-test evaluations of interrater agreement after 
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a web based educational initiative.  Additionally, 12 were meta-analysis or review 
articles.       
The remaining four articles reviewed interrater reliability findings of the Braden 
RAS in a multi-center, long-term care, home care, and intensive care unit (ICU) 
environment.  In their prospective study to evaluate the interrater reliability of the Braden 
RAS in various acute care wards in multiple settings, Halfens, Van Achterberg, and Bal 
(2000) evaluated the Braden scores of 320 patients collected by staff nurses on 11 acute 
care wards.  Various nurses rated each patient five times during the course of the study.  
The interrater reliability for the Braden subscales varied from 0.71 to 0.86 (Cohen’s 
kappa) with the moisture subscale demonstrating the lowest interrater reliability at 0.54 
(Halfens et al., 2000). 
In a cross-sectional study to evaluate the interrater reliability among nurses in two 
German long-term care facilities, Kottner and Dassen (2008) evaluated data on 152 long-
term care residents.  The first Braden score was obtained during a routine pressure ulcer 
prevalence study then repeated scores were obtained by staff nurses up to three days later.  
Kottner and Dassen (2008) reported intraclass correlation coefficients (ICC) on 
individual subscore items from 0.06, 95% CI [-0.31, 0.48] to 0.97, 95% CI [0.93,  0.99] 
with the ICC being lowest for the sensory perception subscale (ICC range 0.16 to 0.62) 
and nutrition subscale (ICC range 0.17 to 0.89).  Overall Braden scores demonstrated a 
higher interrater agreement ranging from an ICC of 0.73, 95% CI [0.26, 0.910] to 0.95, 
95% CI [0.87, 0.98].  Kottner, Halfens, and Dassen (2009) reported similar findings in a 
cross sectional study designed to evaluate the interrater reliability of nurses using the 
Braden RAS in a home care environment.  Data were collected during pressure ulcer 
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prevalence surveys of 691 home care patients during 2007 and 2008.  Patients were 
scored twice; once by the home health nurse and a second time by a certified wound 
nurse during each data collection period.  Range values for the ICC of the Braden 
subscales is not presented for either year; however, the overall summative Braden 
summative scores from 2007 demonstrated an ICC of 0.90, 95% CI [0.88, 0.92] and an 
ICC of 0.88, 95% CI [0.85, 0.91] in 2008.  
One study evaluated the interrater reliability of the Braden RAS in two ICU 
settings (Kottner & Dassen, 2010).  Sequential cross-sectional studies were conducted in 
two ICUs of a large university hospital in Germany between January and April of 2009.  
Three nurses were randomly selected from each ICU to do Braden assessments on a total 
of 45 patients.  Range values for the ICC of the Braden subscales was not presented for 
the study; however, the overall summative Braden summative scores demonstrated an 
ICC of 0.72, 95% CI [0.52, 0.87] for one ICU and 0.84, 95% CI [0.72, 0.92] for the 
second ICU (Kottner & Dassen, 2010).  Based on the 0.71 to 0.86 range of Cohen’s 
Kappa coefficients from the Halfens et al. (2000) study, the reliability of the Braden RAS 
is considered good to very good (Newman, Browner, Cummings, & Hulley, 2007).  
Because ICC agreement levels are considered much like the Kappa agreement levels, 
(Reliability Analysis, n.d.), the 0.72 to 0.95 ICC range of Braden summative scores 
reported by Kottner and Dassen (2008), Kottner, Halfens, and Dassen (2009), and 
Kottner and  Dassen (2010), indicate a similar ranking of good to very good. 
Specificity and sensitivity of the Braden risk assessment scale.  The predictive 
ability of the Braden Scale has been evaluated extensively in the literature (Pancorbo-
Hildalgo, et al., 2006).  As outlined in Table 2.3, most of the specificity and sensitivity 
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studies of the Braden RAS were conducted in long term and acute care settings.  In three 
studies evaluating optimum scores for ICU patients, cutoff scores of 16 or less yielded a 
sensitivity range from 97% to 66.6% with associated specificities ranging from 63.9% to 
22%.  In two of the three studies with larger sample sizes specificities were lower 
(<30%).  The same cutoff score had associated positive predictive values (PPVs) ranging 
from 15.3% to 60.6%.  The results of these studies indicate that a Braden Scale score of 
16 or less adequately identifies patients at risk that do develop a pressure ulcer, but the 
score is not specific enough to adequately screen out patients that do not develop a 
pressure ulcer.    
These values indicate that ICU clinicians may lack an accurate tool that accounts 
for unique pressure ulcer risk factors associated with critically ill patients, resulting in a 
diffuse application of prevention efforts to patients incorrectly identified to be at risk.  
Multiple studies of the sensitivity and specificity of various RAS, including the Braden 
Scale, indicate that none of them adequately identifies pressure ulcer risk across various 
patient populations (Anthony, et al., 2008), raising doubt about the efficacy of any one 
tool to guide treatment decisions in nursing homes, in acute care facilities, and ICUs. 
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Table 2. 3. Summary of Studies Evaluating the Specificity, Sensitivity, Positive, and Negative Predictive Values of the Braden 
Pressure Ulcer Risk Scale in Various Settings 
 
Author Cutoff score Setting Sample size Sensitivity Specificity Positive 
predictive value 
Negative 
predictive value 
Barnes and 
Payton (1993) 
≤16 Acute Care 361 72.7 90.6 33.3 98.1 
Bergstrom, 
Braden et al. 
(1987) 
≤ 16 Acute Care 100 100 90.2 43.8 100 
Bergstrom, 
Demuth et al. 
(1987) 
≤ 16 ICU 60 83.3 63.9 60.6 85.2 
Bergstrom et al. 
(1998) 
≤19 Combined 843 51.9 77.8 25.6 91.7 
Braden and 
Bergstrom 
(1994) 
≤ 18 Long term care 123 78.6 74.3 53.7 90.2 
Capobianco and 
McDonald 
(1996) 
≤16 Acute Care 50 71.4 83.3 62.5 88.2 
Goodridge et al. 
(1998) 
≤19 Long term care 330 50.0 52.3 10.1 90.7 
Hagisawa and 
Barbenel (1999) 
≤ 16 Acute Care 275 38.9 100 100 91.6 
Halfens et al. 
(2000) 
≤20 Acute Care 320 61.7 79.9 34.5 92.4 
Langemo et al. 
(1991)  
≤ 16 Acute Care 1244 54.5 93.7 60.0 92.2 
Langemo et al.  
(1991)  
≤ 18 Long term care 74 57.1 61.1 36.4 78.6 
33 
 
 
 
Author Cutoff score Setting Sample size Sensitivity Specificity Positive 
predictive value 
Negative 
predictive value 
Lewicki et al. 
(2000) 
≤14 ICU (cardiac 
surgery) 
337 66.6 29.6 4.5 94.7 
Lyder et al. 
(1999) 
≤16 Acute Care 84 77.0 50.0 77.0 50.0 
Pang and Wong 
(1998) 
≤ 18 Long term care  
 
138 90.5 62.4 37.3 96.4 
Salvadalena et 
al. (1992) 
≤ 18 Acute Care 100 60.0 54.4 25.0 84.3 
Schoonhoven et 
al. (2002) 
≤18 Acute and 
Geriatric 
1229   43.5 67.8 8.1 94.9 
Seongsook et al. 
(2004) 
≤ 16 ICU 125 97.0 26.0 37.3 95.0 
VandenBosch et 
al. (1996) 
≤17 Acute Care 103 58.6 40.5 27.9 71.4 
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Augmented Braden and Bergstrom Model 
To provide a conceptual framework that incorporates pressure ulcer risk factors 
specific to critically ill patients, the focus of this research, Benoit and Mion (2012) 
augmented Braden and Bergstrom’s (1987) conceptual model with risk factors identified 
in well-designed prospective studies.  Multivariate findings from studies having high or 
medium design quality as defined by the National Institute of Health and Clinical 
Excellence (NICE, 2005) standards were conceptually grouped and subsequently  
integrated into Braden and Bergstrom’s (1987) conceptual model, retaining their original 
constructs and augmenting their concept of intrinsic factors for tissue tolerance.  Thirty-
seven non-unique risk factor variables for pressure ulcer development were identified as 
statistically significant (p ≤.05) at the multivariate level in eight studies identified as 
higher quality using the NICE criteria (Benoit & Mion, 2012).  These were condensed 
into 18 unique risk factors that augment Braden and Bergstrom’s (1987) construct of 
intrinsic Tissue Tolerance. 
The additional risk factors were categorized as affecting metabolic supply and 
demand, pressure distribution capacity, and threats to skin integrity.  Metabolic supply 
and demand included perfusion and oxygenation parameters, Braden’s nutrition subscale, 
surgical treatment, severity of illness, and other physiologic alterations.  Pressure 
distribution capacity included gender, body habitus, and age.  Threats to skin integrity 
included preexisting pressure ulcers, dry or thin skin, edema, skin problems in pressure 
prone areas, and chemical exposure, such as with fecal incontinence.  The resulting 
conceptual model (Figure 2.3) indicates that Tissue Tolerance is composed of Braden et 
al.’s (1987) extrinsic concepts of Moisture and Friction/Shear and that the augmented 
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intrinsic factor concept includes Metabolic Supply and Demand, Pressure Distribution 
Capacity, and Threats to Skin Integrity.  Additionally, Tissue Tolerance assumes a 
moderating effect between Pressure and Pressure Ulcer.  The specific risk factors 
identified by Benoit and Mion (2012) are identified in Table 2.4. 
 
 
Figure 2. 3. Conceptual Model for Pressure Ulcer Etiology in Critically Ill Patients 
 
(Benoit & Mion, 2012) 
 
 
Figure 2.3.  Conceptual model for pressure ulcer etiology in critically ill patients. Metabolic supply 
includes the concepts of perfusion/oxygenation, and the Braden Scale’s nutrition subscale. Metabolic 
demand includes surgical treatment, severity of illness, and physiologic alterations. Pressure distribution 
capacity includes gender, body habitus, and age. Threats to skin integrity include preexisting pressure 
ulcer, dry/thin skin, edema, skin problems in pressure prone areas, and chemical exposure such 
as with fecal incontinence. Items identified as ‘‘Braden’’ are risk factors from The Braden Scale for 
Predicting Pressure Sore Risk_ (Copyright by Braden & Bergstrom, 1988).  
From “Risk Factors for Pressure Ulcer Development in Critically Ill Patients: A Conceptual Model to 
Guide Research,” by R. Benoit and L. Mion, 2012. Research in Nursing & Health, 35(4), 340-362. Used 
with permission. 
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Table 2. 4. Specific Risk Factors Used to Augment Braden and Bergstrom’s Concept of 
Intrinsic Tissue Tolerance 
 
Concept Concept Components Risk Factor Measure 
Metabolic Supply 
Perfusion/Oxygenation 
• Type/amount of IV vasopressor 
use 
• Vascular disease of any type 
except coronary artery and 
cerebral vascular disease  
• Hemoglobin/hematocrit 
• Nicotine use 
1.  
Nutrition • Braden Nutrition subscale score  
2.  
Metabolic Demand 
Surgical Treatment • Required surgery during hospital stay 
3.  
Severity of Illness 
• APACHE II Score on 
admission  
• NYHA** score 
• Hospital LOS 
• Ventilator use 
• ASA* score 
Physiologic Alterations 
• Requires dialysis of any type 
during hospital stay 
• Body temperature  
• Steroid/Anti-Inflammatory use 
 
Pressure Distribution Capacity 
Gender • Gender 
Body Habitus • BMI (weight indexed with 
height) 
Age • Age  
Threats to Skin Integrity 
Existing and potential threats 
to skin integrity not captured 
in Braden Moisture subscale 
score 
 
• Skin problems in areas at risk 
for pressure ulcer development 
(sacrum, elbows, heels) 
• Current Stage II or worse 
pressure ulcer 
• General skin problems (thin, 
edema) 
• Chemical exposure (e.g. fecal 
incontinence) 
 
*American Society of Anesthesiologists;   **New York Heart Association functional classification  
Adapted from “Risk Factors for Pressure Ulcer Development in Critically Ill Patients: A Conceptual Model to Guide 
Research,” by R. Benoit and L. Mion, 2012. Research in Nursing & Health, 35(4), 340-362. 
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Braden and Bergstrom’s modified conceptual framework served as the theoretical 
framework for this study.  Risk factor measures were selected from each of the 
conceptual components based on their feasibility of study in the sample population.  
Their measures and operational definitions are included below.  
 
Definition of Terms 
 
Primary Outcome Measure 
 The definition for pressure ulcer most commonly cited in the US is from the 
National Pressure Ulcer Advisory Panel (NPUAP).  According to the NPUAP, a pressure 
ulcer is a “localized injury to the skin and/or underlying tissue usually over a bony 
prominence, as a result of pressure, or pressure in combination with shear and/or friction.  
A number of contributing or confounding factors are also associated with pressure ulcers; 
the significance of these factors is yet to be elucidated” (NPUAP, 2007, Updated staging 
systems, ¶ 2).  The NPUAP also provides the most commonly used pressure ulcer 
severity or staging system used in the US (NPUAP, 2007).  In 2006, the NPUAP updated 
its staging system to include six categories of pressure ulcer stages that includes stage I, 
stage II, stage III, stage IV, unstageable, and suspected deep tissue injury (SDTI).  
Because of its widely accepted use in the US, the NPUAP definitions from 2006 were 
used to describe pressure ulcer severity in this study (NPUAP, 2007).  The definitions for 
pressure ulcer stages are: 
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• Stage I:  Intact skin with non-blanchable redness of a localized area 
usually over a bony prominence.  Darkly pigmented skin may not have 
visible blanching; its color may differ from the surrounding area. 
• Stage II: Partial thickness loss of dermis presenting as a shallow open 
ulcer with a red pink wound bed, without slough.  This stage may also 
present as an intact or open/ruptured serum-filled blister. 
• Stage III: Full thickness tissue loss.  Subcutaneous fat may be visible but 
bone, tendon or muscle is not exposed.  Slough may be present but does 
not obscure the depth of tissue loss.  This stage may include undermining 
and tunneling. 
• Stage IV: Full thickness tissue loss with exposed bone, tendon or muscle.  
Slough or eschar may be present on some parts of the wound bed.  This 
stage often includes undermining and tunneling. 
• Unstageable: Full thickness tissue loss in which the base of the ulcer is 
covered by slough (yellow, tan, gray, green or brown) and/or eschar (tan, 
brown or black) in the wound bed. 
• Suspected Deep Tissue Injury (SDTI): Purple or maroon localized area of 
discolored intact skin or blood-filled blister due to damage of underlying 
soft tissue from pressure and/or shear.  The area may be preceded by tissue 
that is painful, firm, mushy, boggy, warmer, or cooler as compared to 
adjacent tissue.  (NPUAP, 2007, updated staging systems).   
In case subjects with multiple pressure ulcers, the most severe pressure ulcer stage 
was used.  
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Demographic and Pre-hospital Admission Variables 
 Demographic and pre-hospital admission variables were obtained from the 
nursing admission history and/or the admission history and physical examination.  They  
included: 
• Age defined in years.  Age was recorded as a continuous variable.   
•  Pre-existing skin disease was defined as the presence of any diagnosed skin 
disease or alteration in skin integrity including current or past history of pressure 
ulcers, edema, jaundice, or skin described as fragile and or thin.  Pre-existing skin 
disease was recorded as a dichotomous variable.   
• Diabetes was defined by diagnosis of the disease as a past medical diagnosis on 
admission to the hospital and included Type I and Type II.  Diabetes diagnosis 
was recorded as a dichotomous variable.   
• Body mass index (BMI) was defined as the subject’s admission body weight 
divided by the subject’s height squared.  BMI was recorded as a continuous 
variable.   
• Corticosteroid use was defined as any use of oral, topical, or IV corticosteroid use 
within two weeks of the hospital admission.  Preadmission corticosteroid use was 
recorded as a dichotomous variable.   
• Nicotine use was defined as the use of any products containing nicotine within 
one year prior to the current hospital admission.  Nicotine use was recorded as a 
dichotomous variable. 
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Post-Admission Clinical Study Variables 
 Post-admission study variables were obtained from the subject’s electronic 
medical records (EMR).  They included: 
• Ventilator use: The continuous or discontinuous presence of a ventilator 
delivering respiratory support on any mode via tracheal or endotracheal tube 
within 48 hours of study enrollment.  Ventilator use was recorded as a 
dichotomous variable.  
• The lowest subscale score of the Braden RAS (Braden & Bergstrom, 1987) within 
a 24 and 48-hour period prior to study enrollment.  A complete list of the Braden 
subscales and their weighted definitions are presented in Table 2.5.  
o Moisture: degree of skin exposure to moisture.  Ranked as an ordinal 
variable from least to greatest level of skin exposure on a 4-point scale.  
o  Friction/Shear: no overall summary definition given.  Ranked as an 
ordinal variable from least to greatest level of severity on a 3-point scale. 
o Nutrition: usual food intake pattern.  Ranked as an ordinal variable from 
least to greatest level of intake on a 4-point scale. 
o Sensory/Perception: ability to respond meaningfully to pressure related 
discomfort.  Ranked as an ordinal variable from least to greatest level of 
ability on a 4-point scale. 
o Mobility: ability to change and control body position.  Ranked as an 
ordinal variable from least to greatest level of mobility on a 4-point scale. 
o Activity: degree of physical activity.  Ranked as an ordinal variable from 
least to greatest level of activity on a 4-point scale. 
41 
 
 
 
• Serum albumin:  Primary protein found in blood plasma (Seeley et al., 2006).  
Serum albumin was used as proxy measure for protein stores.  The most recent 
value obtained while the subject was in an ICU prior to study enrollment was 
used.  Normal ranges are 3.5 – 5.0 grams per deciliter (g/dl) per VUH laboratory 
standards.  Serum albumin was recorded as continuous level data.  
• Pre-albumin: Metabolic precursor to serum albumin.  Pre-albumin was used as 
proxy for protein stores.  The most recent value obtained while the subject was in 
an ICU prior to study enrollment was used.  Normal ranges are 18.0 – 45.0 mg/dl 
per VUH laboratory standards.  Pre-albumin was recorded as continuous level 
data.  
• Total lymphocyte count: The total number of lymphocyte types detected in a 
microliter of blood.  Total lymphocyte count was used as proxy for protein stores.  
The most recent value obtained while the subject was in an ICU prior to study 
enrollment was used.  Normal ranges are 1.1 – 3.5 thousand per microliter of 
blood.  Total lymphocyte counts were recorded as continuous level data.  
• Total Protein: A calculated study variable consisting of categorical serum 
albumin, pre-albumin and total lymphocyte count.  Each of these variables was 
separately categorized as high, medium or low, depending on the specified 
normal ranges included in their definitions.  In subjects that had a serum albumin 
reported, that categorical rating was used as the overall Total Protein category 
rating.  Serum albumin was used as the default rating because of its prevalence in 
the nutritional literature as the gold standard proxy measurement for protein 
reserve (Cereda, Zagami, Vanotti, Piffer, & Pedrolli, 2008; Jeejeebhoy, 2004). In 
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subjects that did not have a reported serum albumin, the lowest categorical value 
of pre-albumin or total lymphocyte count was used.  
• Hematocrit:  Percentage of red blood cells found in whole blood.  Hematocrits 
reported 24 and 48 hours prior to study enrollment were used.  Normal ranges are 
36 -43% for females and 41-49% for males per VUH laboratory standards.  
Hematocrit was recorded as continuous level data.  
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Table 2. 5. Braden Sub-Scale Definitions 
 
Risk Factor Variable Scoring Criteria 
SENSORY PERCEPTION 
ability to respond 
meaningfully 
to pressure-related 
discomfort 
 
1. Completely Limited 
Unresponsive (does not moan, 
flinch, or grasp) to painful 
stimuli, due to diminished level 
of consciousness or sedation. 
OR 
limited ability to feel 
pain over most of body 
 
2. Very Limited 
Responds only to painful 
stimuli. Cannot communicate 
discomfort except by moaning 
or restlessness 
OR 
has a sensory impairment 
which 
limits the ability to feel pain or 
discomfort over ½ of body. 
 
3. Slightly Limited 
Responds to verbal commands, 
but cannot always communicate 
discomfort or the need to be 
turned. 
OR 
has some sensory impairment 
which limits ability to feel pain 
or discomfort in 1 or 2 
extremities. 
 
4. No Impairment 
Responds to verbal 
commands. Has no 
sensory deficit which would 
limit ability to feel or voice 
pain or discomfort. 
 
MOISTURE 
degree to which skin is 
exposed to moisture 
 
1. Constantly Moist 
Skin is kept moist almost 
constantly by perspiration, 
urine, 
etc. Dampness is detected every 
time patient is moved or 
turned. 
 
2. Very Moist 
Skin is often, but not always 
moist. Linen must be changed 
at least 
once a shift. 
 
3. Occasionally Moist 
Skin is occasionally moist, 
requiring an extra linen change 
approximately once a day. 
 
4. Rarely Moist 
Skin is usually dry, linen 
only requires changing at 
routine intervals. 
 
ACTIVITY 
degree of physical activity 
 
1. Bedfast 
Confined to bed. 
 
2. Chairfast 
Ability to walk severely 
limited or non-existent. Cannot 
bear own 
weight and/or must be assisted 
into chair or wheelchair. 
 
3. Walks Occasionally 
Walks occasionally during day, 
but for very short distances, 
with or 
without assistance. Spends 
majority of each shift in bed or 
chair 
 
4. Walks Frequently 
Walks outside room at least 
twice a day and inside room at 
least once every two hours 
during waking hours 
 
MOBILITY 
ability to change and control 
body position 
 
1. Completely Immobile 
Does not make even slight 
changes in body or extremity 
position without assistance 
2. Very Limited 
Makes occasional slight 
changes in body or extremity 
position but 
unable to make frequent or 
significant changes 
independently 
3. Slightly Limited 
Makes frequent though slight 
changes in body or extremity 
position independently. 
 
4. No Limitation 
Makes major and frequent 
changes in position without 
assistance. 
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Risk Factor Variable Scoring Criteria 
NUTRITION 
usual food intake pattern 
 
1. Very Poor 
Never eats a complete meal.  
Rarely eats more than a of any 
food offered.  Eats 2 servings or 
less of protein (meat or dairy 
products) per day.  Takes fluids 
poorly. Does not take a liquid 
dietary supplement 
OR 
is NPO and/or maintained on 
clear liquids or IV=s for more 
than 5 days. 
2. Probably Inadequate 
Rarely eats a complete meal 
and generally eats only about 2 
of any 
food offered.  Protein intake 
includes only 3 servings of 
meat or dairy products per day.  
Occasionally will take a dietary 
supplement. 
OR 
receives less than optimum 
amount 
of liquid diet or tube feeding 
 
3. Adequate 
Eats over half of most meals.  
Eats a total of 4 servings of 
protein 
(meat, dairy products per day.  
Occasionally will refuse a meal, 
but will usually take a 
supplement when 
offered 
OR 
is on a tube feeding or TPN 
regimen which probably meets 
most of nutritional needs 
 
 
4. Excellent 
Eats most of every meal. 
Never refuses a meal. 
Usually eats a total of 4 or 
more servings of meat and 
dairy products. 
Occasionally eats between 
meals. Does not require 
supplementation. 
 
 
 
FRICTION & SHEAR 
(no definition given) 
 
1. Problem 
Requires moderate to maximum 
assistance in moving. Complete 
lifting without sliding against 
sheets is impossible. Frequently 
slides down in bed or chair, 
requiring frequent repositioning 
with maximum assistance. 
Spasticity, contractures or 
agitation leads to almost 
constant friction 
 
2. Potential Problem 
Moves feebly or requires 
minimum assistance. During a 
move skin 
probably slides to some extent 
against sheets, chair, restraints 
or 
other devices. Maintains 
relatively good position in 
chair or bed most 
of the time but occasionally 
slides 
down. 
 
3. No Apparent Problem 
Moves in bed and in chair 
independently and has sufficient 
muscle strength to lift up 
completely during move. 
Maintains good position in bed 
or chair. 
 
N A  
Braden Scale for Predicting Pressure Sore Risk© (Copyright by Braden & Bergstrom, 1988).
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• Corticosteroid use:  The total dose of each corticosteroid administered during the 
current hospital stay for up to two weeks prior to enrollment.  Corticosteroids that 
were included for analysis in this study are the short to medium acting 
corticosteroids.  They were 
o Hydrocortisone; 
o Prednisolone; 
o Methylprednisolone; and 
o Prednisone. 
Corticosteroid dosage was recorded as continuous level data for dosages 
administered during the hospital stay.  
• Mean arterial pressure (MAP): An expression of the geometric mean for arterial 
pressures created during the systolic and diastolic phases of the cardiac cycle.  
Under normal conditions when the heart rate is not accelerated and the central 
venous pressure is at or near zero, the mathematic equation where P is pressure is 
expressed as  
MAP = Pdias + 1/3 (Psys – Pdias) 
Because the amount of time the heart spends in diastole is shorter when the heart 
rate accelerates, the relationships between systole and diastole change and are calculated 
more accurately by the cardiac monitor.  The most accurate calculations rely on an 
electronic analysis of the arterial waveform obtained from an invasive arterial line 
(Cardiovascular Physiologic Concepts, n.d.).  Normal MAP is 70-105 mmHg.  MAP was 
recorded as continuous level data.  In situations where MAP was recorded from an 
invasive arterial pressure monitoring line and a blood pressure cuff, the value from the 
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arterial pressure was used.  The lowest documented MAP during the 24 and 48-hour 
period prior to pressure ulcer development was used.  
• Oxygen saturation of hemoglobin: Percentage of the number of circulating 
hemoglobin oxygen binding sites saturated with oxygen (Cardiovascular 
Physiologic Concepts, n.d.).  Values were obtained using an externally 
placed pulse oximeter, usually located on the fingertip or forehead that 
provided a continuous read out of oxygen saturation values.  Normal 
ranges are 95% – 100%.  Oxygen saturation of hemoglobin was recorded 
as continuous level data.  The lowest documented oxygen saturation 
during the 24 and 48-hour period prior to pressure ulcer development was 
used. 
• Vasopressors:  Pharmacologic agents that produce an increase in the 
smooth muscle tone of the vascular system walls by increasing the level of 
intracellular calcium in vascular smooth muscle (Forrest, n.d.).  Table 2.6 
provides an overview of the physiologic effects of each of the 
vasopressors included.  They were: 
o Norepinephrine; 
o Epinephrine; 
o Dobutamine; 
o Milrinone; 
o Midodrine; and 
o Vasopressin. 
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With the exception of Vasopressin, each vasopressor was calculated in total 
micrograms/kg (μg/kg) each day for 24 and 48 hours prior to study enrollment.  
Vasopressin was calculated as total units each day for 24 and 48 hours prior to study 
enrollment.  Vasopressor doses were recorded as continuous level data. 
• Prior vasopressor use:  The use of any additional vasopressor prior to study 
enrollment. Vasopressors in use at the time of study enrollment were excluded.  
Prior vasopressor use was recorded as dichotomous data.   
• Restraint Use: The continuous or discontinuous use of wrist restraints at any time 
during the 24 and 48 hours prior to study enrollment.  Restraint use was recorded 
as dichotomous level data. 
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Table 2. 6. Overview of the Physiologic Effects of Selected Vasopressors 
 
Vasopressor Half-life and 
excretion 
Effect on skin blood flow Comments  
Dobutamine 2 min – renal 
Primarily a beta 1 agonist 
with minimal effect on 
peripheral vascular 
constriction 
 
 
Epinephrine 2 min – renal 
Non-selective adrenergic 
agonist 
Alpha receptor stimulation 
produces pronounced 
vasoconstriction 
  
Cutaneous 
vasoconstriction leads 
to rise in temperature 
and metabolic activity  
Midodrine 25 min – unclear 
Alpha adrenergic agonist 
Alpha receptor stimulation 
produces pronounced 
vasoconstriction 
  
 
Milrinone 2.4 hours – renal 
Phosphodiesterase 
inhibitor 
Produces vasodilation and 
has positive inotropic 
effects 
 
 
Norepinephrine 
Termination of 
effects related to 
degradation to 
metabolites and 
presynaptic uptake 
 
Less potent than 
epinephrine at alpha 
receptor sites 
 
Vasopressin 10-20 min-liver, renal 
Directly stimulates smooth 
muscle V1 receptors but 
effects on skin blood flow 
uncertain  
 
Adapted from “Vasopressors” by P. Forrest (n.d.).  
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Summary 
 
As medical science progresses and patients are living longer with multiple 
comorbidities, pressure ulcer risk becomes stratified among various patient populations, 
requiring additional research to completely understand pressure ulcer etiology in any 
given patient population.  Pressure ulcer risk factor studies are well documented in the 
literature; however, the results have limited generalizability because of methodological 
and definitional inconsistencies.  Additionally, a conceptual framework does not guide 
the majority of studies, producing a myriad of findings that do not substantially 
contribute to evidence-based prevention interventions by clinicians.  Prior to 2012, 
Braden and Bergstrom (1987) and Defloor (1999) provided the only conceptual models to 
guide risk factor research.  Because neither was specifically designed for evaluating risk 
factors in the critically ill patient, the focus population of interest, Braden and 
Bergstrom’s conceptual model was augmented to identify pressure ulcer risk factors that 
disproportionately contributed to pressure ulcer incidence in this patient population.  The 
augmented model (Benoit & Mion, 2012) served as the conceptual model for this study.  
The following chapter describes the methodology employed to meet the aims of this 
study.
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CHAPTER III 
 
STUDY METHODOLOGY 
 
Overview 
This chapter presents the methodology used to investigate the significance of 
patient-specific risk factors identified in the conceptual model for pressure ulcer 
development in critically ill subjects (Figure 2.3).  The methodology is presented in the 
order of:  
1. Design of the research study; 
2. Assumptions surrounding the research design; 
3. Description of the research setting; 
4. Sample and sampling plan; 
5. Data collection methods; and 
6. Data analysis. 
 
Research Design 
This study utilized a prospective, case-control design.  This design is best suited 
for evaluating the effect of risk factors on the development of a relatively rare outcome, 
pressure ulcer development (Cummings, Newman, & Hulley, 2007). 
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Assumptions Surrounding the Research Design 
 
Theoretical Assumption 
Braden and Bergstrom’s (1987) augmented conceptual model (Figure 2.3) served 
as the theoretical basis for this study.  By enhancing the explanatory model, the assumed 
criterion-related validity of the model improved, thereby theoretically enhancing its 
predictive ability (Cummings, et al., 2007).  The predictive ability of the associated 
Braden Scale score, discussed in Chapter 2, could be improved by enhancing the 
criterion-related validity for critically ill patients.  This study did not intend to test a 
modified Braden Scale; its goal was to validate the enhanced model.  Subsequent 
research using the risk factors validated in this study to evaluate the Braden Scale score’s 
predictive ability in critically ill patients will support or refute the assumptions made 
about the criterion-related validity of the enhanced model.    
 
Methodological Assumptions 
Literature describing the timeframes for pressure ulcer onset is scant leading to 
assumptions about when to measure both dependent and the independent variables in this 
study.  Because time-to-event of pressure ulcer genesis is not fully understood, and 
because the temporal relationships between tissue insult and pressure ulcer development 
probably vary with each individual (Nixon, 2001; Pronovost, Goeschel, & Wachter, 
2008), the timing of data collection in this study is based on clinical judgment and 
consensus of the dissertation committee.  Gefen (2008) integrated evidence from various 
studies and concluded that pressure ulcers may form within one to six hours of insult.  
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However, in a multisite study of pressure ulcer incidence, Bergstrom et al. (1998) 
observed some new pressure ulcer onset at 21 days; although it is unclear if the authors 
were able to relate tissue insult to the new pressure ulcer occurrences. 
Annual admissions to the study ICUs, based on fiscal year (FY) 2009 data, were 
7,654 adult patients.  Of those, 5,514 (72%) had a length of stay (LOS) greater than 48 
hours in the ICU.  To minimize sample bias incurred by including case patients with a 
non-ICU acquired pressure ulcer, and to maximize case enrollment, any pressure ulcer 
occurring after 48 hours of admission to an ICU was considered ICU acquired for 
purposes of this study.  This timeframe provided some assurance that tissue insults 
resulting in pressure ulcers occurring before the ICU admission would be evident within 
48 hours and not erroneously considered ICU acquired.   
Similarly, there is no evidence in the literature suggesting optimal timeframes to 
capture cause and effect of vasopressor use, physiologic parameters, and resulting 
pressure ulcer incidence.  Clinical judgment and consensus of the dissertation committee 
suggested that these data be collected retrospectively at 48 and 24-hour increments prior 
to pressure ulcer development.  
 If vasopressor use and alterations in the physiologic parameters identified for 
study occurred prior to the 48-hour cutoff disproportionately contributed to pressure ulcer 
incidence, their effects were not recognized with the timeframe constraints in this study, 
contributing to a Type I error in the interpretation of the findings.  To account for this 
possibility, vasopressor use at any time during the ICU stay prior to pressure ulcer 
development was captured as a dichotomous variable.  Further research using varying 
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timeframes for physiologic data capture will yield better estimates about the temporal 
relationships of these variables to pressure ulcer incidence.  
 
Description of the Research Setting 
The study took place in five adult intensive care units (ICUs) at VUH in 
Nashville, TN.  VUH is an 847-bed teaching hospital that operates the only Level 1 
Trauma Center, and the only Level 3 Burn Unit in Middle Tennessee.  The five ICUs are 
Cardiovascular ICU (CVICU, 27 beds), Medical ICU (MICU, 34 beds), a combined 
neuro-medicine and neuro-surgical ICU (NICU, 34 beds), Surgical ICU (SICU, 34 beds), 
and Trauma ICU (TICU, 14 beds).  
  
Study Concepts and Variables 
The conceptual model used as the theoretical basis for this study (Figure 2.3) 
identifies two constructs containing eight concepts that can be measured by 23 variables 
(Table 3.1).  The three Braden Scale’s sub scores of Mobility, Activity, and Sensory 
Perception exclusively measure the construct of Pressure.  Likewise, the Braden Scale’s 
sub scores of Moisture and Friction/Shear exclusively measure extrinsic factors related to 
Tissue Tolerance.  Intrinsic factors related to Metabolic Supply and Demand contain 10 
risk factors.  Of those, the presence of surgical procedures was not captured because of 
the mixed ICU population used in this study.  Ventilator use, a proxy measure for 
severity of illness, was used to match cases and controls, so was not evaluated as an 
independent risk factor.  Body temperature and the use of hemodialysis were not 
captured. 
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Table 3. 1. Constructs, Concepts, and Associated Risk Factors for the Development of 
Pressure Ulcers in Critically Ill Patients 
 
Pressure Construct Tissue Tolerance Construct 
Risk Factors 
Mobility (Braden) 
Concept of Extrinsic Factors 
Risk Factors 
Activity (Braden) Moisture (Braden) 
Sensory Perception (Braden) Friction/Shear (Braden) 
 Concept of Intrinsic Factors 
Risk Factors  
 • Metabolic Supply 
 o Vasopressor use 
 o Vascular disease of any type except   
cerebral and cardiovascular 
 o Nicotine use 
 o Lower hemoglobin/hematocrit 
 o Nutrition (Braden)/Protein reserve 
 • Metabolic Demand 
 o Surgical procedure 
 o Increased severity of illness 
 • Physiologic demands 
 o Dialysis of any type 
 o Body temperature 
 o Corticosteroid use 
 • Pressure Distribution 
 o Gender (male) 
 o Body habitus 
 o Increased age 
 • Threats to Skin Integrity 
 o Pre-existing pressure ulcer 
 o Dry, thin skin 
 o Edema 
 o General skin problems in pressure prone 
areas 
 o Chemical exposure, such as with 
incontinent diarrhea 
 
 
 Pressure distribution capacity contains three risk factors, all of which were 
included in the study.  They are BMI, age, and gender.  Threats to skin integrity include 
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five unique risk factors.  Four of those (pre-existing pressure ulcer, dry, thin skin, edema, 
and skin problems) were captured as nominal variables.  Chemical exposure, such as with 
diarrhea, was not captured because of the variability of its use as a descriptive term in the 
nursing documentation, and its presence and magnitude could not be visually verified by 
the investigator.  Of the 23 variables identified by the conceptual model, 18 were 
included for data collection.  Table 3.2 summarizes concepts, variables, and variable 
levels collected for data analysis.  Refer to Chapter II for a complete list of term 
definitions and measurement frequency. 
 
Table 3. 2. Variables Included for Study 
Variable Type Aim Purpose† 
Pre-Admission 
variables 
   
Diabetes 
history Dichotomous/Nominal 1,2 D, C 
Nicotine 
history Dichotomous 1,2 D, C 
Steroid history Dichotomous 1,2 D, C 
Pre-existing 
skin disease  Dichotomous/Nominal 1,2 D, C 
Demographic 
variables    
ICU Nominal 1,2 D, C 
Gender Dichotomous 1,2 D, C 
Age Continuous 1,2 D, C 
Pressure ulcer risk    
Braden 
Subscale Score  Nominal 1,2 D, C 
Threats to skin 
integrity    
BMI* Continuous 1,2 D, C 
Corticosteroid 
dose  Continuous 1,2 D, C 
Restraint use Dichotomous 1,2 D, C 
Albumin Continuous 1,2 D, C 
Pre-Albumin Continuous 1,2 D, C 
Total 
lymphocytes Continuous 1,2 D, C 
Total Protein 
Nominal 1.2 D, C  
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Variable Type Aim Purpose† 
Perfusion     
High and low 
hematocrit Continuous 1,2 D, C 
Lowest 
MAP** Continuous 1,2 D, C 
Lowest oxygen 
saturation Continuous 1,2 D, C 
Vasopressor 
use Continuous 1,2 D, C 
Outcome variable     
Pressure ulcer 
and stage Nominal 1,2 O 
*Body mass index; **Mean arterial pressure; † D – descriptor; C – covariate; 
 O – outcome 
 
 
Sample and Sampling Plan 
 
Nature and Size of the Sample 
Standard referenced best practices and statistical powering approaches were used 
to determine the sample size for this research.  The conceptual model guiding this 
research identifies 23 independent variables; however, 18 were measured.  Stability of 
standard errors in logistic regression requires at least 10 cases for each independent 
variable in the smallest of the dependent variable categories (M. Dietrich, personal 
communication, 2009).  Therefore, at least 180 cases were required.  Each case has one 
matched control subject making the total sample size 360 subjects.  Statistical powering 
for minimally detectable effects of a given independent variable (IV) is based on not only 
the desired statistical power and alpha level, but also on the amount of variance in the 
outcome variable that is already explained by the other IVs in the analysis.  For a 
continuous IV, a total sample size of 360  with an observed proportion of the event of 
interest set at 0.50 (50% of the participants had a pressure ulcer), provided 80% statistical 
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power to detect an odds ratio of 1.34 if there was no variance explained by the other IVs.  
If as much as 30% of the variance in the likelihood of a pressure ulcer was explained by 
the other IVs, the sample provided 80% statistical power to detect an odds ratio of 1.42 
(alpha = .05).  For a dichotomous IV, those respective odds ratios were between 1.82 (0% 
variance explained by other IVs) and 2.06 (30% variance explained by other IVs).  
 
Inclusion, Exclusion, and Matching Criteria  
Inclusion criteria for both cases and controls were:  
1. 18 to 79 years of age; and 
2. Admission or transfer within to any of the five ICUs identified above.  
Exclusion criteria for cases were:  
1. Presence of any pressure ulcer on admission to the ICU; 
2. Any pressure ulcer that developed within 48 hours of admission to the ICU; 
3. Cardiopulmonary resuscitation requiring chest compressions and/or 
resuscitation drugs within 48 hours of pressure ulcer development; 
4. Discharge from ICU prior to visual verification of pressure ulcer; and  
5. ICU length of stay less than 48 hours. 
 Exclusion criteria for controls were: 
1. Any stage pressure ulcer on admission to the ICU; 
2. Any pressure ulcer that developed during the ICU stay; 
3. Cardiopulmonary resuscitation during the ICU stay; 
4. ICU length of stay less than 48 hours. 
Matching criteria were: 
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1. Must be from the same ICU; 
2. Must have been in the same ICU within 90 days of each other (i.e., up to 90 days 
prior to the case index date or up to 90 days after the case index date); 
3. ICU length of stay for controls was at least as long as the length of stay as the 
case subjects’ length of stay upon developing a pressure ulcer; and 
4. Must be matched on ventilator use during the 48 hour period prior to case index 
date.  
 See Table 3.3 for a summary of the inclusion, exclusion, and matching criteria. 
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Table 3. 3. Inclusion, Exclusion, and Matching Criteria 
 
 
Rationale for the proposed exclusion criteria in this study was to enhance the 
identification of incident pressure ulcer development that allows for examination of 
patient-specific risk factors.  Persons with pre-existing pressure ulcers were excluded 
because their presence would confound findings intended to identify unique risk factors 
associated with critical illness and consequent ICU placement for medical care.  Persons 
requiring cardiopulmonary resuscitation were excluded because they are subjected to 
periods of unmeasured hypo-perfusion states that affect the skin’s mechanical and 
physiologic tolerance to pressure.  Additionally, resuscitation drug administration 
practices often include intra-venous boluses from existing vasopressor infusions that are 
Criteria Case Subjects Control Subjects  
Inclusion Criteria  • Admission to ICU • Admission to ICU 
• 18 to 79 years of age  • 18 to 79 years of age  
Exclusion Criteria 
• Stage I or worse pressure ulcer 
on admission to ICU 
• Stage I or worse pressure ulcer 
on admission to ICU 
• Stage I or worse pressure ulcer 
that develops within 48 hours 
of admission to ICU 
• Stage I or worse pressure ulcer 
that develops during ICU stay  
• Cardio-pulmonary resuscitation 
requiring chest compressions 
and/or resuscitation drugs  
within 48 hours of stage I or 
worse pressure ulcer 
development 
 
• Cardio-pulmonary 
resuscitation during ICU stay 
• ICU length of stay <48 hours 
• Discharge from ICU prior to 
visual assessment of pressure 
ulcer 
 
• ICU length of stay <48 hours   
Matching Criteria 
• Same ICU 
• Same period in ICU within 90 days of each other 
• Presence or absence of ventilator use within 48 hours 
of enrollment 
• ICU length of stay – control must be in ICU for at least 
the same number of days as case at time of control 
enrollment 
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recorded on the resuscitation forms used by VUMC, but not necessarily captured on the 
nursing flow sheet, which was the documentation record used in collecting vasopressor 
dosage data.  Case subjects who were discharged from the ICU prior to visual verification 
of the pressure ulcer were excluded because of the difficulty in locating and visually 
confirming pressure ulcer presence in a timely manner following ICU discharge.  
Subjects whose ICU length of stay is less than 48 hours were excluded because other risk 
factor influences prior to ICU placement may disproportionately contribute to pressure 
ulcer incidence in case subjects with less than a 48-hour ICU stay.   
The matching criteria increase the comparability of cases and controls (Newman 
et al., 2007).  By matching on the same ICU within 90 days prior or post pressure ulcer 
development, unique nursing practice and staffing patterns associated with the particular 
ICU during a similar period were matched, thereby minimizing potential confounders.  
Additionally, matching on ventilator use enhanced the validity because ventilator use is 
considered a proxy for severity of illness in critical care settings (Horner, Sloane, & 
Kahn, 1998).  Other, established severity of illness scores, such as the APACHE II, are 
not consistently gathered in all VUH ICUs and therefore not available for analysis.  
Because of geographic limitations and fluctuating non-ICU bed availability at VUH, not 
all patients housed in a VUH ICU have the same severity of illness. 
 
Subject Recruitment Methodology 
Institutional Review Board (IRB) approval at Vanderbilt University Medical 
Center (VUMC) was sought and the study was approved.  A convenience sample of 
potential subjects was identified using ICU census data and Star Panel.  The PI then 
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verified inclusion and exclusion criteria.  To help with subject enrollment, Carolyn Watts, 
MSN, RN, CWON and Christy Thomas, RN were recruited by the PI and trained in 
recruitment methodology.  Patients meeting the inclusion criteria were then approached 
by the PI, Carolyn Watts or Christy Thomas for study enrollment using the procedures 
outlined below.  Methods to ensure inter-rater reliability among the PI, Carolyn Watts 
and Christy Thomas are discussed later in this section.   
Human Subjects Protection 
Informed consent.  The patient’s cognitive and sedation status dictates their 
ability to understand and give informed consent.  One study found that more than 75% of 
ventilated patients in an ICU were unable to give informed consent for participation in 
research because of confusion and delirium that persisted after ventilator use was 
discontinued (Fan et al., 2008).  At VUH, sedation status is indicated by the Richmond 
Agitation Sedation Scale (RASS).  The tool is well validated by several studies and is a 
commonly accepted way of objectively measuring the sedation status of a patient (Sessler 
et al., 2002; Ely et al., 2003).  The tool ranges from -5 (unarousable) to +4 (combative).  
A RASS of zero is calm, awake, and alert.  A RASS of +1 is described as restless 
(anxious or apprehensive but movements not aggressive or vigorous).  A RASS of  -1 is 
described as drowsy (not fully alert, but has sustained periods of awakening with eye 
contact to verbal stimuli).  Fan et al. (2008) used the RASS range of -1 to +1 in their 
study about obtaining informed consent and it is the evidence on which this study criteria 
for obtaining informed consent is based.  The RASS score is routinely assessed and 
documented by VUH ICU nurses every four hours.  
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Delirium in the ICU patient is measured with the Confusion Assessment 
Methodology for ICU patients (CAM-ICU).  Delirium is indicated as a positive or 
negative finding and depends on the RASS score as part of its algorithm.  As with RASS, 
the CAM-ICU is well validated in clinical practice (Ely, Inouye, et al., 2001; Ely, 
Margolin et al., 2001).  Fan et al. (2008) used a CAM-ICU negative for their criteria in 
obtaining informed consent and it is the evidence on which this study criteria is based.  
Similar to the RASS score, all ICU nurses at VUH assess the patients for delirium and 
document the CAM-ICU each shift. 
Per the approved IRB protocol, two face-to-face attempts and one phone attempt 
with a surrogate who could give consent were conducted for potential case patients that 
could not give consent themselves.  Consent was waived after the three attempts to obtain 
it were unsuccessful.  Potential case subjects who could not give consent and who did not 
have a contact person or next of kin indicated in the medical record were not enrolled.    
Dignity and Personal Privacy.  The following procedures were used to ensure 
patient dignity and privacy: 
1. The PI, Carolyn Watts or Christy Thomas contacted the nurse caring for the 
patient and arranged a mutually agreeable time to visualize the patient’s skin, 
such as during a bath or during the pressure ulcer dressing change, if applicable.  
Not all pressure ulcers require a dressing.  
2. To maintain respect, the nurse then introduced the PI, C. Watts, or Christy 
Thomas to the patient and/or family, analogous to introducing a medical or 
nursing student. 
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3. The patient’s privacy was ensured by closing room curtains or shades and room 
door. 
4. The nurse then repositioned the patient, if necessary, so that the pressure ulcer 
could be visualized. 
5. The nurse then removed the dressing, if applicable, and the PI, Carolyn Watts, or 
Christy Thomas visualized the ulcer. 
6. The PI, Carolyn Watts, or Christy Thomas then offered assistance to the nurse to 
re-dress the ulcer, if applicable. 
Protection of personal health information.  The data collected involved patient 
demographic and health information, such as age, gender, body mass index, and presence 
of various pre-existing diseases, such as diabetes.  Physiologic data, such as blood 
pressure and oxygen saturation were also collected, as were specific medications that 
were of interest, such as vasopressors.  Patient confidentiality was assured by entering 
medical record numbers and associated demographic information directly from the EMR 
onto the paper Data Collection Form, which remained under double lock in the PI’s 
office.  Data were then entered into Vanderbilt University’s Research, Electronic Data 
Capture (REDCap) database using the completed Data Collection Forms, which remained 
under double lock in the PI’s office.  REDCap  is a secure, web-based application that is 
flexible enough to be used for a variety of types of research.  REDCap provides an 
intuitive user interface that streamlines project development and improves data entry 
through real-time validation rules with automated data type and range checks.  REDCap 
also provides easy data manipulation with audit trails for reporting, monitoring and 
querying patient records, and an automated export mechanism to common statistical 
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packages (Harris et al., 2009).  REDCap servers are housed in a local data center at 
Vanderbilt, and all web-based information transmission is encrypted.  REDCap was 
developed specifically around HIPAA-Security guidelines and is recommended to 
Vanderbilt researchers by both the Privacy Office and Institutional Review Board.  Upon 
completion, all paper forms were destroyed using the shredder in the SICU (where the 
PI’s office is located). 
All data were kept in the REDCap database for the duration of the study.  The 
REDCap data base was de-identified at the conclusion and will be indefinitely maintained 
for reference, should a secondary data analysis be required.  Paper data collection forms 
were maintained under double lock until the PI was satisfied that all data were entered 
correctly, then were shredded.  The Screening Tracking Tool, Data Management Tool, 
and Consent Tracking Tool were maintained on Vanderbilt’s SICU secure ‘M’ drive and 
were only accessible by the PI or Carolyn Watts (Appendix A).  The completed tools 
were deleted from the Vanderbilt’s secured ‘M’ drive at the completion of the study. 
 
Data Collection Methods 
 
Procedures 
Case enrollment.  At least twice a week, the following steps were taken to 
identify case subjects.  
1. The PI reviewed the Star Panel census for each ICU.  The census indicates which 
patients are designated as having a pressure ulcer by the nursing staff.  
Information about the location and stage of the pressure ulcer was also available 
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in Star Panel.  Recording pressure ulcer characteristics is a standard of care and is 
routine care for every patient at VUH.  
2. The Inclusion/Exclusion Screening Tool (Appendix A) was used by the PI to 
determine case eligibility for study enrollment. 
3. Once inclusion criteria were met, the PI, Carolyn Watts, or Christy Thomas 
approached the nurse assigned to the patient.  That nurse determined the patient’s 
ability to consent based on the CAM and RASS assessments that are standard 
nursing assessment practices in all ICU’s at VUH.  At a time designated by the 
nurse caring for the patient, the PI, Carolyn Watts, or Christy Thomas entered the 
room with the nurse.  To maintain respect, the nurse introduced the PI, Carolyn 
Watts, or Christy Thomas, analogous to introducing a medical or nursing student.  
4. Patients who were awake and able to understand (i.e., CAM negative with current 
RASS score of 0, +1 or -1 as documented by the nurse) were asked to give written 
consent for pressure ulcer visualization and access to PHI from the medical record 
using the Informed Consent Form (Appendix A).  Carolyn Watts, the PI, or 
Christy Thomas then visualized the pressure ulcer to ensure that the staff nurse 
documents the location and stage correctly.  
5. The PI or co-investigator did not touch the patient unless the primary nurse giving 
care to the patient requested assistance.  
6. In cases where the patient was  unable to give consent (i.e. CAM positive with 
current RASS score of anything other than 0, +1 or -1), family was sought to 
obtain surrogate consent on two face to face attempts and one phone contact 
attempt using the Surrogate Informed Consent Rider (Appendix A).  After three 
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failed attempts to obtain informed consent, consent was waived and the patient 
enrolled into the study.  A Patient Information Sheet (Appendix A) was left in the 
patient’s room for those patients identified to be possible case or control subjects.  
This information sheet informed family who may not be present that the patient 
was considered for entry into a research study.  Carolyn Watts, the PI, or Christy 
Thomas then visualized the pressure ulcer to ensure that the staff nurse 
documented the location and stage correctly.  The PI or co-investigators did not 
touch the patient unless the primary nurse giving care to the patient requested 
assistance. 
7. Case patients unable to give consent were periodically reevaluated by the PI or 
co-investigators in conjunction with the nurse to determine their ability to give 
written consent.  If a patient became capable of giving consent, the consent 
process was completed.  
8. A copy of the informed consent document was given to the patient or surrogate, 
one copy was placed in the patient’s paper medical record, and the original was 
retained by the PI in accordance with the approved IRB protocol for protecting 
personal health information.   
9. All attempts to obtain informed consent were tracked in the Consent Tracking 
Tool.  (Appendix A) 
Control enrollment.  After a case subject was identified, the PI used the 
following method to identify control subjects.  Efforts were made to match the ICU 
admission dates as closely as possible.   
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1. Each time a case subject was identified, the EMR was used to identify potential 
control subjects using the matching criteria outlined above.  
2. If no control match was located for the case subject on the day of case subject 
enrollment, a period of 10 days elapsed before a second attempt.  On day 11, a 
second search was completed for a control subject within +/- 10 days of the case 
index date.  The process proceeded incrementally until the search for control 
subjects reached 90 days +/- the case index date.  
3. If no control was found, data on the case subject was kept and labeled as an 
unmatched case subject.  
4. All control subjects who were currently in the ICU underwent the same consent 
process as that for cases.  
Data collection.  All data were collected by the PI using either the Case Data 
Collection Form or the Control Data Collection Form (Appendix B) approved by the 
IRB.  Data were collected using the EMR.  Immediately after the data were collected on 
the paper form, the completed forms were stored in a locked file cabinet in the PI’s 
locked office.  For case subjects, the PI entered the medical record number, ICU, length 
of ICU stay, and ventilator use (if patient was ventilated) into the Data Management 
Form spreadsheet (Appendix A).  The spreadsheet automatically calculated the required 
matching criteria for ICU admission dates to assist in identifying a matched control 
subject.  Once a control subject was identified, the medical record number and ICU were 
entered into the Data Management Form, indicating that a match has occurred.  The 
spreadsheet was kept on Vanderbilt’s secure data drive, the SICU’s ‘M’ drive,  accessible 
from workstations in Carolyn Watt’s and the PI’s office, or remotely from the PI’s home 
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computer on Vanderbilt’s secured drive.  The data drive is password protected and only 
the PI and Carolyn Watts  had access.  
Data for case and control subjects were transcribed from the paper data collection 
sheets into REDCap by the PI.  The paper data collection sheets remained under double 
lock in the PI’s office at VUH until the completion of the study, at which time they were 
shredded.  Christy Thomas did not do data entry and therefore did not have access to the 
REDCap database or data collection spreadsheets.  
Data source.  All data were collected from the EMR using Star Panel or the 
nursing documentation system, Horizon Expert Documentation (HED).  Star Panel serves 
as the primary clinical database for VUH.  Star Panel acquires information from 
numerous other databases used in VUH to consolidate patient-specific information into 
one place.  All variables identified in this study were acquired from Star Panel through 
interfaces with provider documentation, laboratory results, medication administration, 
and the Nursing Flow Sheet. 
 
Reliability and Validity of Instruments 
 The instruments used in this study (Appendix B) were designed to capture patient 
demographic data and risk factors identified in the conceptual model.  Therefore, the 
validity, reliability, and credibility of these instruments are assumed because they are 
specific to this study and were not used as measurement instruments.  For this study, 
reliability and validity issues were identified in the methodology, discussed below. 
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Reliability and Validity of the Study Methods 
To assess the reliability and validity of staff nurse documentation of pressure 
ulcers, a feasibility study was conducted prior to the start of this study.  The study, 
designed to determine the completeness and accuracy of documentation regarding 
pressure ulcer presence and stage, demonstrated 100% agreement between the expert 
rater and staff nurses on the presence/absence of a pressure ulcer.  The study also 
demonstrated 100% agreement between staff and expert rater on pressure ulcers with 
regard to location, and 83.3% agreement between staff and expert rater with regard to 
stage of pressure ulcer.  Appendix C presents a detailed description of the feasibility 
study and its findings. 
To ensure that proper pressure ulcer identification and staging was documented 
for each case patient, the PI, Carolyn Watts or Christy Thomas visually inspected the 
pressure ulcer during the process of enrollment.  In cases of disagreement with the staff 
nurse staging, the PI, Carolyn Watts, or Christy Thomas assigned the pressure ulcer stage 
used.  
   To ensure inter-rater reliability among Carolyn Watts, Christy Thomas, and the 
PI during the enrollment process, the PI visually validated the presence and stage of 
every tenth case patient that Carolyn Watts and Christy Thomas each enrolled.  An 
educational session and more frequent validations were planned in the case of any 
discrepancies that were noted; however, the inter-rater reliability demonstrated 100% 
agreement obviating the need for education or more frequent inter-rater reliability 
validations.   
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Data Analysis Strategy 
 
Data Cleaning Procedures 
After all data were collected and prior to analysis, variable data for 18 random 
case subjects and 18 random control subjects were examined for errors and omissions.  
No errors or omissions were found.  Frequencies were checked for all identifier variables 
to ensure that there were no repeated subjects and that no control patient was coded as 
having a pressure ulcer.  Matching criteria for each case-control pair were also analyzed 
to ensure that ICU, ventilator use, and ICU length of stay were identical.  No errors in 
matching were identified.  Unmatched cases (n = 12) were described and removed from 
the database for further analysis (see Chapter 4).   
Statistical Methods 
All data analyses were conducted using SPSS software (SPSS for Windows, 
Graduate Student Version, Rel. 16.0.1.  2007. Chicago: SPSS Inc.).  Initially an 
investigation of the nature of the missing data values was undertaken to determine if there 
were any systematic patterns.  None were detected in the primary study variables and 
thus missing was assumed to be random.  Subsequently, multiple imputations were used 
to estimate the missing values. Results from both completed and imputed data sets are 
reported.  
Aim 1.  To compare the frequency and magnitude of pressure ulcer risk factors 
between critically ill patients that do and do not develop a pressure ulcer during their ICU 
stay and evaluate their influence on the associations between the Braden subscales and 
pressure ulcer outcome. 
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Descriptive statistics were generated to summarize the variables in each of the 
patient groups (with and without pressure ulcers). Frequency distributions summarized 
nominal variables. Due to the skewed nature of the continuous variables, median and 25th 
to 75th interquartile range (IQR) were used to summarize those distributions.  
Logistic regression analysis was used to generate both unadjusted and adjusted 
associations of each risk factor (IV) with the presence of a pressure ulcer (DV).  The 
conceptual model guiding this research identified 18 independent variables.  Simple 
univariate logistic regressions were used to generate estimates of the unadjusted 
associations.  Odds ratios with 95% confidence intervals (CI) were obtained for each 
variable (IV). 
Multiple hierarchical logistic regression was used to generate adjusted odds ratios. 
Age was entered in the first step of this analysis.  Braden subscale values were entered in 
the second step followed lastly by the other proposed risk variables.  Odds ratios with 
95% CI were generated. Both the univariate and adjusted analyses were conducted 
separately for variables collected at 24 hours and at 48 hours of the case index date.  An 
alpha of 0.50 was used for determining statistical significance.   
Sample size and power.  Stability of standard errors in logistic regression 
requires at least 10 cases for each IV in the smallest of the dependent variable categories 
(Dietrich, 2009).  Because a case-control design was proposed, the dependent variable 
categories would be of equal size.  Therefore, for 18 IVs, at least 180 cases (and 
correspondingly 180 controls) were required to meet the minimal sample size 
requirement.  The minimally detectable effects of a given risk factor (IV) in multiple 
regression analyses is based on not only the desired statistical power and alpha level, but 
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also on the amount of variance in the outcome variable that was already explained by the 
other IVs in the analysis.  A total sample size of 360 with an observed proportion of the 
event of interest set at 0.50 (50% of the participants had a pressure ulcer), provided 80% 
statistical power to detect an odds ratio of 1.34 for a continuous IV if there was no 
variance explained by the other IVs.  If as much as 30% of the variance in the likelihood 
of a pressure ulcer was explained by the other IVs, the sample provided 80% statistical 
power to detect an odds ratio of 1.42 (alpha = .05).  For a dichotomous IV, those 
respective odds ratios were between 1.82 (0% variance explained by other IVs) and 2.06 
(30% variance explained by other IVs).   
Aim 2.  To compare the frequency and magnitude of pressure ulcer risk factors 
between critically ill patients that have progression of their Stage I  pressure ulcer during 
the ICU stay to those who do not have a progression of their Stage I pressure ulcer during 
the ICU stay. 
No statistical analysis of subjects with a Stage I pressure ulcers was performed 
because four (1.1%) subjects had their pressure ulcers deteriorate into a Stage II or worse 
during their ICU stay.  Because of the low percentage of those subjects that experienced a 
worsening pressure ulcer during their ICU stay, no statistical inferences can be made.  
Data were examined qualitatively. 
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CHAPTER IV 
 
RESULTS 
 
This chapter provides the results of a prospective case-control study examining 
risk factors for pressure ulcers in critically ill patients.  A review of the primary aim, a 
description of unmatched cases, missing data, and variables with no data are presented.  
Characteristics of case and control subjects, pressure ulcer findings, and unadjusted and 
adjusted OR findings are also presented.  Finally, the secondary aim is reviewed with its 
findings.    
 
Unmatched Cases 
     
There were 12 unmatched case subjects.  Statistically significant differences 
between unmatched and matched (n = 180) case subjects were noted in five variables.  
Unmatched case subjects had statistically significantly less frequency of norepinephrine 
use prior to study enrollment (X2 = 6.49, p = 0.011) than did matched case subjects.  
Unmatched case subjects had statistically significantly lower scores on the  Braden 
Mobility subscale scores 24 hours (z = -2.20, p = 0.028) prior to study enrollment and the 
Braden Moisture subscale scores 48 hours (z = -2.04, p = 0.041) prior to study enrollment 
than did matched case subjects.  Lowest oxygen saturation 24 hours prior to enrollment 
was statistically significantly lower in matched case subjects (z =-2.41, p = 0.016) than in 
unmatched case subjects.  ICU length of stay was statistically significantly higher in 
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unmatched cases than matched cases (z =-5.58, p <0.001).  ICU length of stay prior to 
pressure ulcer development in the unmatched case subjects was the primary reason these 
subjects were not matched.  No further considerations of the unmatched cases were 
required, so they were removed from the data set for further analysis.  See Appendix D, 
Tables 1, 2 and 3 for complete description of the comparisons between unmatched and 
matched case subjects. 
 
Missing Data 
 
Missing data were identified in the pre-admission variables describing presence or 
absence of diabetes, nicotine use within one year of hospital admission, corticosteroid use 
prior to hospital admission, and pre-existing skin disease.  Hematocrit values measured at 
24 and 48 hours prior to study enrollment and measures of protein reserve also contained 
missing data.  Table 4.1 details the variables with missing data and their frequencies.  
Appendix D, Table 4 provides an expanded detail of the variables with missing data.  
Pre-Admission Variables 
Frequencies for missing data among the pre-admission variables ranged from 
6.1% for nicotine use to 18.1% for history of diabetes (see Table 4.1).  Variables with 
more than 10% missing values were excluded from analysis because of the possibility of 
biasing the conclusions (Duffy & Jacobsen, 2005; Cummings, Browning, & Hulley, 
2007).  Consequently diabetes, pre-existing skin disease, and pre-admission 
corticosteroid use were eliminated as variables and not included in further analyses.  
Aspects of pressure ulcer risk contributed by the eliminated variables shared some 
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conceptual overlap with other variables, thereby potentially minimizing the risk of losing 
any explanatory power these variables may have contributed to the study.  Presence and 
type of diabetes had originally been included because of its association with vascular 
disease and detrimental effect on metabolic supply to the tissues.  Other study variables, 
vasopressor use, hematocrit values, nicotine use, and the Braden nutrition subscale scores 
are related to this conceptual component of pressure ulcer risk.  Pre-existing skin disease 
is conceptually identified as a threat to skin integrity.  The Braden moisture subscale, also 
related to the skin integrity concept, provided the one measure to assess the concept of 
skin integrity threats.  Because steroid use was also measured during the hospital 
admission, the effects of steroid use, a conceptual component of metabolic demand, was 
retained for further analyses.  See Table 2.4 for a summary of pressure ulcer risk factor 
concepts and measures.  
Nicotine Use Variable 
Nicotine use was missing in 11 (6.1%) each of case and control subjects.  
Consequently, nicotine use was retained for further analyses and missing nicotine values 
were imputed using a regression equation to predict missing values (Duffy & Jacobsen, 
2005).  
Hematocrit Variables  
 High and low hematocrit levels at both 48 and 24 hours were reported in 
351(97.5%) subjects.  Values for the nine remaining subjects were imputed for further 
data analysis using a regression equation.  After the missing variables were imputed, 
collinearity statistics revealed a collinearity tolerance of 0.165 for high hematocrit and 
0.162 for low hematocrit 24 hours prior to study enrollment and similar collinearity 
76 
 
 
 
statistics were identified for high (0.177) and low (0.181) hematocrits 48 hours prior to 
study enrollment.  Further analyses were conducted using only the low hematocrit values 
because of the collinearity tolerance values. 
Protein Reserve Variables  
Laboratory values for serum albumin, pre-albumin, and total lymphocyte count 
were not reported in a number of case or control subjects.  None of these protein 
variables were reported in 22 (12.2%) of case subjects and 15 (8.3%) of control subjects.  
Serum albumin levels were not reported in 112 (62.2%) of case subjects or 113 (62.7%) 
of control subjects.  Pre-albumin levels were not reported in 100 (55.5%) of case or 
control subjects, and total lymphocyte counts were not reported in 51 (28.3%) of case 
subjects and 41 (22.8%) of control subjects.  To retain any explanatory contribution that 
protein reserve may have on pressure ulcer incidence, a new variable, ‘Protein Store’, 
was calculated to capture the presence of any protein store variable in study subjects (see 
Chapter II for complete definition). To accommodate for the frequency of un-reported 
protein store measures, values were categorized as high, normal or low, using references 
from the VUH clinical laboratory.  In subjects with values reported for more than one of 
the protein reserve variables, the value for serum albumin (high, normal or low) was the 
default ranking.  If serum albumin was not reported the value for either pre-albumin or 
total lymphocyte count was used.  When values for two variables differed, the lower of 
the two was used.  Serum albumin was used as the default ranking because of its use as 
the standard of measure in multiple studies examining nutrition status (Jeejeebhoy, 2004).  
After the variable was categorized into high, normal, and low, seven subjects (1.9%) 
were ranked as ‘high’ and data were missing for 27 subjects.  Because the missing data 
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occurred at random, imputed values were added and analyses from both sets of data (with 
and without imputed values) were analyzed and compared.  Missing variables for protein 
reserve ranged from 25.5% to 62.5% of subjects.  Distributions between all variables for 
protein reserve (serum albumin, pre-albumin, total lymphocyte count) were equally 
distributed between case and control subjects.  The Protein Store variable reduced the 
frequency of missing data from 62.5% to 10.3% in total subjects.  However, there were 
only seven subjects (1.9%) with a protein reserve variable rated as high, so the 
categorical variable was further consolidated to a dichotomous variable representing 
normal and low protein levels.  Data for the 10.3% of missing variables was imputed 
using the regression equation method used for nicotine use and hematocrit. 
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Table 4. 1. Frequency of Missing Data for Case and Control Subjects* 
 
Missing Variable Matched Cases 
N = 180 
         n              (%) 
Matched Controls  
N = 180  
      n            (%) p value
† 
Frequency of  
missing variable in 
both case and 
control pair 
Pre-Admission 
Demographic 
Variables 
    
     Diabetes 35            (19.4)   32               (17.8) 0.755 13     (7.2) 
     Nicotine use      11        (6.1) 11     (6.1) 1.000 2      (1.1) 
     Corticosteroid                
use 31            (17.2)  32     (17.8) 1.000 11     (6.1) 
Skin Disease  27       (15.0)  29     (16.1) 0.874 8       (4.4) 
Perfusion 
Parameter 
Variables 
    
Highest 
hematocrit 48 
hours prior to 
enrollment 
5     (2.8) 4     (2.2) 1.000 0     (0.0) 
Lowest 
hematocrit 48 
hours prior to 
enrollment  
5     (2.8) 4     (2.2) 1.000 0     (0.0) 
Highest 
hematocrit 24 
hours prior to 
enrollment 
4     (2.2) 5     (2.8) 1.000 0     (0.0) 
Lowest 
hematocrit 48 
hours prior to 
enrollment  
4     (2.2) 5     (2.8) 1.000 0     (0.0) 
Protein Reserve 
Variables     
Serum 
Albumin 112     (62.2) 113     (62.7) 1.000 75           (41.7) 
Serum Pre-
albumin 100     (55.5) 100      (55.5) 0.560 71          (39.4) 
Total 
Lymphocyte 
Count 
51        (28.3) 41        (22.8) 0.522 14          (7.8) 
Any Protein 
Store 22     (12.2) 15         (8.3) 0.281 0            (0.0) 
†McNemar  *No missing data for all other demographic variables; no missing data for 
ICU administered medications; no missing data for all Braden subscale scores.  
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Recoded Variables 
 
After investigating the initial variable distributions, variables with low response 
rates were either dichotomized or included with similar variables to create a global 
categorical variable.  Table 4.2 provides summaries of the lack of any vasopressor use in 
case and control subjects.  Vasopressor use frequency ranged from 55 (30.6%) 
occurrences to one occurrence (0.6%) in case subjects and 50 (27.8%) occurrences to 
zero occurrences in control patients.  Because of the high frequency of zero doses across 
types of vasopressor, a global vasopressor variable was included that combined the 
specific types into a single global ordered categorical variable (zero, one, two, and more 
than two vasopressors received). 
 
Table 4.2. Frequency of Zero Dose Vasopressor Occurrences in Case and Control 
Subjects 
 
Vasopressor 
Matched 
Cases 
N = 180 
   n           (%) 
Matched Controls 
N = 180 
 
    n               (%) 
p value† 
Dobutamine 177     (98.3)   174           (96.7) 0.508 
Epinephrine 174     (96.7)   174           (96.7) 1.000 
Milrinone 166     (92.2)   170           (94.4) 0.481 
Midodrine  179     (99.4)   180           (100.0) 1.000 
Norepinephrine 125     (69.4)   139           (77.2) 0.115 
Vasopressin 149     (82.8)   163           (90.6) 0.050 
† McNemar  
 
Similarly, Table 4.3 presents the summaries of the number of subjects in the two 
groups that did not receive corticosteroids during the current hospitalization.  Subjects 
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receiving corticosteroids during the current hospitalization ranged between 25% to zero 
for case subjects and 16.7% to zero for control subjects.  Because of the low frequency of 
corticosteroid administration, the multiple corticosteroids were combined into a single 
global dichotomous variable for analyses (0 = none received, 1=at least one received).   
Table 4.3. Frequency of Zero Dose Corticosteroid Occurrences in Case and Control 
Subjects 
 
Corticosteroid 
Matched Cases 
N = 180 
 
n              (%) 
Matched Controls 
N = 180 
 
n            (%) 
p-value† 
Hydrocortisone 135          (75.0) 150         (83.3) 0.268 
Prednisone 163          (90.6) 155         (86.1) 0.560 
Methylprednisone 160           (88.9) 158        (87.8) 0.864 
Prednisolone 180         (100.0) 180       (100.0)  
† McNemar  
 
 
 
Primary Aim 
  
To compare the frequency and magnitude of pressure ulcer risk factors between 
critically ill patients that do and do not develop a pressure ulcer during their ICU stay and 
evaluate their influence on the associations between the Braden subscales and pressure 
ulcer outcome.  To examine any temporal differences in importance of pressure ulcer risk 
factors, they were measured at 48 hours and 24 hours prior to study enrollment. 
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Subject Profile 
Case subject enrollment followed a defined process (Figure 4.1).  During the data 
collection period from October 2010 through October 2012, 25,180 patients were 
admitted to the study ICUs.  A convenience sample of 1,095 (4.35%) patients was 
screened as potential case subjects.  Eight hundred and eighty-five (80.8%) of the 
potential case subjects did not meet enrollment criteria, leaving 210 potential case 
subjects.  Eighteen of those were not enrolled due to lack of consent.  Of the 192 case 
subjects that were enrolled, 12 (6.3%)  did not have matched controls, so were excluded 
from further study leaving 180 case subjects.  Comparative demographic data between 
subjects and patients admitted to study ICUs during the data collection period are not 
available given patient confidentiality issues.  Matching control subjects were identified 
through the EMR after each case subject was identified.
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Figure 4. 2. Process for Enrolling Case Subjects for Dissertation Study 
 
 
*Later removed as exclusion criterion 
**Identified through medical record documentation
Total Patients Admitted to 
Study ICUS
N = 25,180
Not Screened for 
Inclusion
N = 24,085 
Not a pressure ulcer   N = 87
Admitted with a pressure ulcer  N = 595
Pressure ulcer developed with in 48                
hours of admission N = 131
Discharged before pressure ulcer 
visualized N = 46
Stage I pressure ulcer* N = 9
Required CPR within 48 hours of 
pressure ulcer N = 1
Does not speak English N = 2
Outside age range N =  14
Refused consent
N = 18
Cases with matched 
Controls** N = 180
Cases with no matched 
Controls  N = 12
Potential Case 
Subjects
N = 1095
Eligible Case 
Subjects
N = 210
Case Subjects 
Enrolled N =  192
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Characteristics of Case and Control Subjects 
 
Matching Criteria and Consent Type 
 Matched pairs were most frequently drawn from the SICU (31.1%) and least 
frequently from the Neuro ICU (5.6%).  The Trauma ICU contributed 23.9% of the 
matched pairs, 20.0% were drawn from the MICU, and 19.4% from the CVICU.  
Ventilator use was present in 79.4% of the matched pairs.  
Sixteen percent of case subjects gave consent for study participation.  Surrogates 
gave consent for 49.4% of case subjects.  Following the consent process established for 
the study protocol, 34.4% of consents were waived in case subjects and 99.4% of control 
subjects. 
Description of Variables Assessing Pressure Distribution Capacity  
Table 4.4 provides descriptive statistics and unadjusted odds ratios for likelihood 
of pressure ulcer for variables assessing pressure distribution capacity.  Males comprised 
63.9% of the subjects enrolled.  A statistically significantly higher percentage were in the 
cases (71%) than in the controls (57%)  (p = 0.005).  Subjects’ age ranged from 18 to 89 
years (median = 58, IQR = 47.2 – 67.0).  Average age for patients admitted to the study 
ICUs during the data collection period was 54.7 years.  Subject body mass index ranged 
from 12.8 to 78.27 (median = 27.3, IQR = 23.6 – 32.9) kg/m2.  No statistically significant 
associations with the presence of a pressure ulcer were observed for age or BMI. 
Description of Variables Assessing Metabolic Supply 
Table 4.5 provides descriptive statistics and unadjusted odds ratios for likelihood 
of pressure ulcer for variables assessing metabolic supply.  No statistically significant 
84 
 
 
 
associations with development of a pressure ulcer were observed for nicotine use, 
vasopressor administration, Braden Nutrition scores, or oxygen saturation of hemoglobin 
values (p > 0.05).Nicotine use within one year prior to hospital admission was present in 
39.9% of subjects.  Vasopressor administration was measured at 24 hours prior to study 
enrollment, 48 hours prior to study enrollment, and at any time during the ICU stay prior 
to the 48-hour measure.  A majority of subjects (69.7%) did not receive vasopressors 
within 24 or 48 hours of study enrollment (69.2%).  Vasopressor use prior to the 48-hour 
measure occurred in 44.4% of subjects.  See Appendix D, Table 5 for a complete 
description of vasopressor use prior to study enrollment.  Using VUH laboratory ranges 
as the reference, the combined measures of protein reserve (serum albumin, serum pre-
albumin, and total lymphocyte count) were in the clinically "low" range in 79.3% of 
subjects.  Within the 24 hours prior to study enrollment, minimum Braden Nutrition 
subscale scores were in the low risk range (scores of 3 or 4) in 54.1% of study subjects 
and thus in the high risk range (scores of 1 or 2) in 45.8% of subjects when measured at 
24 hours prior to study enrollment.  Within 48 hours prior to study enrollment, those 
values shifted slightly (Braden Nutrition low risk: 51.9%; high risk: 48.0%).  Lowest 
observed oxygen saturation of hemoglobin measured at 24 hours before study enrollment 
ranged from 71% to 100% (median = 93.0, IQR = 90.0 – 96.0) and measures at 48 hours 
before study enrollment ranged from 67% to 100% (median = 92.0, IQR = 89.0 – 95.0). 
Statistically significant associations with the development of a pressure ulcer were 
observed for hematocrit levels and for MAP (see Table 4.5).  Within 24 hours prior to 
study enrollment, the minimum observed hematocrit levels in case subjects had a median 
hematocrit level of 26.0 (IQR = 24.0 – 29.0) while the controls had a median of 29.0 
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(IQR = 26.0 – 32.0) (p < 0.001).  Highest observed hematocrit levels during the same 
time demonstrated a similar pattern (cases: median = 28.0, controls: median = 29.0, p < 
0.001).  Within 48 hours prior to study enrollment, the minimum observed hematocrit 
levels in case subjects had a median hematocrit level of 27.0 (IQR = 24.0 – 30.0) while 
controls had a median of 29.0 (IQR = 26.0 – 33.0) (p = 0.011).  Highest observed 
hematocrit levels during the same 48 hour period before study enrollment demonstrated a 
similar pattern (cases: median = 28.0, controls: median = 30.0, p = 0.008).   
Within 24 hours prior to study enrollment, the minimum observed MAP in case 
subjects had a median value of 61.0 (IQR = 56.0 – 67.0) mm Hg while the controls had a 
median of 64.0 mm Hg (IQR = 58.0 – 70.0) (p = 0.012).  MAP values obtained 48 hours 
prior to study enrollment demonstrated a similar pattern (cases: median = 61.0, controls: 
median = 63.0, p = 0.023) 
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Table 4. 4. Frequencies and Unadjusted Odds Ratios for Variables Assessing Pressure Distribution Capacity with Pressure 
Ulcer 
 
Variable Variable Descriptor 
Total 
N        % 
Cases 
N           % 
Controls 
N    % 
O.R. p-value CI 95% 
Variables Assessing Pressure Distribution Capacity  
Gender Female 130  (36.1) 52         (28.9) 78    (43.3) Referent  Male 230  (63.9) 128       (71.1) 102  (56.7) 1.88 0.005 1.22 – 2.91 
  Median   (IQR) Median     (IQR) Median    (IQR)    
Age Years 58.0      (47.3 – 67.0) 59       (48.3 – 68.0) 57.5       (46.0 – 67.0) 1.01 0.221 0.99 – 1.02 
BMI* 
Value 27.3      (23.6 – 32.9) 27.6    (23.0 – 33.6) 27.19     (23.9 – 32.5) 1.00 0.775 0.98 – 1.03 
 Total 
N               % 
Cases 
N            % 
Controls 
N            %  
Normal 101        (28.1) 53        (29.4) 48        (26.7) -- 0.677 -- 
Underweight 20          (5.6) 12        (6.7) 8          (4.4) 1.36 0.538 0.51 – 3.60 
Overweight 107        (29.7) 50        (27.8) 57        (31.7) 0.79 0.408 0.46 – 1.37 
Obese 132        (36.7) 65        (36.1) 67        (37.2) 0.88 0.625 0.52 – 1.48 
*Body Mass Index: definitions for categorical ranking from www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
87 
 
 
 
Table 4. 5. Frequencies and Unadjusted Odds Ratios for Variables Assessing Metabolic Supply with Pressure Ulcer 
 
Variable Variable Descriptor 
Total 
N              % 
Cases 
N           % 
Controls 
N            % O.R. p-value CI 95% 
Prior nicotine 
use 
No  
203      (60.1) 
 
[213      (59.2)]* 
 
96       (56.8) 
 
[101    (56.1)] 
107      (63.3) 
 
[112     (62.2)] 
Referent 
Yes 
135      (39.9) 
 
[147      (40.8)] 
73   (43.2) 
 
[79    (43.9)] 
62    (36.7) 
 
[68    (37.8)] 
1.31 
 
[1.29] 
0.222 
 
[0.239] 
0.85 – 2.03 
 
[0.85 – 
1.96] 
Number of 
vasopressors 
used 24 hours 
prior to study 
enrollment 
0 251       (69.7) 117        (65.0) 134       (74.4) -- 0.313 -- 
1 63         (17.5) 36          (20.0) 27         (15.0) 1.53 0.136 0.88 – 2.67 
2 29         (8.1) 17          (9.4) 12         (6.7) 1.62 0.224 0.74 – 3.54 
3 12         (3.3) 8            (4.4) 4           (2.2) 
1.64 0.333 0.60 – 4.44 4 4           (1.1) 1            (0.6) 3           (1.7) 
5 1           (0.3) 1            (0.6) 0           (0.0) 
Number of 
vasopressors 
used 48 hours 
prior to study 
enrollment 
0 249       (69.2) 117        (65.0) 132       (73.3) -- 0.366 -- 
1 68         (18.9) 37          (20.6) 31         (17.2) 1.35 0.279 0.79 – 2.31 
2 27         (7.5) 17          (9.4) 10         (5.6) 1.92 0.119 0.85 – 4.35 
3 9           (2.5) 6            (3.3) 3           (1.7) 1.45 0.474 0.52 – 4.02 
4 6           (1.7) 2            (1.1) 4           (2.2) 
5 1           (0.3) 1            (0.6) 0           (0.0) 
Previous 
vasopressor 
use prior to 48 
hours of study 
enrollment 
No 200      (55.6) 93          (51.7) 107      (59.4) Referent 
Yes 160      (44.4) 87        (48.3) 73        (40.6) 1.37 0.138 0.90 – 2.08 
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Variable Variable Descriptor 
Total 
N              % 
Cases 
N           % 
Controls 
N            % O.R. p-value CI 95% 
Minimum 
protein level 
recorded 
during ICU 
stay prior to 
enrollment 
Normal 
 
67      (20.7) 
 
[83     (23.1)]* 
30      (19.0) 
 
[43      (23.9)] 
37     (22.4) 
 
[40    (22.2)] 
Referent 
 
Low 
256     (79.3) 
 
[277    (76.9)] 
128      (81.0) 
 
[137     (76.1)] 
128      (77.6) 
 
[140    (77.8)] 
 
1.23 
 
[0.91] 
 
0.447 
 
[0.707] 
 
0.72 – 2.12 
 
[0.56 – 
1.49] 
Lowest Braden 
nutrition score 
24 hours 
before study 
enrollment 
4 3       (0.8) 2    (1.1) 1     (0.6) 
-- 0.224 -- 3 192   (53.3) 88   (48.9) 104   (57.8) 
2 121   (33.6) 64   (35.6) 57     (31.7) 1.31 0.244 0.83 – 2.06 
1 44     (12.2) 26    (14.4) 18     (10.0) 1.69 0.123 0.87 – 3.28 
Lowest Braden 
nutrition score 
48 hours 
before study 
enrollment 
4 3       (0.8) 1      (0.6) 2       (1.1) 
-- 0.730 -- 3 184   (51.1) 89    (49.4) 95     (52.8) 
2 133   (36.9) 70    (38.9) 63     (35.0) 1.19 0.427 0.77 – 1.87 
1 40     (11.1) 20    (11.1) 20     (11.1) 1.08 0.830 0.54 – 2.13 
  Total 
Median   (IQR) 
Cases 
Median     (IQR) 
Controls 
Median    (IQR) 
O.R. p-value CI 95% 
Lowest  
hematocrit 
recorded 24 
hours prior to 
study 
enrollment 
  
28.0  (24.0 – 31.0) 
n = 351 
 
[28.0  (24.0 – 31.0)] 
n = 360 
 
26.0 (24.0 – 29.0) 
n = 176 
 
[26.0 (24.0 – 29.0)] 
n = 180 
 
29.0 (26.0 – 32.0) 
n = 175 
 
[29.0 (26.0 – 32.0)] 
n = 180 
 
0.90 
 
 
[0.91] 
 
<0.001 
 
 
[<0.001
] 
 
 
0.86 – 0.95 
 
 
[0.87 – 
0.95] 
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Variable Variable Descriptor 
Total 
N              % 
Cases 
N           % 
Controls 
N            % O.R. p-value CI 95% 
Highest 
hematocrit 
recorded 24 
hours prior to 
study 
enrollment 
  
28.0  (26.0 – 31.0) 
n = 351 
 
[28.0  (26.0 – 31.0)] 
n = 360 
 
28.0 (25.0 – 30.0) 
n = 176 
 
[28.0 (25.0 – 30.0)] 
n = 180 
 
29.0  (26.0 – 33.0) 
n = 175 
 
[29.0  (26.0 – 33.0)] 
n = 180 
0.91 
 
 
[0.91] 
<0.001 
 
 
[<0.001] 
0.87 – 0.95 
 
 
[0.87 – 0.96] 
Lowest  
hematocrit 
recorded 48 
hours prior to 
study 
enrollment 
  
28.0  (25.0 – 31.0) 
n = 351 
 
[28.0  (25.0 – 31.0)] 
n = 360 
 
27.0  (24.0 – 30.0) 
n = 175 
 
[27.0  (24.0 – 30.0)] 
n = 180 
 
29.0  (25.0 – 32.0) 
n = 176 
 
[29.0  (25.0 – 32.0)] 
n = 180 
 
0.95 
 
 
[0.95] 
 
0.011 
 
 
[0.010] 
 
0.91 – 0.99 
 
 
[0.91 – 0.99] 
Highest 
hematocrit 
recorded 48 
hours prior to 
study 
enrollment 
  
29.0 (26.0 – 32.0) 
n =351 
 
[29.0 (26.0 – 32.0)] 
n =360 
 
28.0 (26.0 – 31.0) 
n = 175 
 
[28.0 (26.0 – 31.0)] 
n = 180 
 
30.0  (27.0 – 32.8) 
n = 176 
 
[30.0  (27.0 – 33.0)] 
n = 180 
 
 
0.94 
 
 
[0.94] 
 
0.008 
 
 
[0.005] 
 
0.90 – 0.99 
 
 
[0.90 – 0.98] 
Lowest MAP† 
recorded 24 
hours prior to 
study 
enrollment 
 
63.0  (57.0 – 69.0) 61.0  (56.0 – 67.0) 64.0  (58.0 – 70.0) 0.97 0.012 0.96 – 0.99 
Lowest MAP† 
recorded 48 
hours prior to 
study 
enrollment 
 
62.0  (56.0 – 67.0) 61.0  (55.0 – 66.0) 63.0  (57.0 – 69.8) 0.98 0.023 0.96 – 0.99 
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*Brackets indicate analyses with imputed values †Mean arterial pressure  
Variable Variable Descriptor 
Total 
N              % 
Cases 
N           % 
Controls 
N            % O.R. p-value CI 95% 
Lowest 
oxygen 
saturation 
recorded 24 
hours prior to 
study 
enrollment 
 
92.0  (90.0 – 95.8) 92.5  (90.0 – 95.0) 92.0  (90.0 – 96.0) 1.01 0.631 0.97 – 1.05 
Lowest 
oxygen 
saturation 
recorded 48 
hours prior to 
study 
enrollment 
 
92.0  (90.0 – 95.0) 92.0  (89.3 – 95.0) 92.0  (90.0 – 95.0) 0.99 0.572 0.98 - 1.01 
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Description of Variables Assessing Metabolic Demand 
Metabolic demand summaries are presented in Table 4.6.  No statistically 
significant differences were demonstrated between case and control subjects.  Steroid 
administration during the hospitalization up to 14 days prior to study enrollment occurred 
in 36.7% of case subjects and in 30.6% of control subjects.  See Appendix D, Table 5 for 
a complete description of the type and amount of steroid administration received during 
the hospitalization.  
Description of Variables Assessing Threats to Skin Integrity 
Table 4.6 provides summary and unadjusted associations with pressure ulcers for 
the Braden Moisture (skin integrity) score.  A statistically significantly association with 
pressure ulcer development was observed for values with 24 hours of study enrollment (p 
= 0.002) but not for 48 hours prior to enrollment (p = 0.080).  When measured at 24 
hours prior to study enrollment, low Braden Moisture subscale scores of 1 or 2, indicating 
greatest risk of pressure ulcer incidence, were noted in 31.7% of case subjects and 18.3% 
of control subjects (p < 0.001).  Braden moisture subscale scores of 3 were observed in 
56.1% of case subjects and 57.8% of control subjects (p = 0.031).  
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Table 4. 6. Frequencies and Unadjusted Odds Ratios for Variables Assessing Metabolic Demand and Skin Integrity with 
Pressure Ulcer 
 
Variables Assessing Metabolic Demand 
Variable Variable Descriptor 
Total 
N              % 
Cases 
N            % 
Controls 
N         % O.R. p-value CI 95% 
Steroid 
administration 
within 14 days 
prior to study 
enrollment 
No 239     (66.4) 114      (63.3) 125     (69.4) Referent 
Yes 121     (33.6) 66        (36.7) 55       (30.6) 1.31 0.220 0.85 – 2.04 
Variables Assessing Threats to Skin Integrity 
Lowest Braden 
Moisture 
Score 24 hours 
before study 
enrollment 
4 65      (18.1) 22     (12.2) 43     (23.9) -- 0.002 -- 
3 205    (56.9) 101   (56.1) 104   (57.8) 1.89 0.031 1.06 – 3.39 
2 76      (21.1) 45     (25.0) 31     (17.2) 
3.38 <0.001 1.73 – 6.59 
1 14      (3.9) 12     (6.7) 2       (1.1) 
Lowest Braden 
Moisture 
Score 48 hours 
before study 
enrollment 
4 66      (18.3) 25     (13.9) 41     (22.8) -- 0.080 -- 
3 228    (63.3) 118   (65.6) 110   (61.1) 1.76 0.048 1.00 – 3.08 
2 58      (16.1) 32     (17.8) 26     (14.4) 
2.09 0.037 1.04 – 4.19 
1 8        (2.2) 5       (2.8) 3       (1.7) 
 
 
 
 
 
93 
 
 
 
Table 4. 7. Frequencies and Unadjusted Odds Ratios for Variables Assessing Intensity and Duration of Pressure and Other 
Factors with Pressure Ulcer 
 
Variable Variable Descriptor 
Total 
N              % 
Cases 
N            % 
Controls 
N           % O.R. p-value CI 95% 
Lowest Braden 
Sensory score 
24 hours 
before study 
enrollment 
4 70       (19.4) 28       (15.6) 42       (23.3) -- 0.025 -- 
3 126     (35.0) 57       (31.7) 69      (38.3) 1.24 0.479 0.69 – 2.24 
2 115     (31.9) 63      (35.0) 52      (28.9) 1.82 0.052 0.99 – 3.32 
1 49       (13.6) 32      (17.8) 17      (9.4) 2.82 0.007 1.32 – 6.03 
Lowest Braden 
Sensory score 
48 hours 
before study 
enrollment 
4 60       (16.7) 21      (11.7) 39      (21.7) -- 0.047 -- 
3 129     (35.8) 63      (35.0) 66      (36.7) 1.77 0.076 0.94 – 3.34 
2 121     (33.6) 67      (37.2) 54      (30.0) 2.30 0.011 1.21 -  4.37 
1 50       (13.9) 29      (16.1) 21      (11.7) 2.57 0.017 1.18 – 5.55 
Lowest Braden 
Mobility score 
24 hours 
before study 
enrollment 
4 19       (5.3) 2        (1.1) 17      (9.4) 
-- 0.002 -- 
3 78       (21.7) 34      (18.9) 44      (24.4) 
2 171     (47.5) 86      (47.8) 85      (47.2) 1.71 0.038 1.03 – 2.85 
1 92       (25.6) 58      (32.2) 34      (18.9) 2.89 <0.001 1.60 – 5.22 
Lowest Braden 
Mobility score 
48 hours 
before study 
enrollment 
4 7         (1.9) 1        (0.6) 6        (3.3) 
-- 0.012 -- 
3 86       (23.9) 35      (19.4) 51      (28.3) 
2 164    (45.6) 82      (45.6) 82      (45.6) 1.59 0.082 0.94 – 2.66 
1 103    (28.6) 62      (34.4) 41      (22.8) 2.39 0.003 1.35 – 4.25 
Lowest Braden 
Activity score 
24 hours 
before study 
enrollment 
4 4         (1.1) 0        (0.0) 4        (2.2) 
-- 0.007 -- 
3 24       (6.7) 6        (3.3) 18      (10.0) 
2 83       (23.1) 39      (21.7) 44      (24.4) 3.25 0.021 1.19 – 8.84 
1 249     (69.2) 135    (75.0) 114    (63.3) 4.34 0.002 1.70 – 11.08 
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Lowest Braden 
Activity score 
48 hours 
before study 
enrollment 
4 4         (1.1) 2         (1.1) 2        (1.1) 
-- 0.929 -- 
3 16       (4.4) 8         (4.4) 8        (4.4) 
2 79       (21.9) 38     (21.1) 41      (22.8) 0.93 0.879 0.35 – 2.47 
1 261     (72.5) 132   (73.3) 129    (71.1) 1.02 0.960 0.41 – 2.54  
Lowest Braden 
Friction/Shear 
score 24 hours 
before study 
enrollment  
3 35        (9.7) 9       (5.0) 26      (14.4) -- 0.001 -- 
2 163     (45.3) 75     (41.7) 88      (48.9) 2.46 0.031 1.07 – 5.58 
1 162     (45.0) 96      (53.3) 66      (36.7) 4.20 0.001 1.85 – 9.54 
Lowest Braden 
Friction/Shear 
Score 48 hours 
before study 
enrollment 
3 31      (8.6) 9       (5.0) 22     (12.2) -- 0.018 -- 
2 181    (50.3) 87     (48.3) 94     (52.2) 2.26 0.053 0.99 – 5.18 
1 148    (41.1) 84     (46.7) 64     (35.6) 3.21 0.007 1.38 – 7.44 
 Other Factors 
Restraint use 
No 96        (26.7) 49      (27.2) 47      (26.1) Referent 
Yes 264      (73.3) 131    (72.8) 133    (73.9) 0.95 0.812 0.59 – 1.51 
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Description of Variables Assessing Duration and Magnitude of Pressure and Other 
Variables 
Descriptive statistical summaries and unadjusted associations of the pressure and 
mobility variables in the model with the development of pressure ulcers are presented in 
Table 4.7.  Statistically significant associations with pressure ulcers were observed for he 
Braden Sensory Perception, Mobility, and Friction/Shear scores at both 24 hours and 48 
hours prior to study enrollment (p < 0.05, see Table 4.7).  Activity values within 24 hours 
prior to enrollment were statistically significantly associated (p = 0.007) while values 
within 48 hours were not (p = 0.929). When measured at 24 hours prior to study 
enrollment, low Braden Sensory subscale scores of 1, indicating a high pressure ulcer 
risk, were observed in 17.8% of case subjects and 9.4% of control subjects (p = 0.007). 
When measured at 48 hours prior to study enrollment, Braden Sensory subscales of 1 and 
2 were found to be statistically significantly associated with pressure ulcer (Braden 
Sensory score of 1, p = 0.017; Braden Sensory score of 2, p = 0.011).  When measured at 
both 48 and 24 hours prior to study enrollment, all of the Braden Moisture subscale 
scores were statistically significantly associated with pressure ulcer. Similarly, when 
measured at 24 hours prior to study enrollment, all of the Braden Friction/Shear subscale 
scores were statistically significantly associated with pressure ulcer.  When measured at 
48 hours prior to study enrollment, Friction/Shear subscale scores of 1 and 3 were 
statistically significantly associated (Braden Friction/Shear score 1, p = 0.007; Braden 
Friction/Shear score 3, p = 0.018) while Friction/Shear subscale scores of 2 were not.  
There was no statistically significant association of restraint use with the pressure 
ulcers.  Of the subjects enrolled, 73.3% of them were in restraints prior to study 
enrollment.  (See Table 4.7) 
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Pressure Ulcer Findings 
Multiple pressure ulcers occurred in 51 (28.3%) of case subjects. Of those with 
multiple pressure ulcers, 177 (98.3%) were limited to three or less.  One case subject 
(0.6%) each had four, five, and eight pressure ulcers.  The presence of multiple pressure 
ulcers was confirmed visually per the protocol and had not been documented within 48 
hours after the ICU admission.  They were therefore considered eligible for study 
enrollment.  Table 4.8 describes the frequency, stage, and location of the most severe 
pressure ulcer identified in case patients.  Deep tissue injury occurred the most frequently 
in 72 (40.0%) of case subjects followed by Stage II pressure ulcers.  The sacrum was the 
most commonly occurring location for pressure ulcers (n= 77; 42.8%) followed by the 
right (n=29; 16.1%) and left (n=18; 10.0%) heels.
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Table 4. 8. Distribution and Severity of Pressure Ulcers (N=180) 
 
*No Stage IV pressure ulcers identified
 Pressure Ulcer Stage*  
Pressure Ulcer Location Stage I (n = 24) Stage II (n = 68) Stage III (n = 5) Unstageable 
(n=11) 
Deep Tissue 
Injury (n =72) 
Occiput (n=4) 0 2 0 1 1 
Right ear (n=3) 0 0 0 1 2 
Left ear (n=1) 1 0 0 0 0 
Face (n=2) 0 2 0 0 0 
Left elbow (n=1) 0 1 0 0 0 
Middle back (n=1) 1 0 0 0 0 
Sacrum (n=77) 11 31 4 3 28 
Right ischium (n=1) 0 1 0 0 0 
Left ischium (n=3) 0 1 0 0 2 
Right buttock (n=16) 0 11 0 0 5 
Left buttock (n=11) 0 6 1 2 2 
Right malleolus (n=3) 0 0 0 2 1 
Right leg (n=4) 0 2 0 0 2 
Left leg (n=1) 0 0 0 0 1 
Right heel (n=29) 9 6 0 1 13 
Left heel (n=18) 2 4 0 1 11 
Right foot (n=1) 0 0 0 0 1 
Left foot (n=4) 0 1 0 0 3 
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Summary of Unadjusted (Univariate) Findings 
 
Prior to controlling for the inter-correlations among the factors included in this 
study, gender, a determinate of the capacity to distribute pressure, demonstrated that 
males were more likely to develop pressure ulcers than females (p = 0.005, O.R. = 1.88, 
95% C.I. = 1.22 - 2.91).  Factors contributing conceptually to metabolic supply that did 
show statistical significance were lower hematocrit levels at 24 and 48 hours prior to 
study enrollment, and lower mean arterial pressure recorded within the same timeframe.  
Braden sub-scale scores comprised 15 (68.2%) of the statistically significant findings.  
Subjects with low (1 or 2) Braden Moisture subscales, indicating a higher pressure ulcer 
risk, were statistically significantly more likely to develop a pressure ulcer than subjects 
with Moisture subscale scores of 3 or 4 which represent less pressure ulcer risk.  Similar 
findings were observed in the Braden subscale components of Sensory Perception, 
Mobility, Activity, and Friction/Shear (see Table 4.7).  Of the Braden sub-scales, only 
Nutrition subscale scores, a conceptual component contributing to metabolic supply, were 
not statistically significantly different between case and control subjects.  
 
Multivariate Analysis 
 
Hierarchical multiple logistic regression analysis was conducted controlling for 
the effects of age, then the Braden subscale scores, with the remaining variables added to 
test for the combined effects.  Data analysis was separated into those variables measured 
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at 24 hours prior to study enrollment with and without imputed values, and those 
measured at 48 hours prior to study enrollment with and without imputed values.   
Analysis of Variables Measured 24 Hours Prior to Study Enrollment 
The adjusted associations of age and Braden scores with the likelihood of a 
pressure ulcer are summarized in Table 4.9.   
 
Table 4. 9. Summary of Multivariate Associations with Pressure Ulcer Measured at 24 
Hours Prior to Study Enrollment for Block One and Two 
 
Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95%  
 
O.R. p-value CI 95%  
Block 1  
Age 1.01 0.345 0.99 – 1.02 1.01 0.221 0.99 – 1.02 
Block 2  
Age 1.01 0.327 0.99 – 1.02 1.01 0.193 0.99 – 1.02 
Braden Nutrition 
subscore 3 and 4 -- 0.068 -- -- 0.682 -- 
Braden Nutrition 
subscore 2 1.64 0.068 0.96 – 2.79 1.21 0.436 0.75 – 1.97 
Braden Nutrition 
subscore 1 2.41 0.062 0.96 – 6.07 1.26 0.550 0.59 – 2.69 
Braden Mobility 
subscore 3 and 4 -- 0.753 -- -- 0.551  
Braden Mobility 
subscore 2 1.18 0.667 0.55 – 2.53 1.22 0.583 0.61 – 2.44 
Braden Mobility 
subscore 1 1.48 0.456 0.53 – 4.18 1.67 0.287 0.65 – 4.31 
Braden Activity 
subscore 3 and 4 -- 0.153 -- -- 0.249 -- 
Braden Activity 
subscore 2 4.26 0.054 0.97 – 18.64 2.42 0.112 0.81 – 7.18 
Braden Activity 
subscore 1 3.58 0.107 0.76 – 16.91 1.91 0.285 0.58 – 6.24 
Braden Moisture 
subscore 4 -- 0.005 -- -- 0.027 -- 
Braden Moisture 
subscore 3 2.44 0.024 1.13 – 5.29 1.57 0.185 0.81 – 3.08 
Braden Moisture 
subscore < 3 4.32 0.001 1.79 – 10.43 2.74 0.011 1.27 – 5.92 
Braden Sensory 
Perception subscore 
4 
-- 0.285 -- -- 0.574 -- 
Braden Sensory 
Perception subscore 
3 
0.48 0.071 0.21 – 1.07 0.61 0.184 0.29 – 1.26 
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Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95%  
 
O.R. p-value CI 95%  
Braden Sensory 
Perception subscore 
2 
0.64 0.347 0.26 – 1.62 0.72 0.440 0.31 – 1.65 
Braden Sensory 
Perception subscore 
1 
0.49 0.273 0.14 – 1.74 0.82 0.729 0.27 – 2.51 
Braden 
Friction/Shear 
subscore 3 
-- 0.584 -- -- 0.234 -- 
Braden 
Friction/Shear 
subscore 2 
1.07 0.911 0.35 – 3.23 1.65 0.297 0.64 – 4.26 
Braden 
Friction/Shear 
subscore 1 
1.42 0.563 0.43 – 4.69 2.28 0.117 0.81 – 6.37 
Hierarchical tests without imputed values (N=299): Block 1: Age alone: X2 (df = 1) = 0.89, p = 0.344; Block 
2: Addition of Braden Subscale scores: X2 (df = 13) = 34.72, p = 0.001; Model: X2 (df = 14) = 35.62, p = 0.001  
Hierarchical tests with imputed values (N=360): Block 1: Age alone: X2 (df = 1) = 1.51, p = 0.219; Block 2: 
Addition of Braden Subscale scores: X2 (df = 13) = 30.96, p = 0.003; Model: X2 (df = 14) = 32.46, p = 0.003   
 
 
Consistent with the unadjusted findings, age alone (Block 1) was not statistically 
significantly associated with pressure ulcer outcome.  After controlling for age, there was 
a statistically significant association of the Braden subscales (Block 2) with pressure 
ulcer development for both the complete (X2 (df = 13) = 34.72, p = 0.001) and imputed data 
sets (X2 (df = 13) = 30.96, p = 0.003).  This finding indicates that the Braden subscales are 
statistically significantly related to pressure ulcer outcome, after controlling for the 
effects of age.  Within the set of scores, however, only the moisture subscale score 
contributed uniquely to this effect (see Table 4.9).   
To evaluate the effects of the other variables after controlling for the effects of 
age and the Braden subscales, the remaining variables were entered into the logistic 
regression analysis.  Table 4.10 describes the multivariate associations of all variables 
measured at 24 hours prior to study enrollment. 
101 
 
 
 
Table 4. 10. Summary of Multivariate Associations with Pressure Ulcer Measured at 24 
Hours Prior to Study Enrollment for the Entire Model 
 
Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95%  
 
O.R. p-value CI 95%  
Variables Assessing Pressure Distribution Capacity 
Gender - female Referent Referent 
Gender – male 2.99 < 0.001 1.64 – 5.47 3.09 < 0.001 1.69 – 5.64 
Age 1.03 0.015 1.01 – 1.05 1.03 0.014 1.01 – 1.05 
BMI – normal -- 0.535 -- -- 0.112 -- 
BMI – underweight 1.22 0.766 0.33 – 4.49 1.19 0.789 0.32 – 4.41 
BMI – Overweight  0.65 0.249 0.31 – 1.36 0.66 0.265 0.31 – 1.38 
BMI – Obese 1.00 0.996 0.49 – 2.02 1.00 0.992 0.49 – 2.03 
Variables Assessing Metabolic Supply 
Nicotine use – no Referent Referent 
Nicotine use – yes 1.84 0.051 0.99 – 3.41 1.78 0.064 0.97 – 3.27 
Vasopressor use – 
none  -- 0.769 -- -- 0.841 -- 
Vasopressor use – 1 1.05 0.891 0.52 – 2.14 1.18 0.653 0.58 – 2.41 
Vasopressor use – 2 1.40 0.575 0.43 – 4.54 0.97 0.963 0.31 – 3.05 
Vasopressor use > 2 0.53 0.438 0.11 – 2.63 0.51 0.385 0.11 – 2.33 
Previous vasopressor 
use – no Referent Referent 
Previous vasopressor 
use – yes 1.45 0.193 0.83 – 2.52 1.39 0.245 0.79 – 2.43 
Minimum Protein 
Level – normal  Referent Referent 
Minimum Protein 
Level – low 0.91 0.798 0.44 – 1.89 0.93 0.835 0.45 – 1.91 
Braden Nutrition 
subscore 3 and 4 -- 0.005 -- -- 0.160 -- 
Braden Nutrition 
subscore 2 1.98 0.029 1.07 – 3.55 1.99 0.027 1.09 – 3.69 
Braden Nutrition 
subscore 1 5.39 0.003 1.79 – 16.22 5.24 0.003 1.76 – 15.61 
Low hematocrit 0.89 < 0.001 0.83 – 0.95 0.89 < 0.001 0.83 – 0.95 
Low MAP 0.99 0.344 0.96 – 1.01 0.99 0.332 0.96 – 1.01 
Oxygen saturation of 
hemoglobin 1.04 0.176 0.98 – 1.09 1.03 0.256 0.98 – 1.09 
Variables Assessing Metabolic Demand 
Steroid use during 
hospitalization – no Referent Referent 
Steroid use during 
hospitalization – yes 1.15 0.665 0.61 – 2.15 1.19 0.588 0.64 – 2.22 
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Variables Assessing Threats to Skin Integrity 
Braden Moisture 
subscore 4 -- 0.004 -- -- 0.013 -- 
Braden Moisture 
subscore 3 2.77 0.024 1.15 – 6.72 2.78 0.023 1.15 – 6.72 
Braden Moisture 
subscore < 3 5.34 0.001 1.96 – 14.56 5.49 0.001 2.02 – 14.95 
Variables Assessing Intensity and Duration of Pressure  
Braden Mobility 
subscore 3 and 4 -- 0.770 -- -- 0.425 -- 
Braden Mobility 
subscore 2 1.09 0.846 0.47 – 2.61 1.13 0.779 0.47 – 2.72 
Braden Mobility 
subscore 1 1.46 0. 526 0.46 – 4.68 1.5 0.498 0.47 - 4.84 
Braden Activity 
subscore 3 and 4 -- 0.024 -- -- 0.053 -- 
Braden Activity 
subscore 2 9.91 0.006 1.90 – 51.64 9.92 0.006 1.91 – 51.59 
Braden Activity 
subscore 1 9.98 0.011 1.71– 58.34 9.53 0.012 1.64 – 55.31 
Braden Sensory 
Perception subscore 
4 
-- 0.140 -- -- 0.452 -- 
Braden Sensory 
Perception subscore 
3 
0.44 0.087 0.17 – 1.13 0.45 0.089 0.18- 1.13 
Braden Sensory 
Perception subscore 
2 
0.74 0.576 0.25 – 2.17 0.75 0.594 0.25 – 2.19 
Braden Sensory 
Perception subscore 
1 
0.35 0.158 0.08 – 1.51 0.36 0.170 0.08 – 1.55 
Braden 
Friction/Shear 
subscore 3 
-- 0.403 -- -- 0.237 -- 
Braden 
Friction/Shear 
subscore 2 
0.69 0.551 0.19 – 2.37 0.66 0.513 0.19 – 2.29 
Braden 
Friction/Shear 
subscore 1 
1.02 0.975 0.27 – 3.87 1.02 0.973 0.27 – 3.86 
Other Factors 
Restraint use – no Referent Referent 
Restraint use – yes 0.42 0.022 0.19 – 0.88 0.43 0.025 0.20 – 0.89 
 
Test of the final overall model without imputed data (N = 299): X2 (df = 29) = 81.17, p < 0.001 
Test of the final overall model with imputed data (N = 360): X2 (df = 29) = 86.53, p < 0.001  
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The remaining set of variables (nicotine use, BMI, gender, vasopressor use, 
protein level, steroid use during hospitalization, restraint use, and lowest observed 
hematocrit, MAP, and oxygen saturation of hemoglobin 24 hours before study 
enrollment) were added in the final step of the hierarchical analysis.  After controlling for 
age and the Braden scores, the set added statistically significantly to the model (Complete 
data: X2 (df = 15) = 45.61, p < 0.001; Imputed data set: X2 (df = 15) = 54.07, p < 0.001).  As 
would be expected, the overall model containing all of the variables was statistically 
significant (p < 0.001).  Within the set of added variables the following variables 
contributed to that effect: gender, restraint use, and lowest hematocrit levels.  The 
adjusted effects of restraint use on pressure ulcer outcome indicated that restrained 
subjects were approximately 60% less likely to develop a pressure ulcer than unrestrained 
subjects using variables with (p = 0.025, O.R. = 0.43, 95% C.I. = 0.20 – 0.89) and 
without (p = 0.022, O.R. = 0.42, 95% C.I. = 0.19 – 0.88) imputed data.   
Finally, once all variables were adjusted for in the analysis some findings 
emerged that were not apparent in the unadjusted or in the previous steps.  Age became a 
statistically significant variable.  Subjects were 3% more likely to develop a pressure 
ulcer with each increase in age by one year using variables with (p = 0.014, O.R. = 1.03, 
95% C.I. = 1.01 – 1.05) and without (p = 0.015, O.R. = 1.03, 95% C.I. = 1.01 – 1.05) 
imputed data.  Braden subscales of Nutrition and Activity became statistically significant 
in the overall test of the model only when data without imputed values were used 
(Nutrition p = 0.005; Activity p = 0.024).   
Variables remaining statistically significant in the adjusted analysis included 
Braden Moisture subscale and low hematocrit using the variables with and without 
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imputed values.  Braden Activity subscale maintained the statistical significance 
demonstrated in univariate associations with pressure ulcer in multivariate analysis using 
only the variables without imputed values.   
Finally, variables that appeared to be statistically significant in the unadjusted or 
in the model without the last set of variables but were no longer in the full model 
included Braden Sensory Perception and Friction/Shear subscales.  Similarly, MAP was 
no longer statistically significant in multivariate tests of its association with pressure 
ulcer outcome.  
Analysis of Variables Measured 48 Hours Prior to Study Enrollment 
Another multiple hierarchical logistic regression analysis was conducted using 
variables assessed 48 hours prior to study enrollment. Table 4.11 summarizes that 
analysis.  
 
Table 4. 11. Summary of Multivariate Associations with Pressure Ulcer Measured at 48 
Hours Prior to Study Enrollment for Block One and Two 
 
Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95%  
 
O.R. p-value CI 95%  
Block 1  
Age 1.01 0.303 0.99 – 1.03 1.01 0.221 0.99 – 1.02 
Block 2  
Age 1.01 0.200 0.94 – 1.03 1.01 0.112 0.99 – 1.03 
Braden Nutrition 
subscores 3 and 4 -- 0.638 -- -- 0.586 -- 
Braden Nutrition 
subscore 2 1.24 0.432 0.73 – 2.09 1.22 0.416 0.75 – 1.98 
Braden Nutrition 
subscore 1 0.89 0.788 0.39 – 2.06 0.87 0.715 0.42 – 1.83 
Braden Mobility 
subscore 3 and 4 -- 0.167 -- -- 0.162 -- 
Braden Mobility 
subscore 2 1.72 0.178 0.78 – 3.77 1.47 0.266 0.75 – 2.91 
Braden Mobility 
subscore 1 2.62 0.059 0.97 – 7.09 2.30 0.061 0.96 – 5.51 
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Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95%  
 
O.R. p-value CI 95%  
Braden Activity 
subscore 3 and 4 -- 0.135 -- -- 0.039 -- 
Braden Activity 
subscore 2 0.42 0.203 0.11 – 1.59 0.44 0.154 0.14 – 1.36 
Braden Activity 
subscore 1 0.27 0.058 0.07 – 1.05 0.25 0.019 0.08 – 0.79 
Braden Moisture 
subscore 4 -- 0.603 -- -- 0.492 -- 
Braden Moisture 
subscore 3 1.71 0.178 0.78 – 3.77 1.49 0.234 0.77 – 2.86 
Braden Moisture 
subscore < 3 2.62 0.059 0.97 – 7.09 1.41 0.393 0.64 – 3.08 
Braden Sensory 
Perception subscore 
4 
-- 0.582 -- -- 0.605 -- 
Braden Sensory 
Perception subscore 
3 
1.08 0.85 0.48 – 2.43 1.45 0.322 0.69 – 3.05 
Braden Sensory 
Perception subscore 
2 
1.57 0.345 0.62 – 3.96 1.79 0.175 0.77 – 4.19 
Braden Sensory 
Perception subscore 
1 
1.03 0.95 0.33 – 3.23 1.67 0.335 0.59 – 4.75 
Braden 
Friction/Shear 
subscore 3 
-- 0.300 -- -- 0.249 -- 
Braden 
Friction/Shear 
subscore 2 
1.95 0.207 0.69 – 5.52 1.95 0.171 0.75 – 5.09 
Braden 
Friction/Shear 
subscore 1 
2.36 0.123 0.79 – 7.05 2.36 0.098 0.86 – 6.51 
Hierarchical tests without imputed values (N=301): Block 1: Age alone: X2 (df = 1) = 1.07, p = 0.302; Block 
2: Addition of Braden Subscale scores: X2 (df = 14) = 19.87, p = 0.134; Model: X2 (df = 15) = 20.93, p = 0.139 
Hierarchical tests with imputed values (N=360): Block 1: Age alone: X2 (df = 1) = 1.51, p = 0.219; Block 2: 
Addition of Braden Subscale scores: X2 (df = 13) = 22.59, p = 0.047; Model: X2 (df = 14) = 24.09, p = 0.045 
 
 
Similar to the 24 hour model, age alone (Block 1) was not a statistically 
significantly associated with pressure ulcer outcome.  After controlling for age, addition 
of the Braden subscales (Block 2)  was not statistically significantly associated with 
pressure ulcer outcome using variables without imputed values (X2 (df = 14) = 19.87, p = 
0.134); however, with the larger sample size of imputed data was statistically significant  
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(X2 (df = 13) = 22.59, p = 0.047).  None of the individual Braden subscales was statistically 
significantly associated with pressure ulcer outcome in Block 2 of the model.  After 
controlling for age and the Braden scores, the set added statistically significantly to the 
model when imputed data were used (X2 (df = 14) = 22.01, p = 0.045) but did not add 
statistically significantly to the model when the complete data set was used (X2 (df = 15) = 
22.94, p = 0.139). 
The results of the final model at 48 hours are presented in Table 4.12.  The 
remaining set of variables (nicotine use, BMI, gender, vasopressor use, protein level, 
steroid use during hospitalization, restraint use, and lowest observed hematocrit, MAP, 
and oxygen saturation of hemoglobin 48 hours before study enrollment) were added in 
the final step of the hierarchical analysis.  After controlling for age and the Braden 
scores, the set added statistically significantly to the model (Complete data: X2 (df = 15) = 
32.09, p = 0.006; Imputed data set: X2 (df = 15) = 36.42, p = 0.002).  As with the variables 
measured at 24 hours, the overall model containing all of the variables measured at 48 
hours prior to study enrollment was statistically significant (p < 0.001).  Within the set of 
added variables, gender and low hematocrit contributed to that effect. The adjusted 
effects of restraint use on pressure ulcer outcome indicated that restrained subjects were 
approximately 50% less likely to develop a pressure ulcer than unrestrained subjects 
using variables with imputed data (p = 0.041, O.R. = 0.52, 95% C.I. = 0.28 – 0.97); 
however, restraint use was not statistically significantly associated with pressure ulcer 
using the complete data set (p = 0.117).    
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Table 4. 22. Summary of Multivariate Associations with Pressure Ulcer Measured at 48 
Hours Prior to Study Enrollment for the Entire Model 
Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95% O.R. p-value CI 95% 
Variables Assessing Pressure Distribution Capacity 
Gender - female Referent Referent 
Gender – male 2.52 0.001 1.43 – 4.44 2.29 0.001 1.38 – 3.83 
Age 1.02 0.082 0.99 – 1.04 1.02 0.020 1.00 – 1.04 
BMI – normal -- 0.341 -- -- 0.161 -- 
BMI – underweight 1.39 0.588 0.42 – 4.68 2.02 0.209 0.67 – 6.06 
BMI – Overweight  0.59 0.131 0.29 – 1.17 0.64 0.155 0.35 – 1.18 
BMI – Obese 0.75 0.405 0.38 – 1.48 0.78 0.427 0.43 – 1.43 
Variables Assessing Metabolic Supply 
Nicotine use – no Referent Referent 
Nicotine use – yes 1.32 0.341 0.74 – 2.35 1.53 0.104 0.92 – 2.56 
Vasopressor use – none  -- 0.529 -- -- 0.767 -- 
Vasopressor use – 1 1.48 0.241 0.77 – 2.85 1.16 0.641 0.63 – 2.14 
Vasopressor use – 2 1.88 0.267 0.62 – 5.73 1.37 0.528 0.52 – 3.59 
Vasopressor use > 2 1.12 0.882 0.26 – 4.79 0.69 0.544 0.21 – 2.31 
Previous vasopressor 
use – no Referent Referent 
Previous vasopressor 
use – yes 1.53 0.121 0.89 – 2.63 1.32 0.263 0.81 – 2.16 
Minimum Protein 
Level – normal  Referent Referent 
Minimum Protein 
Level – low 1.14 0.696 0.59 – 2.20 0.75 0.316 0.43 – 1.32 
Braden Nutrition 
subscore 3 and 4 -- 0.831 -- -- 0.705 -- 
Braden Nutrition 
subscore 2 1.16 0.597 0.66 – 2.05 1.21 0.482 0.72 – 2.03 
Braden Nutrition 
subscore 1 0.94 0.897 0.36 – 2.42 0.91 0.826 0.39 – 2.11 
Low hematocrit 0.94 0.030 0.89 – 0.99 0.95 0.017 0.91 – 0.99 
Low MAP 
0.99 0.454 0.97 – 1.01 0.99 0.240 0.96 – 1.01 
Oxygen saturation of 
hemoglobin 0.99 0.557 0.98 – 1.01 0.99 0.550 0.98 – 1.01 
Variables Assessing Metabolic Demand 
Steroid use during 
hospitalization – no Referent Referent 
Steroid use during 
hospitalization – yes 1.06 0.837 0.59 – 1.93 1.23 0.443 0.72 – 2.09 
 
 
Variables Assessing Threats to Skin Integrity 
 
Braden Moisture 
subscore 4 -- 0.566 -- -- 0.317 -- 
Braden Moisture 
subscore 3 1.50 0.318 0.68 – 3.35 1.70 0.144 0.83 – 3.47 
Braden Moisture 
subscore < 3 1.60 0.326 0.62 – 4.13 1.78 0.188 0.75 – 4.22 
Variables Assessing Intensity and Duration of Pressure 
Braden Mobility -- 0.116 -- -- 0.094 -- 
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Variable Without Imputed Values With Imputed Values 
 O.R. p-value CI 95% O.R. p-value CI 95% 
subscore 3 and 4 
Braden Mobility 
subscore 2 1.91 0.128 0.83 – 4.38 1.72 0.147 0.83 – 3.59 
Braden Mobility 
subscore 1 3.12 0.038 1.06 – 9.13 2.87 0.030 1.12 – 7.46 
Braden Activity 
subscore 3 and 4 -- 0.137 -- -- 0.093 -- 
Braden Activity 
subscore 2 0.34 0.151 0.08 – 1.48 0.42 0.165 0.12 – 1.43 
Braden Activity 
subscore 1 0.22 0.051 0.05 – 1.01 0.26 0.038 0.07 – 0.93 
Braden Sensory 
Perception subscore 4 -- 0.598 -- -- 0.740 -- 
Braden Sensory 
Perception subscore 3 0.91 0.839 0.37 – 2.24 1.35 0.481 0.58 – 3.15 
Braden Sensory 
Perception subscore 2 1.43 0.509 0.49 – 4.09 1.68 0.300 0.63 – 4.47 
Braden Sensory 
Perception subscore 1 0.99 0.989 0.28 – 3.55 1.77 0.335 0.55 – 5.69 
Braden Friction/Shear 
subscore 3 -- 0.356 -- -- 0.297 -- 
Braden Friction/Shear 
subscore 2 1.86 0.282 0.60 – 5.74 1.73 0.302 0.61 – 4.91 
Braden Friction/Shear 
subscore 1 2.30 0.163 0.71 – 7.43 2.27 0.143 0.76 – 6.78 
Other Factors  
Restraint use – no Referent Referent 
Restraint use – yes 0.58 0.117 0.29 – 1.15 0.52 0.041 0.28 – 0.97 
Test of the final overall model without imputed data (N = 299): X2 (df = 29) = 81.17, p < 0.001 
Test of the final overall model with imputed data (N = 360): X2 (df = 29) = 86.53, p < 0.001 
 
 
Multivariate associations of age with pressure ulcer outcome again became 
statistically significant in the overall model with imputed values (p = 0.020, O.R. = 1.02, 
95% C.I. = 1.00 – 1.04); however, multivariate associations of age with pressure ulcer 
outcome were not statistically significant using imputed values (p = 0.082, O.R. = 1.02, 
95% C.I. = 0.99 – 1.04).  Braden Activity subscore, identified as a statistically significant 
association with pressure ulcer in Block 2 (p = 0.039) of the 48-hour multivariate analysis 
was no longer statistically significant in Block 3 (p = 0.705).  
Using both the complete (p = 0.001, O.R. = 2.52, 95% C.I. = 1.43 – 4.44) 
variables and variables with imputed data (p = 0.001, O.R. = 2.29, 95% C.I. = 1.38 – 
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3.83), male gender demonstrated a statistically significant association with pressure ulcer 
at 48 hours prior to study enrollment.  Similarly, low hematocrit demonstrated a 
statistically significant association with pressure ulcer at 48 hours prior to study 
enrollment with both complete (p = 0.030, O.R. = 0.94, 95% C.I. = 0.89 – 0.99) and 
imputed data ((p = 0.017, O.R. = 0.95, 95% C.I. = 0.91 – 0.99). None of the Braden 
subscale scores were statistically significantly associated with pressure ulcer in the final 
model using variables obtained 48 hours to study enrollment.   
 
Summary 
 
 Although the Braden subscale scores are statistically significantly associated with 
pressure ulcer outcomes, the addition of other variables at both 24 and 48 hours did 
contribute statistically significantly to the overall model.  With the exception of nutrition, 
all of the Braden subscale scores were statistically significant in unadjusted (univariate) 
analysis.  In multivariate analysis, Braden Nutrition (without imputed values), Activity 
(without imputed values), and Moisture were statistically significantly associated with 
pressure ulcer when analyzed with scores obtained 24 hours prior to study enrollment, but 
did not show a statistically significant association with pressure ulcer when analyzed with 
scores obtained 48 hours before study enrollment. Consequently, none of the Braden 
subscores were uniquely identified as statistically significant predictors when analyzed 
with their scores obtained 48 hours prior to study enrollment.  Increased age and restraint 
use, although not identified as statistically significant in unadjusted, did demonstrate 
statistically significant associations with pressure ulcer when analyzed with data collected 
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at 24 and 48 hours prior to study enrollment. Male gender and low hematocrit were 
statistically significantly associated with pressure ulcer in unadjusted and adjusted 
analyses at both 24 and 48 hours prior to study enrollment.    
 
Secondary Aim 
 
The secondary aim of this study was to compare the frequency and magnitude of 
pressure ulcer risk factors between critically ill patients that have progression of their 
Stage I  pressure ulcer during the ICU stay to those who do not have a progression of 
their Stage I pressure ulcer during the ICU stay. 
Stage I pressure ulcers were identified in 24 of the case subjects.  Of those, four 
(1.1%) subjects had their pressure ulcers deteriorate into a Stage II or worse during their 
ICU stay.  Ages of these four subjects ranged from 27 years to 74 years ( median = 58 
years for entire sample), and length of ICU stay until a pressure ulcer developed ranged 
from nine to 22 days (median = 7 days for the entire sample).  Two were males.  Low 
hematocrit ranged from 24% to 36% (𝜒� = 28.0% for the entire sample).  One of the four 
subjects was quadriplegic requiring permanent ventilator support.  Because of the low 
percentage of those subjects that experienced a worsening pressure ulcer during their ICU 
stay, no statistical inferences can be made.  
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CHAPTER V 
 
DISCUSSION 
 
This chapter provides an overview of the primary and secondary aims of this 
dissertation research and findings for each of the aims are discussed relative to their 
contributions to the conceptual model identified in Chapter II.  Strengths and limitations 
are presented and the implications of this research are discussed.  Finally, an outline of 
recommendations for future research is presented.  
 
Primary Aim 
 
To compare the frequency and magnitude of pressure ulcer risk factors between 
critically ill patients that do and do not develop a pressure ulcer during their ICU stay and 
evaluate their influence on the associations between the Braden subscales and pressure 
ulcer outcome.  To examine any temporal differences in importance of pressure ulcer risk 
factors, they were measured at 48 hours and 24 hours prior to study enrollment.  
  
Predictive Ability of the Braden Score in Critically Ill Patients 
 
A hierarchical test of the independent variables initially controlled for the effects 
of age and then tested for the added effect of the Braden subscale scores.  As indicated 
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from the adjusted effects of the association after controlling for age, the Braden subscale 
scores at 24 hours prior to study enrollment were statistically significant (p < 0.001 with 
and without imputed data).  A similar hierarchical test using Braden subscale scores 
obtained 48 hours prior to study enrollment demonstrated that the added associations of 
the Braden subscale scores after controlling for age were not statistically significant when 
analyzed without imputed data (p = 0.100).  When analyzed with imputed data, the added 
effects of the Braden subscale scores did reach statistical significance (p = 0.047).  The 
findings of this study indicate that the Braden subscale scores reflect more of an 
association with pressure ulcers when measured within 24 hours of pressure ulcer 
occurrence than they do when measured within 48 hours of pressure ulcer occurrence.   
The temporal relationship between Braden Scale and pressure ulcer has not been 
widely evaluated in the literature (Brown, 2004).  In their study of 843 subjects in tertiary 
care, skilled nursing facilities (SNFs), and Veteran’s Administration Medical Centers 
(VAMCs), Bergstrom, Braden, Kemp, Champagne and Ruby (1998) evaluated the 
specificity and sensitivity of the Braden Scale on admission to the facility, 48 to 72 hours 
after admission.  A third measure (indicated as Time 3) was calculated as the time 
between the last observation and first recorded pressure ulcer.  Bergstrom et al.’s findings 
indicated that Time 3 was least useful in pressure ulcer prediction in tertiary care settings 
compared to VAMCs and SNFs, but the authors did not indicate the number of days 
between risk score and pressure ulcers development.   
Although the Braden Scale was not evaluated, Nijs et al. (2008) found that factors 
affecting metabolic supply and demand such as dialysis, vasopressor use, and elevated 
body temperature were statistically significantly associated with pressure ulcer outcome 
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when measured at 24 and 48 hours before the occurrence of a pressure ulcer.  In their 
study of 520 critically ill patients receiving care in a surgical unit, use of sedatives, a 
component that theoretically diminishes a patient’s ability to minimize intensity and 
duration of pressure, was found to be a protective factor 24 hours (p = 0.006, O.R = 0.30, 
95% C.I = 0.13 – 0.70) and 48 hours (p = 0.004, O.R = 0.27, 95% C.I = 0.11 – 0.65).  
Nijs et al. suggested that reduced muscle tension associated with sedative use may 
facilitate preventive measures.  Multivariate analyses in this study were conducted only 
on variables that demonstrated a p-value ≤ 0.2 with univariate logistic regression, thereby 
enhancing the chances of a Type I or II error in the study findings. 
There are two possible explanations for the findings in this study.  First, it is 
possible that patients are assessed as low pressure ulcer risk (higher Braden subscale 
scores) until there is visual evidence of skin damage, such as blanching erythema or 
dermatitis, that leads to pressure ulcer development.  This explanation assumes that the 
presence of skin damage biases the rater toward lower (higher risk) Braden subscale 
scores.  A second explanation may lie with the acute nature of critically ill patients whose 
pressure ulcer risk can change significantly over the course of hours.  This explanation 
favors Benoit and Mion’s (2012) idea that tissue tolerance serves as a moderating factor 
between duration and intensity of pressure and pressure ulcer outcomes.  Components of 
tissue tolerance may be the critical determinates of pressure ulcers in critically ill 
patients.  Patients with depleted tissue tolerance reserve may be susceptible to acute 
changes that pressure ulcers develop more quickly than they would in patients with better 
tissue tolerance reserves. The implication of this second explanation is that the Braden 
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Score, when used alone, may lack the sensitivity to capture acute changes in tissue 
tolerance that quickly lead to pressure ulcer development.   
 
Statistically Significant Variables Assessing Tissue Tolerance for  
Pressure at 24 Hours 
 
Indeed, when variables that assessed tissue tolerance were added to the 
multivariate regression, male gender, increased age, lower hematocrit, and Braden 
Nutrition and Moisture subscale scores were all statistically significant in their 
associations with pressure ulcer outcome when measured at 24 hours prior to study 
enrollment.  All are included in Benoit and Mion’s (2012) conceptual model as affecting 
tissue tolerance for pressure.  Of the remaining variables analyzed in this study, only the 
Braden subscale score for Activity and restraint use were identified as statistically 
significant at 24 hours.  Neither of these variables was considered by Benoit and Mion to 
affect tissue tolerance, but do play a role in affecting magnitude and duration of pressure.  
Gender   
van Rijswijk (2001) and Sayar et al. (2008) questioned the significance of gender 
as a pressure ulcer risk factor, citing conflicting findings in the published literature on the 
influence of gender on pressure ulcer development.  Fisher, Wells, and Harrison (2004) 
postulated that females would be more prone to pressure ulcer development because 
males tend to have better tissue tolerance for pressure due to higher muscle mass and 
anabolic hormones.  Males, however, tend to have less body fat than females, 
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theoretically reducing their ability to distribute pressure across the body surface (Nixon, 
2001), thereby making males more vulnerable to pressure ulcer development.   
Male gender was a statistically significant risk factor for pressure ulcer 
development in both univariate and multivariate analysis findings in this study.  This is 
consistent with those results reported by Nonnemacher et al. (2008); however, female 
gender as an important risk factor has also been reported.  Lindgren et al., 2004 sampled 
a mixed group of surgical patients (n = 286) and reported female gender to be statistically 
significantly associated with pressure ulcers in multivariate analysis (p = 0.003; O.R. = 
0.27, 95% C.I. = 0.11 – 0.68) although the odds ratios reported indicate female gender is 
a protective factor.  Furthermore, the women in Lindgren et al.’s study were significantly 
older than males, and demonstrated higher risk for pressure ulcer development on 
admission to the study, possibly explaining the findings.  In a multisite study of 530 
subjects admitted to a tertiary care facility and a county hospital, female gender was 
identified as a risk factor with univariate analysis, but the variable did not maintain 
significance in multivariate analysis (Lindgren et al., 2005).  It is unclear if the sample 
populations were shared between this study and the previous one by Lindgren et al. 
published a year earlier.  The population in Lindgren et al.’s 2005 study was reported to 
include 286 surgical subjects- the same number of subjects included in Lindgren et al.’s 
2004 study.  
 Because gender was not controlled for in this study, there was a disproportionate 
representation of males (63.9%) in this study.  This sampling bias could account for the 
findings in this study. 
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Age   
The relationship between increasing age and pressure ulcer incidence is well 
documented in the literature.  A PubMed search of the literature using the search terms 
age and pressure ulcer risk with no limits returned 577 articles, indicating that the 
relationship is well studied.  The effects of age on pressure ulcer risk in the critically ill 
patient population share the positive association documented for subjects with less acute 
illness, and there is little evidence that the magnitude of the relationship between 
increased age and pressure ulcers in critically ill patients is more pronounced. In their 
study of 3,026 critically ill patients, Eachempati, Hydo, & Barie (2001) found increased 
age to retain its statistical significance with multivariate analysis (p = 0.003; O.R. = 1.08, 
95% C.I. = 0.003 – 0.013).  Increased age was identified as statistically significant with 
univariate analysis in two other studies of critically ill patients, but age did not maintain 
its statistical significance in multivariate analyses. In their study of 332 critically ill 
patients, Theaker et al., 2000 found that the odds of developing a pressure ulcer increased 
by approximately 80% for each increase in year of age (p = 0.025; O.R. = 1.79, 95% C.I. 
= 0.003 – 0.013).  Papantonio, Wallop, & Kolodner (1994) reported categorical findings 
for age in their study of 136 thoracic surgery patients.  Subjects ≥ 70 years of age were 
five times more likely to develop a pressure ulcer than subjects less than 70  years of age 
(p = 0.001; O.R. = 5.38, 95% C.I. = 1.96 – 14.76).   
Age did demonstrate a slight decrease in p-value from 48 hours (p = 0.020) to 24 
hours (p = 0.014) when imputed values were used, and odds ratios remained 
approximately the same (1.02 at 48 hours; 1.03 at 24 hours).  One possible explanation 
for the lack of statistical change for age in this study was the similar age ranges among 
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case and control patients.  Age ranged between 51 and 70 years for 50.6% of subjects in 
this study (controls = 46.1%; cases = 55.0%).  Subjects older than 70 years accounted for 
16.4% (controls = 16.7%; cases = 16.1%) of the study population.  Patients older than 89 
years were not enrolled in this study because of protective measures of human subjects 
and concerns for this vulnerable population.  The homogenous mix of age in this study is 
representative of the population most likely to require intensive care during their hospital 
stay and may explain the lack of statistical change in odds ratios and significance from 48 
to 24 hours.   
Hematocrit 
Hematocrit levels were randomly missing in nine subjects, and values for this 
variable were imputed.  Lower hematocrit values demonstrated statistical significance 
with univariate and multivariate analyses 24 and 48 hours prior to pressure ulcer 
development using the variable with and without imputed data.  This finding is consistent 
with those reported in several studies of pressure ulcer risk factors.  In studies of 149 
acute care patients, Olson et al. (1996) found decreased hemoglobin on admission to be 
univariately associated with pressure ulcer incidence.  Strordeur, Laurent, and D’Hoore 
(1998) found decreased hemoglobin on admission to be statistically significant in 
univariate and multivariate analyses of 163 cardiac surgery patients.  In studies of 
critically ill patients, Lewicki et al. (1997) reported a statistically significant difference (p 
= 0.004) between hematocrit values in 337 pressure ulcer positive and pressure ulcer 
negative patients.  Nijs et al. (2008) reported statistically significant univariate findings 
for hemoglobin 48 hours prior to pressure ulcer development (p = 0.015; O.R. 0.78; 95% 
C.I. = 0.64 – 0.95) in their study of 520 patients receiving care in a surgical ICU,  but the 
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variable did not maintain its statistical significance with multivariate analysis.  Theaker et 
al. (2000) found anemia to be statistically significant when analyzed at both univariate (p 
= 0.013; O.R. 3.23; 95% C.I. = 1.89 – 5.51) and multivariate (p = 0.013; O.R. 2.81; 95% 
C.I. = 1.24 – 6.34) levels for 286 patients in a general ICU.   
The findings in this study demonstrate stronger p-values at for both imputed and 
non-imputed variables at 24 hours (p < 0.001) than the studies cited above, and similar p-
values for imputed and non-imputed variables at 48 hours (without imputed value, p = 
0.030; with imputed values, p = 0.017) (see Table 4.8 and 4.10).  The implications of this 
finding are discussed below. 
Braden Nutrition Subscale   
Of the Braden subscales, Nutrition is the only one requiring some historical 
knowledge of the patient (see Table 2.5).  Temporary food intake restrictions, such as for 
surgical procedures, do not adversely affect the Braden Nutrition subscale score.  
Additionally, physicians and dieticians closely monitor nutritional status in the ICUs, and 
aggressive measures provide adequate nutritional support during critical illness.  No 
studies were located that described statistical significance of Braden Nutrition subscore in 
isolation; however, depleted protein stores are a common finding among critically ill 
patients (Anthony, et al., 2000).  In their study of 186 patients in a neurologic ICU, Fife 
et al. (2001) did report low serum albumin to be statistically significant with pressure 
ulcers (p = 0.033), but it is unclear how the variables for multivariate analysis were 
selected, and no odds ratios or confidence intervals are reported.  Perhaps the largest 
study to demonstrate a statistically significant multivariate association between 
nutritional status and pressure ulcer outcome was in Nonnemacher et al.’s (2008) study of 
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34,238 patients admitted to a large university hospital.  Multivariate analysis in that study 
demonstrated that patients with insufficient nutrition were 60% more likely to develop a 
pressure ulcer than those patients who did not have nutritional insufficiency (p = 0.002, 
O.R. = 1.61; 95% C.I. = 1.20 – 2.17).  Eachempati et al. (2001) also reported similar 
multivariate findings. 
Measures of protein reserve did not show statistical significance in this study.  
This finding is understandable given that the majority of both case and control subjects 
had low protein levels (79.3% without imputed data and 76.9% with imputed data).  
Braden Moisture Subscale   
Braden’s Moisture subscale assesses threats to skin integrity in the conceptual 
model described in Table 2.4, and is theorized to affect the tissue’s extrinsic tolerance for 
pressure.  Prolonged exposure of skin to moisture contributes to skin integrity problems 
(Nixon, 2001; Sayar et al., 2008), especially with reference to urinary and fecal 
incontinence.  Several studies identified some element of moisture (perspiration, urinary 
or fecal incontinence) as a statistically significant risk factor in univariate or multivariate 
analysis of their findings.  In their study of  286 patients admitted to an urban teaching 
hospital, Allman, et al. (1995) found high incidence of fecal incontinence to be a 
significant risk factor with univariate analysis ( p = 0.04, no O.R. reported).  Halfens, et 
al. (2000) found moisture to co-exist with the summative Braden score (that includes the 
Moisture subscale) as a multivariate statistically significant risk factor (p < 0.01, O.R. = 
2.35, 95% C.I. = 1.40 – 3.94) in 320 subjects enrolled in a multi-center study.  
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Statistically Significant Variables Assessing Intensity and Duration of Pressure  
at 24 Hours 
 
 
Braden Activity Subscale  
In the study by Lindgren et al. (2004, n = 530) decreased physical activity was 
identified as a statistically significant predictor of pressure ulcer incidence in univariate 
analysis of non-ICU patients (p = 0.029, O.R. = 0.77, 95% C.I. = 0.62 – 0.97).  In a study 
of 3026 critically ill patients, Eachempati et al. (2001) identified number of days in bed to 
be a statistically significant predictor with both univariate (p = 0.0328) and multivariate 
analysis (p = 0.0064).  The odds ratio reported in Eachempati et al.’s study is 1.05 and the 
95% confidence interval is reported as -0.0013 – 0.0156.  It is unclear with which p-value 
the odds ratio and confidence interval are associated.   
Restraints  
Use of upper limb restraints is common in ICUs as a method to prevent tube 
dislodgement by patients.  There is some evidence in the literature suggesting that 
restraint use pre-disposes patients to pressure ulcers (Castle & Engberg, 2009), but the 
association has not been widely explored in the literature.  This study demonstrated that 
restraint use was not statistically significantly associated with pressure ulcer incidence 
with univariate analysis, but did show statistical significance as a protective factor in 
multivariate analysis at 24 hours prior to study enrollment with imputed values (p = 
0.025; O.R. 0.43; 95% C.I. = 0.20 – 0.89) and without imputed values (p = 0.022; O.R. 
0.42; 95% C.I. = 0.19 – 0.88).  One possible explanation for this finding is that restraint 
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use reduces the amount of friction and shear experienced by the patient by reducing 
movement across the surface of the bed.  Another explanation for this finding are the 
regulatory and institutional mandates for repositioning restrained patients every two 
hours.   
 
Non-Significant Variables Assessing Pressure Ulcer Risk 
 
Remaining Braden subscales  
The Sensory, Activity, Mobility, and Friction/Shear subscales were not 
statistically significant in multivariate tests of the model in this study.  They are all 
variables used to assess intensity and duration of pressure identified in Benoit and Mion’s 
conceptual model (2012).  As discussed earlier, the findings of this study suggest that 
tissue tolerance for pressure may play a more important role in pressure ulcer 
development than does pressure relief in critically ill patients, especially when considered 
within the context of the enhanced statistical significance of the findings at 24 hours prior 
to study enrollment.  All of the remaining Braden subscales are possibly affected by 
sedative use, a common practice in ICUs.  As discussed earlier, Nijs et al. (2008) 
identified sedative use as a protective factor.  One possible explanation for the findings in 
this study and the study by Nijs et al. is that sedated patients are more receptive to 
nursing interventions to reduce intensity and duration of pressure, such as repositioning; 
however, Nijs et al. also report nursing interventions identified as prevention measures 
and frequency of turning to be positively associated with pressure ulcer outcome.  Nijs et 
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al.’s study design was prospective, so the relationship between nursing intervention and 
pressure ulcer outcome may be causal.  As indicated earlier, Nijs et al.’s multivariate 
analysis consisted of only those variables that demonstrated p-values of <0.20.  
Nonnemacher et al. (2008) reported contradictory findings in their study of 34,238 
patients admitted to a large university hospital.  Those findings indicated that sedative use 
(p = 0.0006, O.R. = 1.61, 95% C.I. = 1.23 – 2.12) and limited mobility and activity (p 
<0.0001, O.R. = 4.42, 95% C.I. = 3.50 – 5.59) were statistically significant in 
multivariate analysis and increased odds of pressure ulcer development. One possible 
explanation for this finding is that Nonnemacher et al. collected dichotomous data and 
combined variables scored as ‘unknown’ with ‘no’ responses, possibly increasing the 
chances for a Type I or II error. 
Other variables assessing pressure distribution capacity  
Body mass index.  There is strong evidence in the literature that lower BMIs are 
disproportionately related to pressure ulcer development.  The relationship between BMI 
and pressure ulcer development is a function of poor nutritional status and resulting loss 
of body fat that results in exaggerated bony prominences (Jirika et al., 1995) with a 
consequent loss of pressure distribution capacity.  In a prospective study of 286 patients 
admitted to an urban teaching hospital, Allman et al. (1995) identified lower BMI as a 
pressure ulcer risk factor (p = 0.03; O.R. 2.18; 95% C.I. = 1.05 – 4.52).  Fife et al. (2001) 
reported a negative correlation between pressure ulcer incidence and body mass (r = -
0.258, p = 0.002) in their study of 186 patients in a neurologic ICU.  Similarly, Lindgren 
et al. (2004) identified increased weight as a protective factor (p= 0.002; O.R. 0.96; 95% 
C.I. = 0.94 – 0.99) as did Tschannen, Baates, Talsma, and Guo (2012) in their 
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retrospective analysis of 3225 patient records (p< 0.001; O.R. 0.97; 95% C.I. = 0.95 – 
0.98).  In a retrospective examination of 64,372 patient records, VanGilder, MacFarlane, 
Meyer, and Lachenbruch (2009) found a higher prevalence of pressure ulcers in 
underweight patients (25.3%) than in normal weight or obese patients, but do not 
hypothesize about the reason for the finding.  Categorical measures of BMI were not 
identified as statistically significant at either univariate or multivariate analyses in this 
study.  One explanation for this finding is the lack of underweight subjects enrolled in 
this study (n = 20; 5.6%) compared to the distribution of normal weight (n = 101; 28.1%), 
overweight (n = 107; 29.7%) and obese (n = 132; 36.7%) subjects.  
   Variables assessing metabolic supply   
Nicotine use.  The study findings indicate that nicotine use was not a statistically 
significant predictor of pressure ulcer formation with univariate or multivariate analyses.  
Nicotine use is a component of the Waterlow Pressure Ulcer Prevention/Treatment Policy 
(Copyright by J. Waterlow, 1985; Revised, 2005).  It was included in the conceptual 
model because of statistically significant findings (p < 0.001; O.R. 1.18; 95% C.I. = 1.13 
– 1.23) involving high Waterlow risk scores and pressure ulcer incidence (Anthony, et 
al., 2000) and the positive relationship between nicotine use and vascular disease.  
Multivariate analyses reported by Nijs et al. (2008) in a study of 520 subjects in a 
surgical ICU indicated that a history of vascular disease was statistically significant for 
pressure ulcer incidence at 24 hours in multivariate analysis (p < 0.001; O.R. 4.51; 95% 
C.I. = 1.99 – 10.24) and 48 hours (p = 0.001; O.R. 2.85; 95% C.I. = 1.29 – 6.30).  
Nonnemacher et al. (2008) reported similar findings with vascular disease after 
multivariate analysis (p = 0.032; O.R. 1.80; 95% C.I. = 1.05 – 3.08) in their study of 
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34,238 subjects admitted to a large university hosptial.  Because medical diagnoses were 
not collected as part of this study, it is unclear if there is any association between nicotine 
use and vascular disease.  Because populations from mixed ICU types were included, it is 
possible that any significance that nicotine use had with pressure ulcer incidence was 
obfuscated by medical diagnoses unrelated to vascular disease – a potential result of 
nicotine use.  
Vasopressor use.  The findings in this study indicate that vasopressor use was not 
a statistically significant predictor of pressure ulcer formation with univariate or 
multivariate analyses.  This finding is not consistent with the results reported in the 
literature, although the studies evaluating vasopressor use as a pressure ulcer risk factor 
are limited.  Nijs et al. (2008) identified low dose dopamine (≤ 5 µg/kg/min) to be an 
independent predictor of  risk 24 hours prior to prior to pressure ulcer development in 
520 subjects with multivariate analysis (p= 0.003; O.R. 6.05; 95% C.I. = 1.88 – 19.54).  
Similarly, Theaker et al. (2000) found norepinephrine to be an independent predictor of 
pressure ulcers in a multivariate analysis of 22 risk factors (p< 0.001; O.R. 8.11; 95% C.I. 
= 3.64 – 18.0) in a study of 286 general ICU patients.  In a more recent cohort study of 
3,225 critically ill patients, Tschannen et al. (2012) identified use of vasopressors to be 
statistically significant with multivariate analysis (p = 0.03; O.R. 1.3; 95% C.I. = 1.03 – 
1.73).  Only variables with a univariate p-value of < 0.30 were selected for inclusion into 
the multivariate analysis conducted by Tschannen et al. which may contribute to Type I 
or II error in the findings.  
The findings in this study are difficult to explain, given that norepinephrine was 
the most commonly used vasopressor in case and control subjects (26.7%) compared to 
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the other vasopressors identified for study.  Norepinephrine works to increase systemic 
vascular resistance by stimulating ɑ-1 and ɑ-2 adrenergic receptor cites in the peripheral 
vasculature (Klabunde, 2011), and has been associated with extremity ischemia when 
used at high doses for long periods.  Because only total amounts of vasopressor infusions 
were collected instead of infusion rates, any significance that higher infusion rates may 
have on pressure ulcer incidence were not captured.  Additionally, the lack of vasopressor 
infusions necessitated the use of vasopressor as a categorical variable, possibly 
contributing to a Type II error with regard to vasopressor use.   
 Mean arterial pressure.  Univariate analyses of lowest recorded MAP was 
statistically significantly associated with pressure ulcer development at 24 and 48 hours 
prior to study enrollment; however, it did not maintain its statistical significance with 
multivariate analysis.  A plausible explanation of this finding is because extremes of 
arterial pressures are treated with medications, such as vasopressors, to maintain arterial 
pressures within a prescribed normal physiologic range.  
Oxygen saturation of hemoglobin.  No measure of oxygen saturation of 
hemoglobin demonstrated statistical significance at either the univariate or multivariate 
level of analysis.  This finding is consistent with ICU practices to provide supplemental 
oxygen as needed to keep oxygen saturations values near to 100%.  
Variables assessing metabolic demand  
Steroid use.  Steroid use did not demonstrate statistical significance at either the 
univariate or multivariate level of analysis in this study.  Steroid use is included in 
Waterlow’s pressure ulcer risk assessment and was included in the conceptual model 
because of Anthony et al.’s (2000) finding that summative Waterlow scores were 
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statistically significant with multivariate analysis of their findings (p < 0.001; O.R. 1.18; 
95% C.I. = 1.13 – 1.23).  In their study of 163 cardiac surgery patients, Stordeur et al. 
(1998) identified post-operative corticosteroid use as being statistically significant in a 
multivariate analysis (p = 0.020).  No odds ratios or confidence intervals were presented 
in the article.  Additionally, the multivariate analysis included only those variables that 
were statistically significant with univariate analysis, possibly contributing to a Type I or 
II error in Stordeur et al.’s interpretation of their study results.  
 
Strengths and Limitations 
 
Strengths and limitations of this study were considered within the contexts of the 
study design, data analysis strategies, and the clinical utility of the findings.  These areas 
are discussed in this section.   
Study Design  
The use of a prospective cohort case-control design was a strength of this study 
because it supported the investigation into potential causes of pressure ulcer incidence 
(Cummings, Newman, et al., 2007) and allowed for the examination of temporal 
sequencing.  Spurious associations due to bias resulting from the study design were 
minimized by enrolling sample subjects from the targeted ICU patient population.  Some 
measures of predictor variables such as protein reserve, medication administration, and 
Braden subscale scoring by staff nurses may have contributed to systematic errors 
because of reduced accuracy of those measures.  Spurious associations due to chance 
were minimized by use of a case-control study design where subjects were individually 
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matched on ICU type, ICU length of stay before pressure ulcer development (cases), and 
severity of illness.  These matching criteria were considered potentially confounding 
variables in this study.  A limitation of this study was that case-control subjects were not 
matched on age or medical diagnoses that are other potential confounding variables in 
this study.  
Analysis Strategies       
To evaluate the relationships among the variables in this study adequately, it was 
necessary to apply statistical methods that allowed for paired analysis of case-control 
subjects and that would allow for evaluation of one set of variables while controlling for 
potential confounding variables.  Analytic strategies that facilitated these statistical 
evaluations were a strength of this study.  Wilcoxon’s Signed Rank test and McNemar’s 
Chi Square were used to evaluate differences in the dependent variables for descriptive 
analysis.  Hierarchical tests controlling for age, then Braden scores, allowed for statistical 
evaluations of the strength of the associations with each variable set.  As noted in the 
previous section, the final block of the model demonstrated that the added associations of 
the remaining variables after controlling for age and Braden subscale scores enhanced the 
statistical significance of the model compared to the effects of the Braden subscales 
alone. 
Clinical Utility   
A strength of this study was that it identified risk factors for pressure ulcer 
development that enhance the predictive ability of the Braden RAS with variables that are 
easily obtained in the ICU setting.  Integrating age, gender, and hematocrit levels into a 
modified Braden RAS would not require extensive effort from clinical staff, especially in 
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facilities where computerized medical records are readily available for laboratory results.  
Another strength of this study is that the findings can easily be implemented in smaller 
community hospitals that do have the resources of tertiary care medical centers.   
 
Implications 
 
The implications of this study are related to healthcare policy and guiding nursing 
practice in the prevention of pressure ulcers.  They are discussed in this section.  
Implications for Healthcare Policy 
As discussed in Chapter I, there is a lack of empirical evidence needed to link 
nursing quality of care and pressure ulcer development (Needleman et al., 2007).  Despite 
the lack of empirical evidence, the NQF placed nosocomially acquired pressure ulcers 
among outcomes considered sensitive to nursing care (Kurtzman & Corrigan, 2007).  
Using the NQF’s   list of “never events” published in 2001, The Centers for Medicare and 
Medicaid Services (CMS) began to scrutinize the Diagnostic Related Group (DRG) 
complication codes related to the NQF’s never events (Wachter, Foster, & Dudley, 2008).  
In October 2008, CMS began to stop payments for three hospital-acquired infections and 
five complications of care.  Pressure ulcers were among the complications of care that 
CMS included in that list (Wachter et al., 2008).  Wachter et al. (2008) suggested that 
these sanctions are reasonable if four criteria concerning the never event are met.  The 
criteria include adequate evidence that the event is preventable, the event is accurately 
measurable, the event results in clinically significant patient harm, and that it is possible 
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to differentiate among those events that are nosocomial versus those that are present on 
admission to the healthcare institution (Wachter et al., 2008).  
The findings from this study tend to refute the NQF’s assertion that pressure ulcer 
outcomes are primarily functions of nursing care quality.  Hematocrit levels demonstrated 
a statistically significant univariate (p < 0.001) and multivariate (p < 0.001 within 24 
hours; p = 0.030 within 48 hours) association with pressure ulcer incidence.  The decision 
to transfuse blood lies within the domain of medicine.  Because of limited resources, 
blood transfusion policies tend to be conservative and the risks of anemia compared to 
the risks of transfusions are evaluated carefully (Shader, Javidroozi, Ozawa, & Hare, 
2011).  Enhanced collaboration on pressure ulcer reduction strategies among providers 
and nursing staff will promote shared responsibility for pressure ulcer prevention by 
considering more aggressive strategies, such as blood transfusion, that are outside the 
purview of nursing.     
Implications for Nursing  
The results of this study have the potential to enhance the specificity of the 
Braden score in critically ill patients.  As discussed in Chapter II (Table 2.3) the 
specificity of the Braden score ranges from 26% to 77.8% in studies of critically patients 
with cutoff scores between 14 and 16 and from 40.5% to 100% in acute care patients with 
cutoff scores between 16 and 20.  Additionally, the findings of this study indicate that the 
Braden Scale, when used alone, does not adequately capture pressure ulcer risk at 48 
hours prior to pressure ulcer development, suggesting that the tool lacks the sensitivity 
required to identify rapidly changing moderators of pressure ulcer incidence in critically 
ill patients.  Augmenting the Braden RAS with the findings in this study may provide 
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higher sensitivity levels in critically ill and acute care patients.  The enhanced sensitivity 
would allow nursing staff to target prevention measures more efficiently.   
 
Recommendations for Future Research 
 
Critically ill patients are a vulnerable and understudied population with regard to 
pressure ulcer risk factors.  Research is needed that is directed at better understanding 
risk factor measurement strategies and pressure ulcer etiology.  This dissertation research 
contributes to the body of knowledge about risk factors, but more work is needed to 
enhance the understanding of pressure ulcer risk factors.  
A first step for future research is to determine appropriate measurement strategies 
for risk factors.  The decision to evaluate some risk factors, such as medication 
administration and Braden subscale scores, was primarily based on clinical experiences 
of the researcher with input from the dissertation committee.  Expanded data collection 
timeframes in future research will provide insight into the optimum time intervals in 
which to collect data.  
A second goal of future research is to evaluate medical diagnoses and any 
confounding effects that exists between pressure ulcer outcomes and other variables.  For 
example, some studies have identified cancer as having a statistically significant 
relationship to pressure ulcers (Flattau & Blank, 2012; Fromantin et al., 2011); however, 
it is unclear if cancer is the direct cause of the pressure ulcer or if cancer is associated 
with another variable, such as malnutrition and cachexia, which is responsible for 
pressure ulcer development.  Another example is the effect of surgery and surgical 
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procedures on pressure ulcer development.  Several studies have evaluated surgery as a 
pressure ulcer risk factor; however, standard approaches to studying the surgical variable 
are lacking.  A better understanding of the relationship between disease states and 
pressure ulcer outcomes may have implications for healthcare policy in the future.  
A third direction for future research involves hospital processes that may 
contribute to pressure ulcer development.  Multiple studies identified surgical procedures 
as a statistically significant effect on pressure ulcer incidence (Nonnemacher et al., 2008; 
Schoonhoven, et al., 2002).  The limited understanding of pressure ulcer etiology 
combined with the complexity of hospital processes impedes the ability to discern which 
processes need improvement.  Patients with long term ICU stays requiring multiple 
surgeries may develop a pressure ulcer that is assigned incorrectly to the care received in 
the ICU.  A better understanding of the processes surrounding high risk areas such as 
ICUs and operating rooms will help to focus prevention and improvement efforts. 
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Appendix A 
Data Management and Study Enrollment Forms 
 
Screening Tracking Tool - Example 
 
 
 
Consent Tracking Tool – Example 
 
 
  
Date Screened ROOM NO. SCREENED AS ELIGIBLE? REASON NOT ELIGIBLE? CODE 
3/7/2011 8633 CASE N PU w/I 48 hours admission 8 Sacrum I 
4/25/2011 8615 CASE N Admitted to ICU w/ PU 2 Buttock, R/L II
10/17/2011 8642 CASE N Admitted w/ PU 2 Sacrum II
8/7/2011 8615 CASE N Not a Pressure Ulcer 1  R Ishcium II
12/22/2010 8656 CASE N Admitted to ICU w/ PU 2
1/27/2011 8641 CASE N Admitted to ICU w/ PU 2 L Buttock/I
5/4/2011 NA CONTROL N Low Vent 5
5/9/2011 8619 CASE N PU w/I 48 hours admission 8 Sacrum II
2/7/2011 8659 CASE N Admitted to ICU w/ PU 2 L Buttock 4
5/15/2011 8639 CASE N Admitted to ICU w/ PU 2 L Hip IV
7/6/2011 8603 CASE N Admitted to ICU w/ pu 2 L Hip IV
1/23/2012 8655 CASE N Admitted w/ PU 2
L Occiput DTI: L 
ishcium DTI
8/31/2011 8615 CASE N Admitted w/ PU 2 Sacrum II
3/27/2011 8657 CASE Y
10/21/2010 8613 CASE N Stage I 3
7/6/2011 8649 CASE N Admitted to ICU w/ pu 2 Sacrum II
12/22/2010 8625 CASE N PU w/I 48 hours admission 8
6/1/2011 8641 CASE N Admitted to ICU w/ PU 2 Sacrum I
10/17/2011 8625 CASE N Admitted w/ PU 2 Sacrum I
5/18/2011 8607 CASE N PU w/I 48 hours admission 8 Sacrum II
1/27/2011 8621 CASE N Admitted to ICU w/ PU 2 Sacrum 2 
10/27/2011 8631 CASE N Admitted w/ PU 2
R heel, ustg; L/R 
scrotum II
5/1/2011 8613 CASE N PU w/I 48 hours admission 8 Sacrum II
ROOM # CASE/CONTROL DATE/TIME 1ST ATTEMPT 
CONSENT OBTAINED ? 
(Yes, No, Refused) DATE/TIME 2ND ATTEMPT 
CONSENT OBTAINED ? (Yes, 
No, Refused) DATE/TIME PHONE ATTEMPT
CONSENT OBTAINED ? 
(Yes, No, Refused) CONSENT WAIVED
CONTROL
CONSENT WAIVED-
D/C at time of 
enrolloment 
CASE 5/23/2011 Y
CASE 6/7/2011 Refused
Case 1/12/2011 N 1/13/2011 N 1/13/2011 Y
CASE 8/29/2011 Y 8/30/2011 Y
CONTROL
CONSENT WAIVED-
D/C at time of 
enrolloment 
CASE 10/27/2011 Y
CASE 12/2/2011 N 12/13/2011 Y
CASE 5/5/2011 Y
CASE 4/26/2011 Y
133 
 
 
 
Informed Consent Tool-Case Subject 
This informed consent applies to Adults.  
 
Name of participant: _________________________________________________________ 
Age: ___________ 
 
The following is given to you to tell you about this research study.  Please read this form with care and ask 
any questions you may have about this study.  Your questions will be answered.  Also, you will be given a 
copy of this consent form.   
 
You do not have to be in this research study. You can stop being in this study at any time.  If we 
learn something new that may affect the risks or benefits of this study, you will be told so that you 
can decide whether or not you still want to be in this study.    
 
     
1. What is the purpose of this study?  
 
You are being asked to take part in this research study because you have developed a 
pressure ulcer (bed sore) in an intensive care unit.  The purpose of this study is to see if 
you have any additional risk factors that may have caused the pressure ulcer  compared 
to other patients in an ICU that have not developed a pressure ulcer (bed sore).  
Examples of risk factors that this study evaluates are your average blood pressure, some 
medications that you may have received, your age and weight, and certain health 
problems that you may have had before you were admitted to the hospital, such as 
diabetes.  Certain laboratory values from your blood work will also be considered, such 
as hemoglobin and hematocrit (the amount of red blood cells you have) and albumin (the 
amount of protein in your blood).   
 
2. What will happen and how long will you be in the study? 
   
 Some types of wounds and skin problems are easily confused with a pressure ulcer (bed 
sore). For that reason, either myself or another investigator will need to look at the wound 
to make sure it is a pressure ulcer (bed sore).  Either myself or another investigator will 
only look at your skin wound during normal routines that you will experience during your 
ICU stay. Examples are when your nurse routinely changes the dressing on the wound or 
positions you to evaluate the wound.  Your nurse will be in the room when we look at the 
wound and will be doing all of the treatments on you. After myself or the other 
investigator have looked at the wound and have determined that it is a pressure ulcer 
(bed sore), you will be entered into the study. We will then look at your medical record 
and use the data about your risk factors to record in a database. The data from your 
medical record will contain your medical record number so that we can make sure that 
we have all the data entered correctly.  At the end of the study, your medical record 
number is removed, and the data from your medical record will be analyzed 
mathematically to see if your risk factors made a difference in why you developed the 
pressure ulcer (bed sore). We will be evaluating the pressure ulcer (bed sore) only one 
time.  
  
 .   
 
3. Costs to you if you take part in this study: 
 
There is no cost to you for taking part in this study. 
 
However, you are still responsible for paying for the usual care you would normally 
receive for the treatment of your illness. This includes treatments and tests you would 
need even if you were not in this study. These costs will be billed to you and/or your 
insurance.  
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4.    Side effects and risks that you can expect if you take part in this study:  
There are no side effects that are associated with this study because the study does not 
involve additional or different treatment than you would normally receive because of your 
illness.  The risks involved in this study are minimal and include possible loss of 
anonymity because your medical record number will be associated with the data we 
collect about you from the medical record.  Multiple safe-guards are in place to prevent 
this from happening as described in section 13, below.  Additional minimal risks involve 
those associated with routine care in the ICU, such as repositioning in bed and possibly 
losing a tube that has been inserted as part of your care.  Your nurse is experienced at 
protecting you from accidentally losing a tube and will be the one helping you to turn or 
reposition in bed.  
 
 
 
4. Risks that are not known: 
 
NONE  
 
6.  Payment in case you are injured because of this research study: 
 
If it is determined by Vanderbilt and the Investigator that an injury occurred as a direct 
result of the tests or treatments that are done for research, then you and/or your 
insurance will not have to pay for the cost of immediate medical care provided at 
Vanderbilt to treat the injury.  
 
There are no plans for Vanderbilt to pay for the costs of any additional care. There are no 
plans for Vanderbilt to give you money for the injury.  
 
7.  Good effects that might result from this study:  
 
a) The benefits to science and humankind that might result from this study. Patients in 
ICUs get pressure ulcers (bed sores) more frequently than do other hospitalized patients.  
This study will help to identify risk factors specific to ICU patients that cause them to get 
pressure ulcers (bed sores) more frequently than do other patients.  If we can identify 
those risk factors before the pressure ulcer (bed sore) develops, then we can take steps 
to prevent them.   
b) The benefits you might get from being in this study. There are no benefits to you from 
participating in this study.  
 
8.  Other treatments you could get if you decide not to be in this study: 
   
Your treatment will be the same if you participate in the study or not.   
 
9.  Payments for your time spent taking part in this study or expenses: 
 
You will not be paid for your time spent participating in this study.  
 
10. Reasons why the study doctor may take you out of this study:  You may be removed 
from the study data base if your are discharged from the ICU before either myself or the 
co-investigator can look at your wound to determine if it is a pressure ulcer (bed sore) or 
if you require CPR within 48 hours of the time that the nurse first noticed the wound.  
 
11. What will happen if you decide to stop being in this study? 
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If you decide to stop being part of the study, you should tell either myself of the co-
investigator. 
 
 
12. Who to call for any questions or in case you are injured: 
 
 If you should have any questions about this research study or if you feel you have been hurt 
by being a part of this study, please feel free to contact Richard Benoit at 322-6565 or the 
Faculty Advisor, Dr. Lorraine Mion at 343-7098.  If you cannot reach the research staff, 
please page Richard Benoit at 835-7701 
 
For additional information about giving consent or your rights as a person in this study, to 
discuss problems, concerns, and questions, or to offer input, please feel free to call the 
Vanderbilt University Institutional Review Board Office at (615) 322-2918 or toll free at (866) 
224-8273. 
 
13. Confidentiality:   
 
All data will be collected by either Richard Benoit, the Principal Investigator (PI) or Carolyn 
Watts, co-investigator, using a paper data collection form. Immediately after the data has 
been collected on the paper form, the completed forms will be stored in a locked file cabinet 
in the PI’s locked office in the SICU at Vanderbilt University Hospital. Data will then be 
transcribed from the paper data collection sheets into Vanderbilt’s secured data base by the 
PI.  The paper data collection sheets will remain under double lock at Vanderbilt until the 
completion of the study, at which time they will be placed in a shredder box located near the 
PI’s office in the SICU. The medical record number will remain attached to the protected 
health information until the study’s completion and the PI is satisfied that the data is complete 
and accurate.  At that time, the records will be de-identified by removing the medical record 
number. Only Richard Benoit and Carolyn Watts will have access to the paper data collection 
forms.  After the information has been entered into Vanderbilt’s secured data base, Richard 
Benoit, Carolyn Watts, Drs. Lorraine Mion and Anne Minnick, the faculty advisors, Dr. Mary 
Dietrich, the statistician, and Dr. Oliver Gunter, the physician advisor, will have access to the 
database.  
 
14. Authorization to Use/Disclose Protected Health Information  
All efforts, within reason, will be made to keep your protected health information (PHI) private. 
PHI is your health information that is, or has been gathered or kept by Vanderbilt as a result 
of your healthcare.  This includes data gathered for research studies that can be traced back 
to you.  Using or sharing (“disclosure”) such data must follow federal privacy rules. By signing 
the consent for this study, you are agreeing (“authorization”) to the uses and likely sharing of 
your PHI.  If you decide to be in this research study, you are also agreeing to let the study 
team use and share your PHI as described below.  
 
As part of the study, Richard Benoit and his study team may share the results of your study 
and/or non-study linked information such as lab values,demographic variables, and severity 
of the pressure ulcer (bed sore) as well as parts of your medical record, to the groups named 
below. These groups may include people from the Federal Government Office for Human 
Research Protections, the Vanderbilt University Institutional Review Board, National 
Database of Nursing Quality Indicators (NDNQI), and the National Pressure Ulcer Advisory 
Panel (NPUAP).  Federal privacy rules may not apply to these groups; they have their own 
rules and codes to assure that all efforts, within reason, will be made to keep your PHI 
private.  
 
Vanderbilt may give or sell your health data, without identifiers, to others or use it for other 
research projects not listed in this form. Vanderbilt, Richard Benoit and his staff will comply 
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with any and all laws regarding the privacy of such information.  There are no plans to pay 
you for the use or transfer of this de-identified information. 
 
The study results will be kept in your research record for at least six years after the study is 
finished.  At that time, the research data that has not been put in your medical record will be 
kept for an unknown length of time.  Any research data that has been put into your medical 
record will be kept for an unknown length of time. 
 
Unless told otherwise, your consent to use or share your PHI does not expire. If you change your 
mind, we ask that you contact Richard Benoit in writing and let him know that you withdraw your 
consent. His mailing address is  
 
1211 Medical Center Drive 
9612B CCT 
Nashville, TN 37232-7417 
 
 At that time, we will stop getting any more data about you.  However, the health data we stored 
before you withdrew your consent may still be used for reporting and research quality. 
 
 
 
 
 
If you decide not to take part in this research study, it will not affect your treatment, payment or 
enrollment in any health plans or affect your ability to get benefits. You will get a copy of 
this form after it is signed.  
 
 
 
STATEMENT BY PERSON AGREEING TO BE IN THIS STUDY 
 I have read this consent form and the research study has been explained to me 
verbally.  All my questions have been answered, and I freely and voluntarily 
choose to take part in this study.    
 
 
            
Date    Signature of patient/volunteer     
 
Consent obtained by:  
  
            
Date    Signature    
 
            
    Printed Name and Title  
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SURROGATE RIDER-CASE PATIENT  
 
 
I,       __________   [name of decision-
maker/surrogate], 
am the ____________   __________   [state relationship to 
participant]  
of       __________   [state participant’s name].  I 
have read the informed consent document or it has been explained to me.  I have had 
the opportunity to ask any questions and all of my questions have been answered.  I 
believe participating in this research would be in the interests of     
   [participant’s name] and is consistent with what he/she would have 
decided had he/she been able to do so. 
 
Your decision to allow your family member/friend to participate in this research study is 
voluntary. You may choose not to allow his/her participation and he/she will receive the 
same treatments. The decision not to participate in the research will not affect his/her 
healthcare/services or other rights. You are also free to withdraw him/her from this study 
at any time.  In the event new information becomes available that may affect the risks or 
benefits associated with this research study or your willingness to allow continued 
participation in this research study, you will be notified so that you can make an informed 
decision whether or not to continue your family member/friend’s participation in this 
study.     
 
Your family member/friend will periodically be re-evaluated for the capacity to give 
consent.  If he/she is found to be capable, continued participation in this study would 
only occur with his/her consent. 
 
 
________________________________________________  ___/___/___ 
Signature of Health Care Decision-Maker/Surrogate                Date 
 
________________________________________________  ___/___/___ 
Signature of Witness                     Date 
 
________________________________________________  ___/___/___ 
Name and Signature of person obtaining consent      Date 
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Informed Consent Tool – Case Subject 
This informed consent applies to Adults.  
 
Name of participant: _________________________________________________________ 
Age: ___________ 
 
The following is given to you to tell you about this research study.  Please read this form with care and ask 
any questions you may have about this study.  Your questions will be answered.  Also, you will be given a 
copy of this consent form.   
 
You do not have to be in this research study. You can stop being in this study at any time.  If we 
learn something new that may affect the risks or benefits of this study, you will be told so that you 
can decide whether or not you still want to be in this study.    
 
     
5. What is the purpose of this study?  
 
You are being asked to take part in this research study because you are a patient in an 
intensive care unit who has not developed a pressure ulcer (bed sore).  The purpose of 
this study is to see if any risk factors you may have for pressure ulcer development are 
different from other patients that have developed a pressure ulcer.  Examples of risk 
factors that this study evaluates are your average blood pressure, some medications that 
you may have received, your age and weight, and certain health problems that you may 
have had before you were admitted to the hospital, such as diabetes.  Certain laboratory 
values from your blood work will also be considered, such as hemoglobin and hematocrit 
(the amount of red blood cells you have) and albumin (the amount of protein in your 
blood).   
 
6. What will happen and how long will you be in the study? 
   
 Once you give permission, one of the study team will go to your medical record and use 
risk factor information that has already been collected as part of your routine care at 
Vanderbilt. There will be no additional tests or procedures performed as a result of your 
entry into the study.  The data from your medical record will contain your medical record 
number so that we can make sure that we have all the data entered correctly.  At the end 
of the study, your medical record number is removed, and the data from your medical 
record will be analyzed mathematically to see if your risk factors made a difference in 
why you did not develop a pressure ulcer (bed sore).  
  
 .   
 
7. Costs to you if you take part in this study: 
 
There is no cost to you for taking part in this study. 
 
However, you are still responsible for paying for the usual care you would normally 
receive for the treatment of your illness. This includes treatments and tests you would 
need even if you were not in this study. These costs will be billed to you and/or your 
insurance.  
 
 
 
4.    Side effects and risks that you can expect if you take part in this study:  
There are no side effects that are associated with this study because the study does not 
involve additional or different treatment than you would normally receive because of your 
illness.  The risks involved in this study are minimal and include possible loss of 
anonymity because your medical record number will be associated with the data we 
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collect about you from the medical record.  Multiple safe-guards are in place to prevent 
this from happening as described in section 13, below.   
 
 
 
8. Risks that are not known: 
 
NONE  
 
6.  Payment in case you are injured because of this research study: 
 
Because we will only be reviewing your medical record, there is no chance of injury to 
you by participating in this study.   
 
There are no plans for Vanderbilt to pay for the costs of any additional care.  
 
7.  Good effects that might result from this study:  
 
a) The benefits to science and humankind that might result from this study. Patients in 
ICUs get pressure ulcers (bed sores) more frequently than do other hospitalized patients.  
This study will help to identify risk factors specific to ICU patients that cause them to get 
pressure ulcers (bed sores) more frequently than do other patients.  If we can identify 
those risk factors before the pressure ulcer (bed sore) develops, then we can take steps 
to prevent them.   
b) The benefits you might get from being in this study. There are no benefits to you from 
participating in this study.  
 
8.  Other treatments you could get if you decide not to be in this study: 
   
Your treatment will be the same if you participate in the study or not.   
 
9.  Payments for your time spent taking part in this study or expenses: 
 
You will not be paid for your time spent participating in this study.  
 
10. Reasons why the study doctor may take you out of this study:  You may be removed 
from the study data base if your are discharged from the ICU and we find that some of 
the important information in your medical record is missing or incomplete.  
 
11. What will happen if you decide to stop being in this study? 
 
If you decide to stop being part of the study, you should tell either myself of the co-
investigator. 
 
 
12. Who to call for any questions or in case you are injured: 
 
 If you should have any questions about this research study or if you feel you have been hurt 
by being a part of this study, please feel free to contact Richard Benoit at 322-6565 or the 
Faculty Advisor, Dr. Lorraine Mion at 343-7098.  If you cannot reach the research staff, 
please page Richard Benoit at 835-7701 
 
For additional information about giving consent or your rights as a person in this study, to 
discuss problems, concerns, and questions, or to offer input, please feel free to call the 
Vanderbilt University Institutional Review Board Office at (615) 322-2918 or toll free at (866) 
224-8273. 
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15. Confidentiality:   
 
All data will be collected by either Richard Benoit, the Principal Investigator (PI) or Carolyn 
Watts, co-investigator, using a paper data collection form. Immediately after the data has 
been collected on the paper form, the completed forms will be stored in a locked file cabinet 
in the PI’s locked office in the SICU at Vanderbilt University Hospital. Data will then be 
transcribed from the paper data collection sheets into Vanderbilt’s secured data base by the 
PI.  The paper data collection sheets will remain under double lock at Vanderbilt until the 
completion of the study, at which time they will be placed in a shredder box located near the 
PI’s office in the SICU. The medical record number will remain attached to the protected 
health information until the study’s completion and the PI is satisfied that the data is complete 
and accurate.  At that time, the records will be de-identified by removing the medical record 
number. Only Richard Benoit and Carolyn Watts will have access to the paper data collection 
forms.  After the information has been entered into Vanderbilt’s secured data base, Richard 
Benoit, Carolyn Watts, Drs. Lorraine Mion and Anne Minnick, the faculty advisors, Dr. Mary 
Dietrich, the statistician, and Dr. Oliver Gunter, the physician advisor, will have access to the 
database.  
 
16. Authorization to Use/Disclose Protected Health Information  
All efforts, within reason, will be made to keep your protected health information (PHI) private. 
PHI is your health information that is, or has been gathered or kept by Vanderbilt as a result 
of your healthcare.  This includes data gathered for research studies that can be traced back 
to you.  Using or sharing (“disclosure”) such data must follow federal privacy rules. By signing 
the consent for this study, you are agreeing (“authorization”) to the uses and likely sharing of 
your PHI.  If you decide to be in this research study, you are also agreeing to let the study 
team use and share your PHI as described below.  
 
As part of the study, Richard Benoit and his study team may share the results of your study 
and/or non-study linked information such as lab values,demographic variables, as well as 
parts of your medical record to the groups named below. These groups may include people 
from the Federal Government Office for Human Research Protections, the Vanderbilt 
University Institutional Review Board, National Database of Nursing Quality Indicators 
(NDNQI), and the National Pressure Ulcer Advisory Panel (NPUAP).  Federal privacy rules 
may not apply to these groups; they have their own rules and codes to assure that all efforts, 
within reason, will be made to keep your PHI private.  
 
Vanderbilt may give or sell your health data, without identifiers, to others or use it for other 
research projects not listed in this form. Vanderbilt, Richard Benoit and his staff will comply 
with any and all laws regarding the privacy of such information.  There are no plans to pay 
you for the use or transfer of this de-identified information. 
 
The study results will be kept in your research record for at least six years after the study is 
finished.  At that time, the research data that has not been put in your medical record will be 
kept for an unknown length of time.  Any research data that has been put into your medical 
record will be kept for an unknown length of time. 
 
Unless told otherwise, your consent to use or share your PHI does not expire. If you change your 
mind, we ask that you contact Richard Benoit in writing and let him know that you withdraw your 
consent. His mailing address is  
 
1211 Medical Center Drive 
9612B CCT 
Nashville, TN 37232-7417 
 
 At that time, we will stop getting any more data about you.  However, the health data we stored 
before you withdrew your consent may still be used for reporting and research quality. 
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If you decide not to take part in this research study, it will not affect your treatment, payment or 
enrollment in any health plans or affect your ability to get benefits. You will get a copy of 
this form after it is signed.  
 
 
 
 
STATEMENT BY PERSON AGREEING TO BE IN THIS STUDY 
 I have read this consent form and the research study has been explained to me 
verbally.  All my questions have been answered, and I freely and voluntarily 
choose to take part in this study.    
 
 
            
Date    Signature of patient/volunteer     
 
Consent obtained by:  
  
            
Date    Signature    
 
            
    Printed Name and Title  
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SURROGATE RIDER – CONTROL PATIENT  
 
I,       __________   [name of decision-
maker/surrogate], 
am the ____________   __________   [state relationship to 
participant]  
of       __________   [state participant’s name].  I 
have read the informed consent document or it has been explained to me.  I have had 
the opportunity to ask any questions and all of my questions have been answered.  I 
believe participating in this research would be in the interests of     
   [participant’s name] and is consistent with what he/she would have 
decided had he/she been able to do so. 
 
Your decision to allow your family member/friend to participate in this research study is 
voluntary. You may choose not to allow his/her participation and he/she will receive the 
same treatments. The decision not to participate in the research will not affect his/her 
healthcare/services or other rights. You are also free to withdraw him/her from this study 
at any time.  In the event new information becomes available that may affect the risks or 
benefits associated with this research study or your willingness to allow continued 
participation in this research study, you will be notified so that you can make an informed 
decision whether or not to continue your family member/friend’s participation in this 
study.     
 
Your family member/friend will periodically be re-evaluated for the capacity to give 
consent.  If he/she is found to be capable, continued participation in this study would 
only occur with his/her consent. 
 
 
________________________________________________  ___/___/___ 
Signature of Health Care Decision-Maker/Surrogate                Date 
 
________________________________________________  ___/___/___ 
Signature of Witness                     Date 
 
________________________________________________  ___/___/___ 
Name and Signature of person obtaining consent      Date 
 
 
 
 
 
Patient Information Sheet  
Hello: Your family member/friend is being considered for enrollment in a study at 
Vanderbilt. 
This sheet is provided as information only and does not mean that your family 
member/friend 
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has been enrolled. A member of the study team will be attempting to contact you in 
person or by 
phone to get consent from you to enroll your family member/friend in the study. 
 
Information about the Pressure Ulcer Risk Factor Study 
 
What is the Study About? 
This is a nursing study we are doing in the intensive care units at Vanderbilt. The study is 
to 
help us see what risk factors cause pressure ulcers in critically ill patients. There are 
many risk 
factors, such as older age or poor nutrition, that can lead to the development of pressure 
ulcers. 
We do not know which combination of risk factors are the ones most likely to predict a 
pressure 
ulcer. The study will help us find out which risk factors are most important. We can then 
plan 
better ways to prevent them from happening. 
 
Why is my family member/friend being asked to participate? 
Your family member/friend is a patient in an ICU. Studies show that patients in ICUs 
have a 
higher risk for developing pressure ulcers, commonly known as bedsores. We want to see 
what 
risk factors (such as nutrition status and some types of medications) contribute to 
pressure ulcer 
development. Your family member/friend may or may not have a pressure ulcer. In either 
case, 
we want to compare risk factors between patients that do and do not have a pressure 
ulcer. 
 
What will happen and how long will my family member/friend be in the study? 
If your family member/friend has a pressure ulcer, one of the research nurses will observe 
the 
pressure ulcer when the nurse does usual care and turns him/her. In addition, the research 
nurse 
will get information from the chart on your family member/friend’s illness, medications, 
and 
some blood work. Your family member/friend will be in the study until discharged from 
the 
ICU. 
If your family member/friend does not have a pressure ulcer, the research nurse will get 
information from the chart on your family member/friend’s illness, medications, and 
some blood 
work. Your family member/friend will be in the study until discharged from the ICU. 
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Are there costs to my family member/friend for being in the study? 
There are no costs or charges for being in this study. 
 
Are there any side effects or risks? 
There are no side effects since we are only looking at the pressure ulcer (if there is one) 
and 
gathering information from the chart. The only risk is the loss of anonymity. We will 
make sure 
that any study forms with your family member/friend’s name or medical record are kept 
locked 
in a private office. Only the nurse researchers will be able to see that information. We 
will 
destroy all forms with the name and medical record number at the end of this study. 
 
Can my family member/friend expect to get paid? 
No. We do not plan on paying people who are in this study. 
 
Are there any good effects for being in this study? 
There are no direct benefits to your family member/friend. The findings from this study 
will 
help future ICU patients. 
 
If I decide to not enroll my family member/friend in the study, are there other treatments? 
The treatment will be the same if your family member/friend participates in this study or 
not. 
 
Can I stop my family member/friend from being in the study after I give consent? 
You may withdraw from participating in the study. Please contact the investigator, 
Richard 
Benoit, at 322-6565, to discuss this. 
 
Who do to call for any questions? 
If you have questions about the study, please contact Richard Benoit at 322-6565 or on 
his pager 
at 835-7701. If you have any questions about your rights in participating in research, 
please call 
the Vanderbilt IRB at 322-2918. 
 
How will privacy and information be protected? 
The study forms will be in a locked office. Only the nurse researchers will be able to get 
to the 
study forms. After the study is over, all paper forms will be shredded. We will enter the 
study 
information into the Vanderbilt computer system, but that information will not include 
the name 
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or medical record number. All publications will be in group results only; no individual 
will have 
results published. Certain groups, such as the Vanderbilt IRB, the National Database of 
Nursing 
Quality Indicators (NDNQI), may look at the information. Richard Benoit and the other 
nurse 
researchers will comply with any and all laws that protect the privacy of your family 
member/friend’s information. 
 
Will I be able to see the results of the study? 
Because the specific results do not include any details other than those located in the 
medical 
record, you will need to follow Vanderbilt’s procedures for accessing information in 
personal 
records. You must address your request in writing to the Medical Information Services 
Department. You may download a copy of the request form at 
http://www.vanderbilthealth.com/main/11323 or you may ask your nurse to get a copy of 
it for 
you from E-docs, Vanderbilt’s electronic document service. 
 
Mail or fax the completed form to: 
Medical Information Services 
1211 22nd Avenue N. 
B-334 VUH 
Nashville, TN 37232 
Fax # (615)343-0126 
 
 
 
 
If you have any questions about accessing a medical record, please call: (615) 322-2062. 
The overall findings of the study will be published in an appropriate journal after the 
findings 
have been analyzed. If you would like information about the journal name and 
publication date, 
please email the Principal Investigator at Richard.Benoit@vanderbilt.edu to request this 
information once it is available. 
 
 
 
Inclusion/Exclusion Tracking Tool 
PRESSURE ULCER RISK FACTOR 
Inclusion/Exclusion Tool  
 
Date of Screening:   ____/____/____ 
Your Initials ________ 
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INCLUSION CRITERIA:  
Subject 18 years of age or older? _________ 
Current ICU  ________________________ 
EXCLUSION CRITERIA: 
 
CASE CONTROL 
ICU LOS < 48 hours ICU LOS < 48 hours 
Stage II or worse pressure ulcer on admission to 
ICU  
Stage II or worse pressure ulcer on admission to 
ICU  
Stage II or worse pressure ulcer that develops 
within 48 hours of ICU admission 
Stage II or worse pressure ulcer development 
during ICU stay  
CPR within 48 hours prior to pressure ulcer 
development  
CPR during ICU stay  
Discharge from ICU prior to visual assessment of 
pressure ulcer  
Discharge from ICU with any missing pre-admission 
or demographic information  
 
 
Is this subject a CASE   or      CONTROL?  (Circle one) 
If this is a CASE subject, is the patient able to give consent as assessed by the nurse? YES      NO 
If YES, date consent form signed      ____________ 
If NO, is there a surrogate present during the pressure ulcer screening? If yes, date surrogate consent 
form signed ______________________ 
If no surrogate and patient unable to consent, date “Written Information about the Pressure Ulcer Study” 
left in room _______________ 
Study ID: _____________________             (001- 174 Case numbers for CW) 
     (1001-1174 Control numbers for CW) 
     (175-350 Case numbers for RB) 
     (1175-1350 Control numbers for RB)  
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Appendix B 
Data Collection Forms 
 
Data Collection Form – Case Subjects 
Subject Information-CASE 
 
  
Study ID __________________________________ 
CASES:(001-350) 
(CW Use 001-174; RB use 175 to 350)  
 
Total # P U __________________________________ 
 
Wrst P U Stg 
 Stage II 
Stage III 
Stage IV 
Unstageable 
SDTI 
 
 
Wrst P U location  
Occiput 
R Ear 
L Ear 
Face 
R Scapula 
L Scapula 
R Elbow 
L Elbow 
R Hand 
L Hand 
Upper Back 
Middle Back 
Sacrum/Coccyx 
R Ischium 
L Ischium 
R Buttocks 
L Buttocks 
R Scrotum 
L Scrotum 
R Trochanter 
L Trochanter 
R Knee/Peri-knee 
L Knee/Peri-knee 
R Malleous/Ankle 
L Malleous/Ankle 
R Leg 
L Leg 
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R Heel 
L Heel 
R Foot 
L Foot 
 
 
 
ICU Adm Date __________________________________ 
(Continuous ICU stay-even if transferred from 
another ICU. ) 
 
Date P U ided by RN __________________________________ 
 
Ht (in) __________________________________ 
Wt (lbs) __________________________________ 
 
Vent use? (Has the patient required a ventilator at ANY TIME 
during the ICU stay? ) 
 
No 
Yes 
 
IF YES:  Curr Vent use? (Is the patient CURRENTLY requiring vent use? ) 
 
 
No 
Yes 
 
 
IF NO:  Contin Vent use hrs __________________________________ (Longest # hrs 
continuous vent use up to midnight before study enrollment (Includes time on vent prior to 
transfer from another ICU, if 
applicable) 
 
IF YES: Prior cont Vent use __________________________________ (Longest # hrs continuous 
vent use up to midnight before study enrollment ) 
 
Sens 48     1    2    3    4 
(may be from either day or night Braden) 
Sens 24      1    2    3    4 
(may be from either day or night Braden) 
 
Nut 48      1    2    3    4 
(may be from either day or night Braden ) 
Nut 24      1    2    3    4 
(may be from either day or night Braden) 
 
Mob 48      1    2    3    4 
(may be from either day or night Braden) 
Mob 24      1    2    3    4 
(may be from either day or night Braden) 
 
Act 48      1    2    3    4 
(may be from either day or night Braden) 
Act 24      1    2    3    4 
(may be from either day or night Braden) 
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Moi 24      1    2    3    4 
(may be from either day or night Braden) 
Moi 48      1    2    3    4 
(may be from either day or night Braden) 
 
F/S 24      1    2    3     
(may be from either day or night Braden) 
F/S 48      1    2    3    
(may be from either day or night Braden ) 
 
 
 
 
 
HYDRO? (Hydrocortisone use) 
 
 
No 
 
Yes 
HYDRO 14 d __________________________________ 
 
PREDSOL (Prednisolone use) 
 
No 
 
Yes 
PREDSOL 14d __________________________________ 
 
METH (Methylprednisolone use) 
 
No 
 
Yes 
METH 14d __________________________________ 
 
PRED (Prednisone use ) 
 
No 
 
Yes 
PRED 14d __________________________________ 
 
 
Serum Albumin 24 __________________________________ 
(Enter 888 if no value available) 
 
Serum Albumin 48 __________________________________ 
(Enter 888 if no value available) 
 
Total Lymphocyte count 24 __________________________________ 
(Enter 888 if no value available) 
 
Total Lymphocyte count 48 __________________________________ 
(Enter 888 if no value available) 
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High Crit 24 __________________________________ 
(Enter 888 if no value available) 
 
Low Crit 24 __________________________________ 
(Enter 888 if no value available) 
 
High Crit 48 __________________________________ 
(Enter 888 if no value available) 
 
Low Crit 48 __________________________________ 
(Enter 888 if no value available) 
 
MAP 48 __________________________________ 
(Enter 888 if no value available) 
 
MAP 24 __________________________________ 
(Enter 888 if no value available) 
Ox 24 __________________________________ 
(Enter 888 if no value available) 
 
Ox 48 __________________________________ 
(Enter 888 if no value available) 
 
Norepi? (Noreipnepherine use within 48 hours of study 
enrollment? ) 
  
No 
 
Yes 
Norepi 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Norepi 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Epi? (Epinepherine use within 48 hours of study 
enrollment? ) 
 
 No 
 
Yes 
Epi 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Epi 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
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Dobut? (Dobutamine use within 48 hours of study 
enrollment? ) 
 
No 
 
Yes 
Dobut 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Dobut 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
 
Mil? (Milrinone use within 48 hours of study 
enrollment? ) 
 
No 
 
Yes 
 
Mil 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Mil 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Mid? (Midodrine use within 48 hours of study 
enrollment? ) 
 
 No 
 
Yes 
Mid 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Mid 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
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Vaso? (Vasopressin use within 48 hours of study 
enrollment? ) 
 
 No 
 
Yes 
Vaso 48 __________________________________ 
(In total units during 24 hour block 2 days before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
Vaso 24 __________________________________ 
(In total units during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Prssors? (Did the patient require pressor use at any point 
during the ICU stay PRIOR to 48 hours of study 
enrollment? Use only the pressors identified in this study) 
 
 
 
No 
Yes 
Pressor use Norepinepherine 
Epinepherine 
Dobutamine 
Dopamine 
Milrinone 
Midodrine 
Vasopressin 
 
 
Restr? (Is the patient currently in wrist restraints or 
were wrist restraints used within 48 hours of 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
No 
 
Yes 
 
 
 
 
 
Data Collection Form – Control  
Subject Information-CONTROL  
 
Assigned Study ID __________________________________ 
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CONTROL 1001-1350  
(CW use 1001-1174; RB use 1175 to 1350)  
 
 
ICU Adm Date __________________________________ 
(Continuous ICU stay-even if transferred from 
another ICU. ) 
 
Date Control met inclusion criterion for study __________________________________ 
 
Ht (in) __________________________________ 
Wt (lbs) __________________________________ 
 
Vent use? (Has the patient required a ventilator at ANY TIME 
during the ICU stay? ) 
 
No 
Yes 
 
IF YES:  Curr Vent use? (Is the patient CURRENTLY requiring vent use? ) 
 
 
No 
Yes 
 
 
IF NO:  Contin Vent use hrs __________________________________ (Longest # hrs 
continuous vent use up to midnight before study enrollment (Includes time on vent prior to 
transfer from another ICU, if 
applicable) 
 
IF YES: Prior cont Vent use __________________________________ (Longest # hrs continuous 
vent use up to midnight before study enrollment ) 
 
Sens 48     1    2    3    4 
(may be from either day or night Braden) 
Sens 24      1    2    3    4 
(may be from either day or night Braden) 
 
Nut 48      1    2    3    4 
(may be from either day or night Braden ) 
Nut 24      1    2    3    4 
(may be from either day or night Braden) 
 
Mob 48      1    2    3    4 
(may be from either day or night Braden) 
Mob 24      1    2    3    4 
(may be from either day or night Braden) 
 
Act 48      1    2    3    4 
(may be from either day or night Braden) 
Act 24      1    2    3    4 
(may be from either day or night Braden) 
 
Moi 24      1    2    3    4 
(may be from either day or night Braden) 
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Moi 48      1    2    3    4 
(may be from either day or night Braden) 
 
F/S 24      1    2    3     
(may be from either day or night Braden) 
F/S 48      1    2    3    
(may be from either day or night Braden ) 
 
 
 
 
 
HYDRO? (Hydrocortisone use) 
 
 
No 
 
Yes 
HYDRO 14 d __________________________________ 
 
PREDSOL (Prednisolone use) 
 
No 
 
Yes 
PREDSOL 14d __________________________________ 
 
METH (Methylprednisolone use) 
 
No 
 
Yes 
METH 14d __________________________________ 
 
PRED (Prednisone use ) 
 
No 
 
Yes 
PRED 14d __________________________________ 
 
 
Serum Albumin 24 __________________________________ 
(Enter 888 if no value available) 
 
Serum Albumin 48 __________________________________ 
(Enter 888 if no value available) 
 
Total Lymphocyte count 24 __________________________________ 
(Enter 888 if no value available) 
 
Total Lymphocyte count 48 __________________________________ 
(Enter 888 if no value available) 
 
High Crit 24 __________________________________ 
(Enter 888 if no value available) 
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Low Crit 24 __________________________________ 
(Enter 888 if no value available) 
 
High Crit 48 __________________________________ 
(Enter 888 if no value available) 
 
Low Crit 48 __________________________________ 
(Enter 888 if no value available) 
 
MAP 48 __________________________________ 
(Enter 888 if no value available) 
 
MAP 24 __________________________________ 
(Enter 888 if no value available) 
Ox 24 __________________________________ 
(Enter 888 if no value available) 
 
Ox 48 __________________________________ 
(Enter 888 if no value available) 
 
Norepi? (Noreipnepherine use within 48 hours of study 
enrollment? ) 
  
No 
 
Yes 
Norepi 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Norepi 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Epi? (Epinepherine use within 48 hours of study 
enrollment? ) 
 
 No 
 
Yes 
Epi 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Epi 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Dobut? (Dobutamine use within 48 hours of study 
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enrollment? ) 
 
No 
 
Yes 
Dobut 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Dobut 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
 
Mil? (Milrinone use within 48 hours of study 
enrollment? ) 
 
No 
 
Yes 
 
Mil 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Mil 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Mid? (Midodrine use within 48 hours of study 
enrollment? ) 
 
 No 
 
Yes 
Mid 48 __________________________________ 
(In total mcg/kg during 24 hour block 2 days 
before study enrollment (use midnight of study 
enrollment as reference)) 
 
Mid 24 __________________________________ 
(In total mcg/kg during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Vaso? (Vasopressin use within 48 hours of study 
enrollment? ) 
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 No 
 
Yes 
Vaso 48 __________________________________ 
(In total units during 24 hour block 2 days before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
Vaso 24 __________________________________ 
(In total units during 24 hour block 1 day before 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
Prssors? (Did the patient require pressor use at any point 
during the ICU stay PRIOR to 48 hours of study 
enrollment? Use only the pressors identified in this study) 
 
 
 
No 
Yes 
Pressor use Norepinepherine 
Epinepherine 
Dobutamine 
Dopamine 
Milrinone 
Midodrine 
Vasopressin 
 
 
Restr? (Is the patient currently in wrist restraints or 
were wrist restraints used within 48 hours of 
study enrollment (use midnight of study 
enrollment as reference)) 
 
 
No 
 
Yes 
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Appendix C 
Feasibility Study 
 
 
The Efficacy of Using the Electronic Medical Record as a  
Data Source for a Prospective Cohort Study to Determine Pressure Ulcer Risk in 
Critically Ill Patients 
 
 
Abstract 
 Objective: To determine the feasibility of using the electronic medical record (EMR) as a 
data source for a future study to identify pressure ulcer risk factors in critically ill patients. 
Design: Prospective cohort study.  Setting: Six intensive care units (ICUs) in a 847 bed tertiary 
care center.  Subjects: All patients, aged 18 years, admitted the ICUs during the study without a 
pre-existing pressure ulcer. Interventions: None.  Methods: Daily concurrent chart reviews for 
pressure ulcer incidence.  Data were abstracted from the EMR and entered into the database for 
pressure ulcer positive subjects.  Variables: ICU, age, height, weight, pre-existing skin disease, 
and history of diabetes or nicotine use.  Subsequent measures were collected until subjects 
were discharged from the ICU, developed a stage I or worse pressure ulcer, or died.  Measures: 
Worst mean arterial pressure, oxygen saturation, albumin, vasopressor use, and Braden sub- 
and summative scores.  Expert visual screening assessment and Braden scores were conducted 
independently to evaluate the validity of the documentation.  Results: 100 subjects were 
enrolled; six developed a pressure ulcer.  There was 100% agreement between staff nurse and 
expert on pressure ulcer status among pressure ulcer positive and negative subjects, and 83% 
agreement on pressure ulcer stage.  Braden sub-scores weighted Kappa coefficient agreement 
ranged from 0.25 to 0.67.  Expected electronic medical record (EMR) variable information was 
available 66% of the time.  Transient technical difficulties precluded a higher data retrieval rate.  
Time required exceeded 100 hours.  Conclusion:  The EMR is a reliable source of data for 
pressure ulcer research.  However, the prospective cohort design used in this study was time 
intensive.  To limit the time required for future studies, a case-control study designed will be 
used.  
  
 
Introduction 
 Pressure ulcers are a complication of acute and chronic illness that affect approximately 
8.5% to 15% of institutionalized (i.e. nursing homes, acute care facilities) patients per year, 
representing between 2.4 and 5.2 million persons annually.  Patients who are critically ill and 
require placement in an ICU during their hospitalization are more likely to develop pressure 
ulcers than patients who are less critically ill and do not require ICU placement for their care 
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needs (Bours, De Laat, Halfens, & Lubbers, 2001; De Laat, Schoonhoven, Pickkers, Verbeek, & 
van Achterberg, 2006; Frankel, Sperry & Kaplan, 2007; Keller, Wille, van Ramshorst, & van der 
Werken, 2002; Kirby & Gunter, 2008; Shahin, Dassen & Halfens, 2008; Theaker, Mannan, Ives, & 
Soni, 2000).  Pressure ulcer prevention interventions are predicated on identifying salient risk 
factors for pressure ulcer development in specific patient populations (De Laat et al., 2006).   
The predominant approach to studying pressure ulcer risk factors in the related 
literature is the prospective cohort study.  Prospective cohort studies are particularly valuable 
for establishing causality.  By measuring variables in all study subjects before the outcome 
occurs, the researcher establishes a temporal relationship between pre-existing risk factors and 
the incidence of the dependent variable (Cummings, Newman, & Hulley, 2007).  Prospective 
cohort studies are not without their limitations, however.  Prospective cohort studies can be 
expensive and time consuming.  Many studies designed to identify pressure ulcer risk factors 
relied on teams of observers to collect data, which adds to study costs and introduces the risk of 
inter-rater reliability issues.  Data availability and inter-rater reliability on pressure ulcer staging 
and risk scoring are missing in a large number of prospective cohort studies evaluating pressure 
ulcer risk factors.  Prior to initiating a large, prospective cohort study, a feasibility study was 
necessary to determine the accuracy and timeliness of nurses’ documentation of pressure ulcers 
in the ICU population, and the ease of extraction of physiologic risk factors from the electronic 
medical record (EMR).  This feasibility study was designed to identify potential problems with 
data collection and evaluate the reliability of staff nurses regarding pressure ulcer presence and 
staging, and their agreement with expert raters on the Braden score.  
Methods 
Study Design 
This study used a prospective cohort design.  
Study Setting 
Data were collected in each of the six intensive care units (ICUs) in a 847 bed tertiary 
care center.  The six ICUS included Burn (BICU, 9 beds), Cardiovascular (CVICU, 27 beds), Medical 
(MICU, 34 beds), combined neuro-medicine and neuro-surgical (NICU, 34 beds), Surgical (SICU, 
34 beds), and Trauma (TICU, 14 beds).   
Sample 
 Subjects were recruited to this study if they met the inclusion criteria of: 
• 18 years of age or older 
• Admitted to one of six ICUs during the course of the study 
• Had no pre-existing pressure ulcer on admission to the ICU 
Due to the nature of this study, subjects were not excluded based on lack of data in the EMR. 
Study Procedures 
Beginning on the first Monday of the study, EMR census logs were reviewed by the PI, 
Richard Benoit, MSN, RN, CCRN, or Carolyn Watts, MSN,RN, CWON, for admissions the previous 
day.  Demographic information on subjects that met the inclusion criteria were entered into the 
database.  The following day, clinical information from the previous 24 hours was abstracted 
from the EMR and entered into the database.  Nursing documentation in the EMR was examined 
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and the identified physiologic and medication information was entered into the database.  The 
data on subjects was collected each day for 14 days with newly admitted patients captured for 
study the following day.  Any patient that developed a pressure ulcer during the 14-day study 
(as indicated in the EMR) was visually evaluated by either the PI or Carolyn Watts to ensure 
accurate staging of the pressure ulcer as entered by the staff nurse. A Braden score was also 
performed by the PI or Carolyn Watts at the time that the pressure ulcer was evaluated.  Each 
day, study subjects that did not have a documented pressure ulcer in the EMR were randomly 
selected d by the PI or Carolyn Watts for a skin evaluation and Braden score.  Twenty-seven 
subjects were randomly evaluated.  
Data Collection Procedures 
The study was approved Vanderbilt University’s Institutional Review Board.  Written 
consent was waived in all cases, and verbal consent was required for those patients who were 
chosen to have a random assessment of their skin by an expert rater.  Following a literature 
review to identify demographic and physiologic variables that potentially contribute to pressure 
ulcer development in critically ill patients, data extraction from the EMR was conducted over a 
two-week period on 100 patients meeting the inclusion criteria for the study.  Baseline 
demographic information was entered into the data base on the day the patient qualified for 
the study, and daily physiologic parameters were entered throughout the duration of the 
patient’s eligibility to be in the study.  Subjects in the study were randomly selected for 
reliability testing on pressure ulcer presence and Braden scores generated by the staff nurses.  
 
 
 
Baseline Measures 
Baseline measures were collected on any patient meeting the inclusion criterion.  Age, 
weight and height were abstracted from the EMR primarily using the institution’s nursing 
admission and history form.  BMI was calculated using the standard formula weight/height2.  
History of diabetes and history of nicotine use was located in either the nursing admission form 
or the physician’s history and physical.  History of diabetes was recorded as either present or 
absent.  Similarly, nicotine use was recorded as present if the patient admitted to its use within 
one year of the current hospitalization.  Pre-existing skin disease was also coded as present or 
absent on admission.  Where possible, the description of any pre-existing skin disease was noted 
in the database.  The type of ICU the subject was admitted to was recorded in the database.  
The six possible ICU admissions were to the Trauma, Burn, Medical, Surgical, Neurologic, and 
Cardiovascular ICUs.  
Daily Measures 
 The day following a subject’s enrollment in the study, measures were obtained using 
data from the previous 24 hours until the subject was either discharged from the ICU, developed 
a stage I or worse pressure ulcer, died, or the study concluded.  All measures but the Braden 
score and lab values for the previous 24-hour period were extracted from the electronic nursing 
vital sign flowsheet.  For MAP, the worst value during the previous 24 hours from either an 
invasive arterial line reading or non-invasive cuff reading was utilized.  In cases where there 
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were both types of readings, the arterial line measurement was used.  Similarly, the worst 
oxygen saturation of hemoglobin was used.  Vasopressor use was indicated as either present or 
absent for the previous 24 hours.  When vasopressors were used, the type and highest dose 
during the 24-hour period were recorded.  Lowest serum albumin and hematocrit levels from 
the previous 24-hour period were recorded.  
Staff nurses’ assessments of the subject’s Braden scores are documented with the 
location and stage of any pressure ulcers present.  The Braden score and any associated 
pressure ulcer documentation are required every 12 hours.  The results from the most recent 
Braden scores and pressure ulcer documentation were used and entered into the study 
database.  
Data Analysis 
Data collected in this feasibility study were analyzed based on their availability and 
reliability.  Demographic and laboratory variables were analyzed for their frequency of 
availability.  Daily clinical variables were analyzed for their expected frequency, based on 
number of subjects enrolled in the study on any given day.  Braden scores were analyzed for the 
level of agreement between staff nurse and expert rater by manually calculating weighted 
Kappa scores.  
 
Results  
Subject Profile 
One hundred subjects were enrolled in the study.  Subjects ranged in age from 19 years 
to 94 years, mean 53.5 years.  BMI ranged from 16.23 to 54.04 with a mean of 28.6.  ICU length 
of stay ranged from 1 day to 14 days.  Thirty eight patients (38%) had a history of nicotine use 
prior to admission, 9 (9%) had pre-existing skin disease, and 20 (20%) had a history of diabetes.  
Table 1 represents the frequency of those demographic and clinical variables that were 
obtained.  Given that there were 100 subjects enrolled in the study, the maximum number of 
results for each demographic variable was 100.  As subjects were added and removed from the 
study, the number of daily maximum clinical variables changed, depending on how many 
subjects were enrolled on any given day.  By calculating the number of subjects enrolled in the 
study on each of the 14 days, the total number of patient days evaluated were 476.  Because of 
the standard frequency of collecting MAP, oxygen saturation, and Braden scores, at least 476 
variables were expected for each of those variables.  Laboratory values for hematocrit and 
serum albumin were collected as they were available.   
Table 1 gives a summary of the availability of expected variables.  Because vasopressor 
use in critically ill patients is highly variable, no expected number of variables was possible to 
calculate.  Of the 100 subjects enrolled, 31 received vasopressors during the study, and 
vasopressors were in use during 85 of the 476 patient days.  All data regarding vasopressor type 
and infusion rates were available in the EMR.  
Braden score agreement between staff nurse and expert rater were evaluated using 
manual calculations of a weighted Kappa score.  Twenty-seven subjects were randomly 
evaluated for their skin integrity and Braden score by an expert rater.  Additionally, the expert 
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raters performed Braden scores on the six pressure ulcer positive subjects.  Weighted Kappa 
scores are presented in Table 2.   
Of the six subjects that developed a pressure ulcer during the 14 day study, there was 
100% agreement between the staff nurse documentation and expert rater validation regarding 
presence and location of the pressure ulcer.  There was discrepancy on one pressure ulcer stage, 
giving an 83.3% agreement between staff nurse documentation and expert rater on pressure 
ulcer staging.   
Discussion 
The feasibility of data retrieval and the quality of that data are prime concerns to a 
researcher wishing to use the EMR.  Added concerns about the quality of nursing 
documentation around pressure ulcer presence, staging, and risk stratification are particularly 
troublesome.  The quality and quantity of pressure ulcer documentation is generally poor 
(Gunningberg & Ehrenberg, 2004).  Studies of ward nurses conducted in Europe report that 
pressure ulcers were often classified incorrectly and report Kappa statistics slightly greater than 
0.3 (Beeckman et al., 2007; Defloor, Schoonhoven, Katrien, Weststrate, & Myny, 2006).  This 
study was designed to answer questions about data availability and quality with regard to the 
study of pressure ulcers and their risk factors.   
Demographic and daily clinical information were readily available.  The EMR was easily 
accessible and the information was easily located.  The laboratory values of hematocrit and 
serum albumin were chosen as potential risk variables based on a review of the literature and 
for their physiologic importance in maintaining skin integrity.  Hematocrit values were 
performed on each subject almost daily.  Serum albumin values, used extensively in the 
literature as a proxy measure for protein stores, were sparse, with only 25 values being 
recorded during any previous 24 hour observation period for the 100 subjects enrolled.  
Assuming this level of serum albumin testing will continue, other proxy measures for protein 
stores or funding for serum albumin testing is necessary.   
The 66% availability of the staff nurse Braden scores was primarily a function of the 
EMR.  As each new Braden score was entered into the EMR, the previous one was automatically 
archived and consequently was not available for analysis.  As the data collection was designed to 
evaluate clinical parameters and Braden scores from the previous 24 hours, Braden score 
evaluation became problematic if the data collection was occurring in the afternoon.  By that 
time, the nurse had entered a new Braden score for the day, and the scores from the previous 
day were not accessible.  Since the study, the author has learned how to retrieve archived 
information, so future studies should show higher availability of the Braden scores.  
Agreement between Braden scores performed by the staff nurse and those conducted 
by the expert rater had good to excellent agreement.  All weighted Kappa scores were above 
0.53 with the exception of the moisture subscale.  The low agreement on the moisture subscale 
is confounding, but probably of little clinical significance.  When staff nurse and expert rater 
Braden scores were dichotomized into high risk (Braden scores ≤ 16) and low risk (Braden scores 
≥ 17), the non-weighted Kappa score was 0.698 (p< 0.001). 
The agreement between staff nurse and expert rater on the presence, location, and 
stage of pressure ulcer positive subjects is encouraging.  It should be noted that the six subjects 
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that developed pressure ulcers did not have massive tissue damage, and staging was relatively 
straightforward.  One pressure ulcer was stage I, two were stage II, and two were unstageable.  
The disagreement between nurse and expert rater occurred on a pressure ulcer that developed 
because of naso-gastric tube erosion into the nares.  The staff nurse staged the lesion as a stage 
II; however, the expert rated it as unstageable a day later because of the scabbing that was 
obscuring the wound base.  
Given the availability and accuracy demonstrated by this study, the EMR can be utilized 
as a data source for future pressure ulcer studies.  The time constraints required to abstract the 
data, complete random skin assessments, and validate extant pressure ulcers was extensive.  
The two data collectors spent in excess of 100 hours during the two-week study.  To reduce the 
excessive amount of time required for data collection, future studies will use a case-control 
study design, thereby eliminating the need for data collection on every patient admitted to the 
ICU.   
 
Table C.1. Variable availability for Pressure Ulcer Feasibility Study 
Variable Number of 
times 
variable 
present  
Maximum no. 
observations 
possible 
% of times 
data 
available  
Age 100 100 100 
Diabetes 99 100 99 
BMI 95 100 95 
Nicotine 97 100 97 
Skin Disease 99 100 99 
Worst MAP 459 476 96 
Worst O2 Sat 467 476 94 
Hematocrit 
Level* 
433   
Serum 
Albumin* 
25   
Staff RN 
Braden 
Scores 
317 476 66 
*Maximum no. possible observations assuming lab values completed at least once every 24 
hours 
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Table C.2. Weighted Kappa Agreement Between expert and Staff Nurse (N=33) 
 
Braden Sub-Scale  Weighted Kappa Value  
Sensory 0.535 
Moisture 0.248 
Activity 0.666 
Mobility 0.577 
Nutrition 0.56 
Friction/Shear  0.581 
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Appendix D 
Tables  
 
Table D.1. Comparison of Dichotomous Data between Marched and Unmatched Case 
Subjects 
Variable Unmatched Cases  
N = 12 
         n         (%) 
Matched Cases 
N = 180 
         n           (%) 
p value† 
Gender    
Male 10        (83.3) 128 (71.1) 0.362 Female 2          (16.7) 52 (28.9) 
Consent    
Self 2         (16.7) 29 (16.1) 
0.421 Surrogate 8         (66.7) 89 (49.4) 
Waived 2         (16.7) 62 (34.4) 
ICU*    
CVICU          3          (25) 35 (19.4) 
0.254 
     MICU 0 36 (20.0) 
     Neuro    2          (16.7)       10       (5.6) 
     SICU 3          (25) 56 (31.1) 
     Trauma    4          (33.3) 43 (23.9) 
Ventilator use*    
No   1          (8.3)       37           (20.6) 0.304 Yes     11        (91.7)       143         (79.4)                     
Diabetes     
      No   7         (58.3)       96            (53.3) 
0.705      Yes    2         (16.7)       49            (27.2) 
      Missing 3         (25)       35            (19.4) 
Nicotine    
      No    7          (58.3) 96 (53.3) 
0.866      Yes     4          (33.3) 73 (40.6) 
     Missing           1          (8.3) 11 (6.1) 
Steroid use    
      No 9         (75) 124 (68.9) 
0.348      Yes 0 25 (13.9) 
     Missing 3          (25) 31 (17.2) 
Skin disease    
No   11        (91.7) 114 (63.3) 
0.368      Missing 0 27         (15.0) 
Yes           1          (8.3) 39 (21.7) 
Pre-existing 
pressure ulcer 
 1          (8.3) 24 (13.3) 0.618 
Edema 0 11 (6.1) 0.378 
Jaundice 0 5 (2.8) 0.559 
Thin, fragile 
skin 
0 1 (0.6) 0.796 
IV vasopressor use 
prior to enrollment 
   
     No        3            (25) 93             (51.7) 0.074 
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Variable Unmatched Cases  
N = 12 
         n         (%) 
Matched Cases 
N = 180 
         n           (%) 
p value† 
     Yes         9            (75) 87             (48.3) 
Dobutamine 0      14         (7.8) 0.316 
Dopamine 0 9 (5.0) 0.428 
Epinephrine         1          (8.3)  23   (12.8) 0.652 
Midodrine 0 0 -- 
Milrinone         1          (8.3)       17        (9.4) 0.898 
Norepinephrine         9          (75) 68 (37.8) 0.011 
Vasopressin 5          (41.7) 39 (21.7) 0.110 
Restraint use    
No          6          (50) 49 (27.2) 0.091      Yes         6          (50) 131 (72.8) 
† X2 
*Matching criteria 
 
Table D.2. Comparison of Braden Subscale Scores between Matched and Unmatched 
Case Subjects 
Braden Sub Scale 
Score  
Unmatched Cases 
N = 12 
 
            n         (%) 
Matched Cases 
N = 180 
         
        n           (%) p value† 
Lowest Sensory 48 
hours prior to 
enrollment  
   
1 2 (16.7) 29 (16.1) 
0.973 2 4 (33.3) 67 (37.2) 3 5 (41.7) 63 (35.0) 
4        1             (8.3) 21 (11.7) 
Lowest Sensory 24 
hours prior to 
enrollment  
  
 
1 2 (16.7) 32 (17.8) 
0.953 2 4 (33.3) 63 (35.0) 3 5 (41.7) 57 (31.7) 
4        1        (8.3) 28 (15.6) 
Lowest Nutrition 48 
hours prior to 
enrollment  
  
 
1        1        (8.3) 20 (11.1) 
0.587 2 4 (33.3) 70 (38.9) 3 7 (58.3) 89 (49.4) 
4 -- 1 (0.6) 
Lowest Nutrition 24 
hours prior to 
enrollment  
  
 
1        1        (8.3) 26 (14.4) 
0.133 
2 2 (16.7) 64 (35.6) 
3 9 (75.0) 88 (48.9) 
4 -- 2 (1.1) 
 
Lowest Mobility 48    
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Braden Sub Scale 
Score  
Unmatched Cases 
N = 12 
 
            n         (%) 
Matched Cases 
N = 180 
         
        n           (%) p value† 
hours prior to 
enrollment  
1 5 (41.7) 62 (34.4) 
0.236 2 7 (58.3) 82 (45.6) 3 -- 35 (19.4) 
4 -- 1 (0.6) 
Lowest Mobility 24 
hours prior to 
enrollment  
  
 
1 6 (50.0) 58 (32.2) 
0.080 
2 6 (50.0) 86 (47.8) 
3 -- 34 (18.9) 
4 -- 2 (1.1) 
 
 
 
 
 
Lowest Activity 48 
hours prior to 
enrollment  
  
 
1 10 (83.3) 132 (73.3) 
0.408 2 2 (16.7) 38 (21.1) 3 -- 8 (4.4) 
4 -- 2 (1.1) 
Lowest Activity 24 
hours prior to 
enrollment  
  
 
1 7 (58.3) 135 (75.0) 
0.246 2 5 (41.7) 39 (21.7) 3 -- 6 (3.3) 
4 -- -- 
Lowest Moisture 48 
hours prior to 
enrollment  
  
 
1        1        (8.3) 5 (2.8) 
0.041 2 5 (41.7) 32 (17.8) 3 5 (41.7) 118 (65.6) 
4        1         (8.3) 25 (13.9) 
Lowest Moisture 24 
hours prior to 
enrollment  
  
 
1        1        (8.3) 12 (6.7) 
0.050 2 6 (50.0) 45 (25.0) 3 5 (41.7) 101 (56.1) 
4 -- 22 (12.2) 
Lowest 
Friction/Shear 48 
hours prior to 
enrollment  
  
 
168 
 
 
 
Braden Sub Scale 
Score  
Unmatched Cases 
N = 12 
 
            n         (%) 
Matched Cases 
N = 180 
         
        n           (%) p value† 
1 5 (41.7) 84 (46.7) 
0.891 2 7 (58.3) 87 (48.3) 
3 -- 9 (5.0) 
Lowest 
Friction/Shear 24 
hours prior to 
enrollment  
  
 
1 6 (50.0) 96 (53.3) 
0.756 2 5 (41.7) 75 (41.7) 
3        1         (8.3) 9 (5.0) 
†Mann-Whitney 
 
 
Table D.3. Comparison of Continuous Data between Matched and Unmatched Case 
Subjects 
 
Variable   
Unmatched Cases 
N = 12 
Median       (n; IQR) 
 
Matched Cases 
N = 180 
Median       (n; IQR) 
 p value†† 
Age 
 
58.5        (12; 41.3 - 61.8) 
 
 
59.0     (180;  48.3 – 68.0) 
 
0.530 
ICU length of stay 
before enrollment* 
 
24.5       (12;  21.0 - 27.5) 
 
 
7.0          (180; 4.0 – 11.0) 
 
< 0.001 
BMI** 
 
27.6       (12; 23.9 - 34.3) 
 
 
27.6      (180; 23.0 - 33.6) 
 
0.826 
Total corticosteroid 
dose 14 days before 
enrollment  
   
Hydrocortisone 
dose 
 
 
1275.0    (4; 343.8 – 1625.0) 
 
 
 
450.0  (45; 200.0 – 1000.0) 
 
0.182 
Methylprednisone 
dose 
 
 
1250.0    (1; 1250.0 – 1250.0) 
 
 
342.5   (20; 125.0 - 1117.5) 0.280 
Prednisolone dose 0   0   -- 
Prednisone dose 0   
 
 
140.0   (17; 62.5 – 230) 
 
 
 
-- 
Protein store     
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Variable   
Unmatched Cases 
N = 12 
Median       (n; IQR) 
 
Matched Cases 
N = 180 
Median       (n; IQR) 
 p value†† 
Serum albumin 
 
 
2.8     (7; 2.6 – 3.0) 
 
 
2.8    (68; 2.4 - 3.2) 0.763 
Pre-albumin 
 
12.5      (10; 8.0 – 23.0) 
 
 
11.0     (80; 8.0 – 14.0) 0.354 
Lymphocyte count 
 
1.0     (8; 0.6 - 1.4) 
 
 
1.0     (129; 0.6 - 1.6) 
 
 
0.765 
 
 
Perfusion parameters  
   
Highest 
hematocrit 48 
hours prior to 
enrollment 
27.0    (11; 23.0 – 32.0) 
 
28.0     (175; 26.0 – 31.0) 
 
0.528 
Lowest hematocrit 
48 hours prior to 
enrollment 
27.0     (11; 23.0 – 31.0) 
 
27.0     (175; 24.0 – 30.0) 
 
 
0.871 
 
Highest 
hematocrit 24 
hours prior to 
enrollment 
29.0   (11;  25.0 – 33.0) 
 
28.0     (176; 25.0 – 30.0) 
 
0.624 
Lowest hematocrit 
24 hours prior to 
enrollment 
29.0    (11; 25.0 – 33.0) 
 
26.0     (176; 24.0 – 29.0) 
 
0.225 
Lowest MAP† 48 
hours prior to 
enrollment 
57.5    (12; 51.5 – 65.0) 
 
61.0     (180; 55.0 – 66.0) 
 
0.197 
Lowest MAP 24 
hours prior to 
enrollment 
53.0    (12;  42.3 – 66.3) 
 
61.0     (180; 56.0 – 67.0) 
 
0.064 
Lowest O2 
saturation  48 
hours prior to 
enrollment 
 
95.0    (12; 87.0 – 98.3) 
 
 
92.0     (180; 89.3 – 95.0) 
 
0.400 
Lowest O2 
saturation 24 
hours prior to 
enrollment 
95.5     (12; 93.3 – 98.5) 92.5     (180; 90.0 – 95.0) 
 
0.016 
 
Vasopressor dose in 
total micrograms/kg   
   
Norepinephrine 
dose 48 hours 
prior to enrollment 
 
73.6    (2; 1.2  – 0.0) 
 
 
44.5     (49; 15.8 – 86.0) 
 
0.633 
Norepinephrine 
dose 24 hours 
prior to enrollment 
37.1   (1; 37.1 -37.1) 
  
51.3   (43; 9.4 - 117.3) 
 
0.098 
Epinephrine dose 
48 hours prior to 
enrollment 
0 
 
 
9.4     (6; 5.9 - 53.2) 
 
-- 
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Variable   
Unmatched Cases 
N = 12 
Median       (n; IQR) 
 
Matched Cases 
N = 180 
Median       (n; IQR) 
 p value†† 
 
Epinephrine dose 
24 hours prior to 
enrollment 
0  17.0     (3; 1.5 - 17.0†††) -- 
Dobutamine dose 
48 hours prior to 
enrollment 
0  4463.9  (2; 1448.8 - 4463.9†††) -- 
Dobutamine dose 
24 hours prior to 
enrollment 
0 
 
1373.0   (3; 483.0 – 1373.0†††) 
 
-- 
Milrinone dose 48 
hours prior to 
enrollment 
134.4    (1; 30.3 – 0.0) 
 
150.0   (13; 40.8 - 323.4) 
 
0.751 
Milrinone dose 24 
hours prior to 
enrollment 
435.7   (1; 199.7 – 0.0) 
 
224.5   (10; 65.8 - 406.1) 
 
1.000 
Midodrine dose 48 
hours prior to 
enrollment 
0 
 
333.0   (1; 333.0 – 333.0) 
 
-- 
Midodrine dose 24 
hours prior to 
enrollment 
0 
 
333.0   (1; 333.0 – 333.0) 
 
-- 
Vasopressin dose 
48 hours prior to 
enrollment (total 
units/kg) 
2.4    (1; 2.4 - 2.4) 
 
31.2   (23; 19.2 - 57.6) 
 
0.100 
Vasopressin dose 
24 hours prior to 
enrollment 
 
26.4     (1; 26.4 - 26.4) 
 
39.6   (24; 16.9 - 49.8) 
 
0.550 
†† Mann-Whitney 
*Matching criteria; **Body mass index; †Mean arterial pressure, † † † 25th and 50th percentile 
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Table D.4. Summary of Missing Data 
 
Missing Variable Matched Cases 
N = 180 
         n              (%) 
Matched Controls  
N = 180  
      n            (%) 
p value† 
Pre-Admission 
Demographic 
Variables 
   
     Diabetes 35            (19.4)   32               (17.8) 0.755 
     Nicotine use      11        (6.1) 11     (6.1) 1.000 
     Corticosteroid                
use 31            (17.2)  32     (17.8) 1.000 
Skin Disease  27       (15.0)  29     (16.1) 0.874 
Perfusion 
Parameter 
Variables 
   
Highest 
hematocrit 48 
hours prior to 
enrollment 
5     (2.8) 4     (2.2) 1.000 
Lowest 
hematocrit 48 
hours prior to 
enrollment  
5     (2.8) 4     (2.2) 1.000 
Highest 
hematocrit 24 
hours prior to 
enrollment 
4     (2.2) 5     (2.8) 1.000 
Lowest 
hematocrit 48 
hours prior to 
enrollment  
4     (2.2) 5     (2.8) 1.000 
Protein Reserve 
Variables    
Serum 
Albumin 112     (62.2) 113     (62.7) 1.000 
Serum Pre-
albumin 100     (55.5) 100      (55.5) 0.560 
Total 
Lymphocyte 
Count 
51        (28.3) 41        (22.8) 0.522 
Any Protein 
Store 22     (12.2) 15         (8.3) 0.281 
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Table D.5. Summary of Vasopressor Use and Steroid Administration in Case and Control 
Subjects 
 
Variable   
Matched Cases 
N = 180 
 
Median       (n; IQR) 
 
Matched Controls 
 N = 180 
 
Median       (n; IQR) 
 
 
p value* 
Total corticosteroid dose within 14 days of enrollment  
Hydrocortisone 
dose 
 
450.0  (45; 200.0 – 1000.0) 
 
 
700.0   (30; 250.0 – 1225.0) 
 
0.223 
Methylprednisone 
dose 
 
342.5  (20;  125.0 - 1117.5) 
 
 
285.5   (22; 123.8 – 875.0) 
 
0.988 
Prednisolone dose 0    (0.0) 0    (0.0) -- 
Prednisone dose 
 
140.0   (17; 62.5 – 230.0) 
 
 
100.0   (25; 37.5 – 215.0) 
 
0.361 
Vasopressor dose in total micrograms/kg   
Norepinephrine 
dose 48 hours 
prior to enrollment 
 
 
44.5     (49; 15.8 – 86.0) 
 
 
 
41.5   (34; 13.4 – 78.0) 
 
0.095 
Norepinephrine 
dose 24 hours 
prior to enrollment 
  
 
51.3   (43; 9.4 - 117.3) 
 
 
 
38.3   (31; 14.3 - 128.6) 
 
0.107 
 
Epinephrine dose 
48 hours prior to 
enrollment 
 
 
9.4     (6; 5.9 - 53.2) 
 
 
120.1    (6; 28.0 - 518.9) 
 
0.272 
 
Epinephrine dose 
24 hours prior to 
enrollment 
 
17.0    (3; 1.5 – 17.0††) 
  
67.1     (5; 12.4 – 75.4) 
 
0.401 
Dobutamine dose 
48 hours prior to 
enrollment 
4463.9  (2; 1448.8 –                                                    
4463.9††) 
 
3445.5 (4; 858.3 -                                          
5847.0) 
 
0.600 
Dobutamine dose 
24 hours prior to 
enrollment 
 
1373.0   (3; 483.0 – 
1373.0††) 
 
 
2610.9   (6; 454.6 -  
               4474.7) 
 
0.374 
 
Milrinone dose 48 
hours prior to 
enrollment 
 
 
150.0   (13; 40.8 - 323.4) 
 
 
294.7  (8; 70.7 -1155.5) 
 
0.936 
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Variable   
Matched Cases 
N = 180 
 
Median       (n; IQR) 
 
Matched Controls 
 N = 180 
 
Median       (n; IQR) 
 
 
p value* 
 
Milrinone dose 24 
hours prior to 
enrollment 
 
 
224.5   (10; 65.8 - 406.1) 
 
 
364.1   (9; 78.7 – 629.0) 
 
0.795 
 
Midodrine dose 48 
hours prior to 
enrollment 
 
 
333.0   (1; 333.0 – 333.0) 
 
0    (0.0) -- 
 
Midodrine dose 24 
hours prior to 
enrollment 
 
 
333.0  (1; 333.0 – 333.0) 
 
0    (0.0) -- 
 
Vasopressin dose 
48 hours prior to 
enrollment (total 
units/kg) 
 
31.2   (23; 19.2 - 57.6) 38.4   (13; 19.8 - 57.6) 0.263 
 
Vasopressin dose 
24 hours prior to 
enrollment (total 
units/kg) 
 
39.6   (24; 16.9 - 49.8) 52.8   (13; 18.6 - 57.6) 0.138 
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